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Gastric cancer is a complex disease influenced by strong genetic and
environmental factors. Hereditary gastric cancer syndromes are thought to
account for between 1-3% of all cases. The most common hereditary gastric
cancer syndrome is Hereditary Diffuse Gastric Cancer (HDGC), an autosomal
dominant cancer syndrome that is primarily characterised by an extreme risk
of developing diffuse-type gastric cancer. Approximately 40% of families that
fit the clinical criteria for HDGC carry a pathogenic variant in germline CDH1.
An explanation for the remaining 60% of cases remains largely elusive.
While New Zealand as a whole is a country with a low-incidence of gastric
cancer, Māori have an age-standardised incidence of gastric cancer more than
three times that of non-Māori. Additionally, Māori have an average age of
diagnosis approximately 10 years younger than non-Māori, and are one of the
few populations worldwide with a higher incidence of the diffuse-type
disease. To assess the contribution of HDGC to the high-incidence of diffuse
gastric cancer for Māori, we analysed the CDH1 sequence from an unselected
cohort of 94 Māori gastric cancer patients and 200 healthy matched controls
using next-generation amplicon sequencing, multiplex ligation-dependent
probe amplification, and Sanger sequencing. Pathogenic CDH1 variants were
identified in 18% of all cases, 34% of diffuse gastric cancers, and 66% of
early-onset cases (< 45 years of age). After adjusting for the effect of clinical
genetic testing for known Māori HDGC families, we estimate 6% of all Māori
gastric cancer patients and 13% of diffuse gastric cancer patients carry
pathogenic germline CDH1 variants.
Chile is a country with a high-incidence of gastric cancer and no formal genetic
screening programme for gastric cancer patients. To explore pathogenic
i
germline CDH1 variants as a cause of gastric cancer in Chile, next-generation
amplicon sequencing and Sanger sequencing were used to screen a cohort of
51 Chilean gastric cancer patients that presented with a striking family history
or early-onset disease. Overall, one clear pathogenic CDH1 variant was
identified, representing 2.0% of all probands and 3.6% of probands who met
the clinical criteria for HDGC. Although pathogenic CDH1 variants were rare
in this Chilean cohort, we were able to screen the extended family of the one
proband with a confirmed mutation and identify five further carriers. These
carriers will now benefit from surveillance and early intervention.
Finally, whole-exome sequencing was used to examine 14 diffuse gastric
cancer patients that fit the clinical criteria for HDGC and did not carry a
pathogenic variant in their germline CDH1. Variants in these patients were
filtered and prioritised for further evaluation and validation using Sanger
sequencing. Single probands were found to carry pathogenic variants in ATM
and TP53, genes which are not associated with HDGC, but are known to
increase gastric cancer risk. Additional mutations of interest were identified in
FARP2, FGD4, and LMO7, genes that are important in the coordination of the
actin cytoskeleton and/or cell adhesion, pathways which are dysregulated in
diffuse-type gastric tumours. Until now, FARP2, FGD4, and LMO7 were not
linked with diffuse gastric cancer risk. It is clear from the current study and
other HDGC studies, that there is no other common gene for HDGC, however
families may carry private variants in genes rarely associated with disease.
Taken together, these studies demonstrate the variable frequency of
pathogenic variants in germline CDH1 in different populations, the absence of
other commonly mutated genes in familial diffuse gastric cancers, and the
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C MLPA ratios 245
D Validation of rare variants in Chilean gastric cancer cohort 251




1.1 The E-cadherin protein. . . . . . . . . . . . . . . . . . . . . . . . . 18
1.2 Cadherin-catenin protein complex . . . . . . . . . . . . . . . . . . 20
2.1 Two-step PCR strategy for creating next-generation amplicon sequencing
libraries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.2 Base diversity of first four sequenced bases. . . . . . . . . . . . . . 44
2.3 Summary of pre-processing and variant calling analysis of CDH1
amplicon sequencing data workflow. . . . . . . . . . . . . . . . . . 53
2.4 Schematic diagram of MLPA reaction . . . . . . . . . . . . . . . . 57
2.5 Summary of pre-processing and variant calling analysis for whole-exome
sequencing data. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.1 Age-standardised gastric cancer incidence rate in New Zealand,
1980-2013. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.2 Age-standardised registration rate of gastric cancer in New Zealand,
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Gastric cancer is a complex disease influenced by strong genetic and
environmental factors. Hereditary gastric cancer syndromes, in which
inherited deleterious variants are predisposing to a heightened risk of
developing gastric cancer, are thought to account for between 1-3% of all
gastric cancer cases. The most frequent hereditary gastric cancer syndrome is
Hereditary Diffuse Gastric Cancer (HDGC), an autosomal dominant syndrome
characterised by an extreme risk of developing diffuse gastric cancer and
lobular breast cancer. Germline CDH1 explain approximately 40% of families
meeting the clinical criteria for HDGC. An explanation for the other 60% of
HDGC cases remains largely elusive. Here, I have used next-generation
sequencing (NGS) and bioinformatic tools to explore how pathogenic germline
CDH1 variants contribute to the diagnosis of gastric cancer in the Māori and
Chilean populations, and search for predisposing variants in HDGC patients
whom do not carry pathogenic germline CDH1 variants.
1.1.1 Gastric cancer
Gastric cancer is the fifth leading cause of cancer globally and is ranked third
for cancer related mortality (Ferlay et al., 2015). Globally, gastric cancer affects
nearly one million individuals each year, of whom 70-85% die within 5-years
of diagnosis (Ferlay et al., 2015). The high mortality associated with the disease
is the main result of typically late diagnoses and limited therapeutic options.
The incidence of gastric cancer is twice as high in men as in women and varies
greatly across countries and ethnicities. Geographic variation, in part, reflects
differences in exposure to environmental risk factors. The incidence of gastric
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cancer is highest in Eastern Asia, Central Europe, Eastern Europe, and South
America; and lowest in Northern America, most parts of Africa, Australia, and
New Zealand (Oliveira, Senz, et al., 2009; Ferlay et al., 2015). Due to a
reduction in the prevalence of risk factors, the incidence of gastric cancer has
been declining in most parts of the world (Oliveira, Senz, et al., 2009).
1.1.1.1 Classification and staging
Histopathologically, approximately 90% of gastric cancer diagnoses are
classified as adenocarcinomas and 10% are classified as mucosa-associated
lymphoid tissue (MALT) lymphomas or carcinoid tumours (Bosman, Carneiro,
Hruban, & Theise, 2010). According to the Lauren classification system, gastric
adenocarcinomas can be divided into two main histological subtypes,
intestinal and diffuse (Lauren, 1965). The relative frequency of the intestinal
and diffuse gastric cancers are approximately 54% and 32%, respectively. The
remaining 15% of gastric adenocarcinomas are characterised as
intermediate-type and are histologically made up of a mixture of the two main
subtypes (Polkowski et al., 1999). It is widely accepted that the intestinal and
diffuse subtypes represent distinct disease entities with marked pathology,
epidemiology, and etiology (Hu et al., 2012). Although the Lauren
classification system dates back to 1965, it is still widely accepted and
employed by pathologists and physicians as a simple but robust classification
approach.
Intestinal gastric cancer is defined by the presence of tumour cells with
glandular, tubular, or papillary growth patterns, with various degrees of
differentiation. These tumours typically grow in a unifocal, expanding
fashion, and are commonly a response to chronic inflammation (Lauren, 1965).
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Intestinal gastric cancer typically presents in older patients and is often
associated with environmental factors, such as Helicobacter pylori (H. pylori)
infection, diet, and life style (Kaneko & Yoshimura, 2001). The incidence of
intestinal gastric cancer is declining in most parts of the world.
In contrast, diffuse gastric cancer is defined by solitary or small clusters of
poorly cohesive cells that frequently infiltrate the stomach wall in a diffuse
pattern, with or without a small component of gland formation (Lauren, 1965).
Diffuse gastric cancer frequently presents with signet ring cells and is
sometimes referred to as signet ring cell carcinoma (SRCC) (Lauren, 1965).
SRCC is a rare form of highly malignant adenocarcinoma that is characterised
by mucin filled vacuoles and present with an appearance similar to a signet
ring. Family history is the strongest risk factor for diffuse gastric cancer, and
unlike intestinal-type gastric cancer, is not strongly associated with
environmental factors (Caldas et al., 1999). Additionally, diffuse gastric cancer
typically presents at an earlier age compared to intestinal-type disease
(Lauren, 1965).
Another set of criteria commonly used to classify gastric tumours is the World
Health Organisation (WHO) classification (Bosman et al., 2010). The WHO
classification is based on the predominant histological pattern of each tumour
and recognises four major subtypes of gastric adenocarcinomas: tubular,
papillary, mucinous, and poorly cohesive (including signet ring cell
carcinoma) (Bosman et al., 2010). When compared to the Lauren classification:
papillary, tubular, and mucinous adenocarcinomas are all categorised as
intestinal-type gastric cancer; signet ring cell carcinomas and other poorly
cohesive carcinomas are categorised as diffuse-type gastric cancer, and mixed
carcinomas are categorised as intermediate-type gastric cancer (Berlth,
Bollschweiler, Drebber, Hoelscher, & Moenig, 2014).
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Recent advances in sequencing technologies have made it possible to classify
tumours by their genetic profiles, rather than by their histology. The Cancer
Genome Atlas (TCGA), in the most comprehensive study to date, classified
gastric adenocarcinomas into four molecular subtypes,
Epstein–Barr-virus-associated (EBV), microsatellite instability (MSI),
genomically stable (GS); and chromosomal instability (CIN) (Bass et al., 2014).
Importantly, classification of these molecular subtypes has provided valuable
insight into some of the molecular mechanisms underling the different
histological subtypes. TCGA showed, GS tumours were enriched for
diffuse-type tumours and frequently contain pathogenic variants in RHOA
and CDH1, or harboured a CLDN18-ARHGAP translocations, all of which
impact cell adhesion (Bass et al., 2014). Conversely, the EBV subtype,
characterised by Epstein–Barr virus infection, pathogenic PIK3CA variants,
DNA hypermethylation, and amplification of the genes JAK2, CD274, and
PDCD1LG2; the MSI subtype, characterised by elevated genome wide
mutation rates; and the CIN subtype, characterised by marked aneuploidy
and focal amplification of receptor tyrosine kinases, were all enriched for the
intestinal subtype (Bass et al., 2014).
The extent to which a cancer has spread is known as its stage. The earliest
stage stomach cancers is called stage 0 (carcinoma in situ), and then range from
stages I (1) through IV (4). Generally, the lower the number, the less the cancer
has spread. Although each person’s cancer is unique, cancers with a similar
stage tend to have a similar prognosis and are often treated in the same way.
The staging system most often used for gastric cancer is the American Joint
Committee on Cancer (AJCC) TNM system (Washington, 2010), which is based
on the size of the primary tumour (T), spread to nearby lymph nodes (N), and
spread (metastasis) to distant sites (M). The "T" plus a letter or number (0 to 4)
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is used to describe the how far the tumour has grown into the stomach wall.
Some tumour stages are divided into even smaller groups that help describe in
more detail. The "N" uses a system of numbers and letters as an indicator of if
the cancer has spread to regional lymph nodes (defined as lymph nodes
within the abdomen), and if it has, how widespread the cancer is. The "M" is
described using a 0 or 1, indicating whether the cancer has spread to other
parts of the body, called distant metastasis.
1.1.2 Risk factors
Gastric cancer risk is complex and is modified by a number of environmental
exposures and genetic factors. Individually, these factors may only contribute
a minimal amount towards an individuals risk of disease risk, but together
they may explain larger population trends. To improve the management of
gastric cancer patients, we must identify and understand both the
environmental and genetic factors that influence the risk of this disease.
Known risk factors for gastric cancer include diet, obesity, low socioeconomic
status, H. pylori infection, and a family history of gastric cancer (Alemán et al.,
2014; Kelley & Duggan, 2003).
1.1.2.1 Diet
In 2007, salt and salty/salted foods were classified as a ’probable’ risk factor
for gastric cancer (Marmot et al., 2007). Diets with a high intake of salt and
various traditional salt preserved foods such as salted fish, cured meat, and
salted vegetables have been linked to a 22% increased risk of gastric cancer (Ge
et al., 2012; Peleteiro, Lopes, Figueiredo, & Lunet, 2011; Tsugane & Sasazuki,
2007). Additionally, in rodents, high salt intake was shown to damage the
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stomach mucosa by inducing proliferative change, and increase susceptibility
to gastric carcinogens (Takahashi, Kokubo, Furukawa, Kurokawa, & Hayashi,
1984; Tatematsu, Takahashi, Fukushima, Hananouchi, & Shirai, 1975). The
global decline in the incidence of gastric cancer over the last 50 years has, in
part, been attributed to the increased use of refrigeration, decreasing the need
for salting and other salt-based food preservation methods (Karimi, Islami,
Anandasabapathy, Freedman, & Kamangar, 2014; B. Park et al., 2011).
Additionally, with increased awareness of hypertension there has been a shift
towards lowering salt intake.
Low consumption of fruit and vegetables has also been associated with an
increased risk of gastric cancer. Fruit and vegetables are a rich source of
vitamin C, folate, and carotenoids, all of which are suggested to inhibit
carcinogenesis by regulating metabolism of xenobiotic-enzymes (Wiseman,
2008). A 100 gram increase in vegetable and fruit intake was shown to reduce
the relative risk of gastric cancer to 0.81 (95% CI 0.75-0.87) and 0.74 (95% CI
0.69-0.81), respectively. However, support for this association remains
inconsistent, with some reports showing no association between fruit and
vegetable consumption and gastric cancer risk (Freedman et al., 2008;
Gonzalez et al., 2012).
1.1.2.2 Obesity
Obesity is a growing problem in modern societies and is a well-established
risk factor for several diseases, including gastric cancer (M. Ng et al., 2014;
Yang et al., 2009). Individuals with a body mass index (BMI) of 30-35 and > 40,
have a 2-fold and 3-fold increased risk of cancer of the gastroesophageal
junction, respectively, when compared to individuals with a BMI of < 25
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(Hoyo et al., 2012). The biochemical mechanisms linking obesity to cancer
include: hyperinsulinemia, increased levels of insulin-like growth factors
(IGF), and altered IGF/IGF-binding protein ratios that promote cell division
and inhibit cell death (Alemán et al., 2014). Additionally, excess body weight
may directly cause gastroesophageal reflux disease, another known risk factor
for gastric cancer (Alemán et al., 2014).
1.1.2.3 Low socioeconomic status
Low socioeconomic status is a well established risk factor for most cancer
types (Ward et al., 2004). Markers of low socioeconomic status, including low
income and low education, are associated with gastric cancer and its precursor
lesions (Eusebi, Zagari, & Bazzoli, 2014). Low socioeconomic groups tend to
have higher rates of H. pylori infection, obesity, and high salt diets, which may
also mediate this relationship (Eusebi et al., 2014; Guggenheim & Shah, 2013).
1.1.2.4 Helicobacter pylori
H. pylori is the strongest known risk factor for gastric cancer and the most
common agent for infection related cancers (Helicobacter and Cancer
Collaborative Group, 2001). In 1994, the International Agency for Research on
Cancer (IARC) and the WHO classified H. pylori as a type-I carcinogen (IARC
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a).
H. pylori is normally acquired in childhood, and without antimicrobial
intervention, can persist for a lifetime. It is estimated that half of the worlds
population is infected with H. pylori , of which 1-3% will consequently develop
gastric cancer (Everhart, 2000; Peek & Crabtree, 2006). It is estimated that
8
65-80% of all gastric cancer cases are caused by a H. pylori infection
(Helicobacter and Cancer Collaborative Group, 2001).
The association between H. pylori infection and gastric carcinoma is not fully
understood. It is thought H. pylori induces chronic gastric inflammation,
which can lead to mucosal atrophy, metaplasia, dysplasia, and in some cases,
carcinoma (Correa, 1992). H. pylori infection significantly increases the risk of
developing both diffuse-type and intestinal-type gastric adenocarcinoma;
however, only the intestinal-type is linked to chronic inflammation, suggesting
that a different mechanism is required for the development of diffuse-type
disease (Polk & Peek, 2010).
Certain strains of H. pylori positive for specific virulence factors are more likely
to cause gastric cancer. One virulence factor that clearly influences gastric
cancer risk is the cytotoxin-associated gene A (CagA) pathogenicity island
(Parsonnet et al., 1991). When compared to an uninfected person,
CagA-positive H. pylori are associated with a 5.8-fold increased risk of
developing gastric cancer. In comparison, CagA-negative stains have a
reduced 2.2-fold increased risk (Parsonnet, Friedman, Orentreich, &
Vogelman, 1997). Another virulence factor strongly linked to an increased
gastric cancer risk is the VacA toxin, encoded by the vacA gene (Boquet &
Ricci, 2012). All H.pylori possess vacA; however, there is considerable variation
in the 5’ of the gene, for which only certain alleles are associated with a higher
gastric cancer risk (Parsonnet et al., 1997). H. pylori strains containing the s1
and m1 alleles are associated with a particularly high risk of cancer. Notably,
H. pylori strains with multiple virulence factors are at a greater risk compared
to strains lacking these factors (Cover & Peek, 2013).
The risk of gastric cancer is not only influenced by H. pylori strain specific
virulence factors, but also by host and environmental factors. As previously
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described, diets high in salt increase the risk of developing gastric cancer
(Section 1.1.2.1). Markedly, H. pylori infections appear to synergise with
high-salt diets to further increases gastric cancer risk, relative to those who
consumed less salt (Lee et al., 2003; Tsugane & Sasazuki, 2007). The association
between H. pylori and gastric cancer risk is supported by animal models, for
which both Mongolian gerbils and IL-10 deficient mice infected with H. pylori
and fed a high salt diet have shown increased incidence of gastric cancer
(Gamboa-Dominguez et al., 2007; J. Park et al., 2014). Although the mechanism
causing this effect is not fully understood, recent work has shown that both
cagA and vacA are upregulated when H. pylori is cultured in a media with a
high salt content (Gancz, Jones, & Merrell, 2008; Loh, Torres, & Cover, 2007),
suggesting these virulence factors are important. Additionally, host genetic
factors can influence the immune and inflammatory response to H. pylori
infection and contribute to carcinogenesis. For example, polymorphisms in the
human interleukin-1 gene cluster enhance production of interleukin-1-beta
(IL-1beta) in response to H. pylori infection and create favourable conditions
for carcinogenesis (El-Omar, Carrington, Chow, & McColl, 2000). It is likely
that both host and environmental factors explain why some individuals
infected with H. pylori develop gastric cancer, while others do not.
1.1.2.5 Family history
Familial aggregation occurs in approximately 10% of gastric cancers and is
significantly associated with an increased risk of disease (Yaghoobi, Bijarchi, &
Narod, 2010). In most populations, having a first-degree relative with gastric
cancer increases the risk of developing gastric cancer by between 1.5 and
3.5-fold (Yaghoobi et al., 2010). Shared environmental exposures, such as H.
pylori infections or a common diet could also all explain this increased familial
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risk. Alternatively, low penetrance genetic variants or a pathogenic variant in
a gene associated with a highly penetrant cancer susceptibility syndrome
could explain the aggregation of cancers within these families (Lynch, Grady,
Suriano, & Huntsman, 2005).
1.1.2.6 Alcohol consumption
A relation between alcohol consumption and gastric cancer risk is biologically
plausible. Heavy alcohol consumption could cause gastric inflammation and
chronic gastritis, which could increase gastric cancer risk (Franceschi &
La Vecchia, 1994). In 1988, the IARC concluded that there was inadequate
evidence for alcohol to be classified as a risk factor for gastric cancer
(International Agency for Research on Cancer and World Health Organization,
1988). In 2007, the IARC reviewed the evidence and concluded that there were
suggestions that alcohol consumption might be associated with an increased
risk (Tramacere et al., 2011). Recently, in a meta-analysis of 44 case-control and
15 cohort studies, there was a risk associated with moderate alcohol drinking
(≤ 4 drinks per day; RR 1.07, 95% CI 1.01-13), and a stronger association with
heavy alcohol consumption (> 4 drinks per day; RR 1.20, 95% CI 1.01–1.44)
(Tramacere et al., 2011). The study by Tramacere et al. (2011) suggests that
alcohol is a modest risk factor for gastric cancer, however, confounding effects
due to dietary habits and H.pylori infections could not be ruled out (Tramacere
et al., 2011).
1.1.2.7 Smoking
Smoking is a well established risk factor for multiple cancer types. Despite
this, it wasn’t until 2002 that the IARC classified smoking as a risk factor for
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gastric cancer (IARC Working Group on the Evaluation of Carcinogenic Risks
to Humans, 2010b). The reason for the delay, in part, is due to inconstancies in
the relationship between smoking and gastric cancer risk between studies.
While most studies have reported a small risk (less than two-fold increased
risk), some studies had reported no risk (Kelley & Duggan, 2003). A recent
meta-analysis of cohort studies concluded that when compared to ’never
smokers,’ the relative risk for male and female smokers was 1.62 (95% CI
1.50–1.75) and 1.20 (95% CI 1.01–1.43), respectively (Ladeiras-Lopes et al.,
2008). Trend estimation analysis by Ladeiras-Lopez et al, (2008) found that the
relative risk of gastric cancer increased from 1.3 to 1.7 for low and high
consumption of cigarettes, respectively (Ladeiras-Lopes et al., 2008).
1.1.2.8 Other Risk Factors
Numerous other factors have been proposed to increase gastric cancer risk.
However, evidence for these risk factors is limited and sometimes
contradictory. Other risk factors include: exposure to radiation
(D. E. Thompson et al., 1994), blood-type A (Aird, Bentall, & Roberts, 1953),
prior gastric surgery (Stalnikowicz & Benbassat, 1990), and infection with
Epstein-Barr virus (Shibata & Weiss, 1992). Further research will be required
before these are considered putative gastric cancer risk factors.
1.1.3 Familial Gastric Cancer
Hereditary gastric cancer syndromes, where inherited pathogenic variants are
predisposing to a heightened risk of developing gastric cancer, are thought to
account for between 1-3% of all gastric cancers. These syndromes predispose
affected individuals to an extreme risk of developing gastric cancer, and may
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also cause the early-onset of the disease. There are three main gastric cancer
syndromes: hereditary diffuse gastric cancer (HDGC), familial intestinal
gastric cancer (FIGC), and gastric adenocarcinoma and proximal polyposis of
the stomach (GAPPS). Furthermore, gastric cancers have been identified as a
part of the tumour spectrum in several other hereditary cancer syndromes.
The considerable uncertainty associated with hereditary cancer syndromes
makes the identification of genetic factors and families who are at risk of great
importance.
1.1.3.1 Hereditary Diffuse Gastric Cancer (HDGC)
HDGC is an autosomal dominant cancer syndrome primarily characterised by
an extreme risk of developing diffuse gastric cancer. Women with HDGC
syndrome have an additional risk of developing lobular breast cancer (van der
Post et al., 2015). Familial clustering of diffuse gastric cancer was first reported
in 1964 (Jones, 1964), however it wasn’t until 1998 when a genetic basis for the
disease was identified for the syndrome to be recognised (Guilford et al.,
1998). In 1999 the International Gastric Cancer Linkage Consortium (IGCLC)
proposed the first clinical criteria for the recommended screening of CDH1
(Caldas et al., 1999). In 2010, and again in 2015, as more about this syndrome
was discovered and the cost of sequencing declined, the criteria were relaxed
to include more families that may be at risk (Fitzgerald et al., 2010; van der
Post et al., 2015). The current 2015 criteria for HDGC include: (1) families with
two or more patients with gastric cancer at any age, one confirmed diffuse
gastric cancer; (2) individuals with diffuse gastric cancer before the age of 40;
and (3) families with diagnoses of both diffuse gastric cancer and lobular
breast cancer (one diagnosis before the age of 50) (van der Post et al., 2015).
Additionally, the 2015 criteria identified families whom may benefit from
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testing as: (1) patients with bilateral or familial lobular breast cancer before the
age of 50; (2) patients with diffuse gastric cancer and cleft lip/palate; and (3)
those with precursor lesions for signet ring cell carcinoma (van der Post et al.,
2015).
Pathogenic germline variants in the E-cadherin gene CDH1 are responsible for
approximately 40% of families that meet the clinical criteria for HDGC
(Hansford et al., 2015). More than 120 HDGC families with pathogenic CDH1
variants have been described in published literature (Hansford et al., 2015),
although there are more than 500 known HDGC families worldwide (P.
Guilford, personal communication). An explanation of the remaining 60% of
HDGC cases remains largely elusive. Germline variants in the α-catenin gene
CTNNA1 have been identified in a small number of HDGC families, but do not
appear to be common (Hansford et al., 2015; Majewski et al., 2013; Schuetz et
al., 2012). A small number of additional candidate genes have been identified
(described in detail in Section 1.1.4.3), but still require further validation before
they can be considered putative HDGC genes.
1.1.3.2 Familial Intestinal Gastric Cancer (FIGC)
Guidelines for the classification of FIGC include: (1) intestinal gastric cancer in
two or more first or second degree relatives, with at least one confirmed case
of intestinal pathology diagnosed before age 50; and (2), intestinal gastric
cancer in three or more first or second degree relatives, independent of age
(Kluijt et al., 2012). The few cases of FIGC that have been documented have
shown an autosomal dominant inheritance pattern (Caldas et al., 1999; Kluijt
et al., 2012). Aggregates of FIGC are believed to be a combination of both
genetic and environmental factors, with any genetic cause yet to be identified
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(Kluijt et al., 2012). Currently no clinically relevant recommendations are
available for the management of FIGC families (Kluijt et al., 2012).
1.1.3.3 Gastric Adenocarcinoma and Proximal Polyps of the Stomach
GAPPS is characterised by the autosomal dominant transmission of fundic
gland polyposis (including dysplastic lesions and intestinal-type gastric
adenocarcinoma, or both) that are restricted to the proximal stomach, with no
evidence of duodenal or colorectal polyposis (Worthley et al., 2012). Clinical
criteria from GAPPS include: (1) gastric polyps restricted to the body of the
fundus with no evidence of colorectal or duodenal polyposis; (2) more than
100 polyps in the index case or more than 30 polyps in a first degree relative of
another case; (3) mainly fundic gastric polyps, some with regions of dysplasia;
(4) an autosomal dominant pattern of inheritance; and (5), exclusion of other
heritable gastric polyposis syndromes. Recently, specific variants in the APC
promoter 1B were found to be a cause of GAPPS in six families (J. Li et al.,
2016).
1.1.3.4 Other hereditary cancer syndromes
Hereditary cancer syndromes can predispose to cancer at a large set of
different body sites. Gastric cancer is recognised as a part of some specific
cancer syndromes. These syndromes are detailed below:
Lynch syndrome is a highly penetrant colorectal cancer syndrome. Mismatch
repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) are frequently
mutated, causing microsatellite instability and mismatch repair deficiency
(Rahner et al., 2010). While Lynch syndrome predominantly predisposes to
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colorectal and endometrial cancers, it is estimated that 1.6% of all Lynch
syndrome patients will develop gastric cancer, typically of the intestinal-type
(Capelle et al., 2010). Strikingly, patients whom carry pathogenic variants in
specific Lynch syndrome associated genes have a much greater risk of the
developing gastric cancer. For example, individuals with a germline defect in
MLH1 or MSH2 have a 4.8% and 9.0% risk of developing gastric cancer,
respectively (Capelle et al., 2010). Gastric surveillance is recommended for
patients diagnosed with Lynch syndrome (Capelle et al., 2010).
Li-Fraumeni syndrome is an autosomal dominant inherited cancer
predisposition syndrome that predisposes to a wide range of tumour types.
Cancers associated with Li-Fraumeni syndrome typically present with an
early-onset (< 45 years of age) (Malkin et al., 1990). Pathogenic germline
variants in the DNA repair gene TP53 have been identified in approximately
70% of cases whom fit the clinical criteria for Li-Fraumeni syndrome (Malkin
et al., 1990). While sarcomas, breast carcinomas, brain tumours, and leukemia
are most common, gastric cancer represents 1.8-4.9% of cancers in Li-Fraumeni
syndrome families (Masciari et al., 2011). Furthermore, 40% of families with a
pathogenic TP53 variant will have at least one family member diagnosed with
gastric cancer (Malkin et al., 1990; Masciari et al., 2011). Currently, both
intestinal- and diffuse-type gastric cancers appear to be associated with
Li-Fraumeni syndrome (Masciari et al., 2011).
Familial adenomatous polyposis (FAP) is caused by pathogenic germline
APC variants and is characterised by early-onset colorectal cancer with colonic
and rectal adenomas (Lipton & Tomlinson, 2006). Adenomas can also develop
in the upper gastrointestinal tract, and if left untreated, can progress to
malignant disease. Gastric fundic gland polyps and adenomas in the atrum of
the stomach can also occur (Lipton & Tomlinson, 2006). Gastric
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adenocarcinomas in FAP are generally thought to arise from fundic gland
polyps (Spigelman, Talbot, Williams, Domizio, & Phillips, 1989; Vasen et al.,
2008). Notably, the risk of gastric cancer in these families is not much higher
than the general population (Vasen et al., 2008).
Peutz-Jeghers syndrome (PJS) is primarily caused by pathogenic variants in
the gene STK11. PJS is characterised by the development of hamartomatous
gastrointestinal polyps with mucocutaneous pigmentation, and an increased
risk of gastrointestinal and breast cancers at a young age (Utsunomiya, Gocho,
Miyanaga, Hamaguchi, & Kashimure, 1975). After small intestine and
colorectal carcinoma, gastric cancer is the third most common tumour in PJS
(Chun & Ford, 2012). Meta-analysis suggests a cumulative risk of gastric
cancer for pathogenic variant carriers of 29% by the age of 65 years. Increased
surveillance is recommended for these families (Van Lier et al., 2010).
Juvenile polyposis syndrome (JPS) is characterised by numerous juvenile
polyps developing in the colon and/or stomach. It is an autosomal dominant
syndrome that is caused by pathogenic variants in several different genes,
most commonly SMAD4 and BMPR1A (Allen & Terdiman, 2003). Gastric
cancer develops in 21% of patents who are affected by gastric polyps (Howe et
al., 2004). Regular surveillance and screening is recommended for patients
from an early age or when symptoms of polyps present (Allen & Terdiman,
2003; Howe et al., 2004).
Familial breast and ovarian cancer syndrome is predominantly caused by
pathogenic germline BRCA1 and BRCA2 variants and predisposes women to
both breast and ovarian cancer (Breast Cancer Linkage Consortium, 1999).
Pathogenic variants in BRCA1 and BRCA2 also predispose both women and
men to an increased risk of gastric cancer (Friedenson, 2004). A large
meta-analysis study has shown the average relative risk of gastric cancer is
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Figure 1.1: The E-cadherin protein. The CDH1 gene maps to chromosome
16q22.1 and consists of 16 exons. The CDH1 gene encodes the 120-kDa protein
E-cadherin. This protein has three major components: signal peptide
consisting of 27 amino acids encoded by exons 1 and 2 (purple), precursor
peptide consisting of 154 amino acids encoded by exons 2 to 4 (red), and
mature protein containing 728 amino acids encoded by exons 4 to 16. The
mature protein segment has an extracellular domain that includes exons 4–13
(orange), a smaller transmembrane domain that includes exons 13 and 14
(green), and a cytoplasmic domain that comprises exons 14–16 (blue).
collectively higher for BRCA1 and BRCA2 pathogenic variant carriers, first
degree relatives of pathogenic variant carriers, women that have had a breast
cancer diagnosis, and woman that meet the clinical criteria for BRCA1 and
BRCA2 sequencing (RR = 1.69; 95% CI 1.21-2.38) (Friedenson, 2004). Currently,
it is not known if a particular histological subtype is associated with familial
breast and ovarian cancer syndrome (Jakubowska et al., 2003).
1.1.4 The cell adhesion molecule E-cadherin (CDH1)
The human E-cadherin gene CDH1 is located on chromosome 16q22.1 and
belongs to a family of genes encoding calcium-dependent cell-adhesion
molecules. The CDH1 gene comprises 16 exons and spans a region of
approximately 100 kb (Figure 1.1). CDH1 is tightly regulated and has a high
density CpG island regulatory region in intron 1 (Berx et al., 1995).
The E-cadherin protein is composed of three main parts: a large extracellular
domain, comprised of five tandem repeats that contains sites with adhesive
activity for forming bonds with E-cadherin on opposing cells; a small
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transmembrane segment, that binds p120-catenin and supports cadherin
clustering and adhesive strength between cells; and a short cytoplasmic tail,
that binds beta-catenin and interacts with the actin-cytoskeleton via a protein
complex with α-catenin (Weber, Bjerke, & DeSimone, 2011) (Figure 1.2).
E-cadherin is expressed very early in development and is important for the
differentiation and polarisation of cells (Papusheva & Heisenberg, 2010).
Animal models heterozygous for mutated E-cadherin show normal
development, while animals homozygous for mutated E-cadherin show severe
developmental abnormalities that are lethal during embryonic development
(Larue, Ohsugi, Hirchenhain, & Kemler, 1994). E-cadherin is one of the most
important molecules for cell-cell adhesion in normal epithelial tissue, where it
is predominantly expressed at the basolateral membrane of epithelial cells and
is an essential part of the adherens junction (Vleminckx, Vakaet, Mareel, Fiers,
& Van Roy, 1991). In addition to its primary roles in the structure and
maintenance of adherens junctions, there is strong evidence that E-cadherin
mediates complex interactions between signalling pathways that establish and
maintain cell-polarity, migration, proliferation, differentiation, and apoptosis
(Van Roy & Berx, 2008).
1.1.4.1 E-cadherin and cancer
The E-cadherin gene CDH1 is a well established tumour suppressor
(Vleminckx et al., 1991). Loss of E-cadherin is associated with malignant
transformation and tumour progression (Jeanes, Gottardi, & Yap, 2008).
E-cadherin negative tumours are often characterised by major changes in the
organisation of the cytoskeleton, loss of adhesion, and abnormal










Figure 1.2: A schematic diagram of the E-cadherin, beta-catenin and α-catenin
complex. Opposing E-cadherin extracellular domains bind to one another via
calcium-dependent dimerisation. Intracellular E-cadherin domain binds to
beta-catenin which complexes with α-catenin and the actin cytoskeleton.
aberrations in the CDH1 gene and subsequent loss of functional E-cadherin is
a feature of many epithelial tumours, including prostate, ovarian, and lung
carcinomas; and is the hallmark of both the sporadic and familial forms of
diffuse gastric cancer and lobular breast cancer (Van Roy & Berx, 2008).
Consistent with classical tumour suppressor activity, a two-hit mechanism
often occurs in tumours, mutating or down-regulating both copies of CDH1,
for a complete loss of functional E-cadherin (Grady et al., 2000; Oliveira, de
Bruin, et al., 2004). Tumours with loss of E-cadherin sometimes undergo an
epithelial-mesenchymal transition (EMT), characterised by the altered
expression of transcription factors, cell surface receptors, and cytoskeletal
proteins. An EMT causes epithelial cells to take on a mesenchymal phenotype,
that enhances their migration, invasion, and resistance to apoptosis (Onder et
al., 2008; Tiwari, Gheldof, Tatari, & Christofori, 2012).
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1.1.4.2 Germline CDH1 and HDGC
As previously described, pathogenic variants in germline CDH1 are associated
with an extreme risk of developing diffuse gastric cancer and explain
approximately 40% of families that meet the clinical criteria for HDGC
(Hansford et al., 2015). More than 120 pathogenic CDH1 variants have been
identified across all coding regions of CDH1 and do not appear to be restricted
to any particular functional domain of the E-cadherin protein (Hansford et al.,
2015). Strikingly, three pathogenic variants (c.1137G>A, c.1565+1G>A, and
c.1792C>T) have been found in multiple families from seemingly unrelated
backgrounds, raising the possibility of variant hotspots (Hansford et al., 2015).
Geographically, the frequency of reported pathogenic variants in germline
CDH1 varies substantially between low-incidence and middle/high-incidence
areas. In a recent meta-analysis describing 122 pathogenic germline CDH1
variants, 94 (77.0%) were described in low-incidence areas, 16 (13.1%) were
described in middle/high-risk incidence areas, and 9.9% were without
ethnicity information (Corso, Marrelli, Pascale, Vindigni, & Roviello, 2012).
The large enrichment of pathogenic variants from low-incidence areas
suggests that pathogenic germline CDH1 variants are rarely identified in
middle/high-incidence areas (Corso et al., 2012). It is likely that in these
middle/high-incidence areas, true HDGC families are lost in a background of
family clusters caused by a shared environmental factors.
The stomachs of CDH1 germline variant carriers contain multifocal, stage T1a
signet-ring cell carcinomas, that are generally indolent but can show an
unpredictable tendency towards progression (Blair, 2012). Nearly all stomachs
from pathogenic CDH1 variant carriers who have undergone total
gastrectomies have multiple foci of stage T1a signet-ring cell carcinomas (Blair,
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2012). The number of foci observed per patient is highly variable. The average
number of foci ranged between 2 and 487 per family when multiple members
of different HDGC families have had their foci number determined (Blair,
2012; Charlton et al., 2004). Foci are typically less than 1 mm in diameter but
can be as large as 10 mm (Charlton et al., 2004). In some families, the transition
zone of the stomach have the greatest number of signet-ring cell carcinomas
(Charlton et al., 2004), however this is not always the case (Rogers et al., 2008).
The great variability in the number, size, and location of foci suggests that
background genetics or environmental exposures are important in the
progression of these tumours.
The trigger for the initial development of these cancer foci is downregulation
of the second CDH1 allele (Humar & Guilford, 2009). It is hypothesised that
the loss of E-cadherin expression disrupts the normal orientation of the mitotic
spindle, allowing a proportion of epithelial cells to divide out of the normal
epithelial cell plane of division and invade the lamina propria (Humar &
Guilford, 2009). It has been proposed a proportion of the foci of signet-ring
cells that make it to the the lamina propria are transient, while others undergo
an EMT and progress (P. Guilford, personal communication). The EMT in
early HDGC is often incomplete, with some cells retaining expression of some
epithelial cell markers (Humar et al., 2007). Mesenchymal-like morphology
can be seen in some of the larger early lesions and is a dominant feature of all
tumour stages beyond T1a (Humar et al., 2007). The shift to the mesenchymal
cell type correlates with the activation of the EMT-inducer c-SRC and its
downstream targets (Humar et al., 2007).
The average age of onset for HDGC is approximately 38 years, but has affected
some as young as 14 years of age (Guilford et al., 1998; Hansford et al., 2015).
Recent penetrance analysis of HDGC families with pathogenic germline CDH1
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variants have estimated the cumulative risk of developing diffuse gastric
cancer by the age of 80 years is 70% for men (95% CI 59%-80%) and 56% for
women (95% CI 44%-69%). In addition, women carry a 42% (95% CI 23%-
68%) cumulative risk of developing lobular breast cancer by the age of 80
years (Hansford et al., 2015). The variable penetrance is not well understood
and it is likely that both environmental and genetic factors act as modifiers of
risk in these families.
Families found to meet the clinical criteria for HDGC are recommended to
undergo genetic screening for CDH1 variants (van der Post et al., 2015). If a
pathogenic CDH1 variant is found, unaffected relatives may be offered genetic
counselling services and subsequent testing for risk stratification. Genetic
counselling for pathogenic variant carriers is extensive and tailored to the
individuals age, sex, and nutritional issues (Kluijt et al., 2012). Those found to
carry a pathogenic CDH1 variants are offered a total prophylactic gastrectomy,
a radical procedure with high morbidity that removes the risk of disease.
Alternatively, pathogenic variant carriers can elect for regular endoscpoic
screening to survey the stomach for early stage foci. Currently, it is still very
difficult to detect diffuse gastric cancer at its earliest stages using endoscopic
screening making prophylactic gastrectomy the recommended procedure for
individuals with a strong family history. The recommended age for
prophylactic gastrectomy surgery for CDH1 variant carriers is greater than 20
years (van der Post et al., 2015).
1.1.4.3 Beyond CDH1 variation as a cause of HDGC
For families that meet HDGC criteria but don’t carry a pathogenic variant in
CDH1, there is major uncertainty in how to best manage risk and identify
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those who would benefit from intervention. In a recent study of CDH1
variant-negative families, analysis of 55 genes associated with HDGC and
other gastrointestinal cancer syndromes revealed candidate variants in 11% of
probands. Pathogenic variants were found in genes of high and moderate
penetrance including ATM, BRCA2, CTNNA1, MSR1, PALB2, PRSS1, SDHB,
and STK11 (Hansford et al., 2015).
Of particular interest were the variants in α-catenin (CTNNA1), that have now
been observed in multiple families that meet HDGC criteria (Hansford et al.,
2015; Majewski et al., 2013). α-catenin is also a part of the cadherin-catenin
complex at the cell membrane, suggesting that a similar mechanism may be
responsible for the progression of disease in these families. Early studies that
have screened α-catenin in HDGC families did not discover a large number of
pathogenic variant carriers, suggesting CTNNA1 is not a common HDGC gene
(Schuetz et al., 2012). Unfortunately, there is currently insufficient data to
determine the penetrance of CTNNA1 variants. The most recent clinical
guidelines for HDGC families now include sequencing of CTNNA1 as an
option for CDH1 variant-negative families (van der Post et al., 2015).
Additional studies have implicated a small number of genes as directly
predisposing to HDGC. A variant in the mitogen-activated protein kinase
kinase kinase 6, encoded by the gene MAP3K6, was identified in one large
family with a history of diffuse gastric cancer (Gaston et al., 2014). In analysis
of further CDH1 variant-negative HDGC families, an additional five variants
in six unrelated families were identified (one nonsense and four missense). In
another family with a strong history of diffuse gastric cancer, rare variants in
the genes DOT1L, FBXO24, and INSR were identified. While these gene
variants may be of importance to these families, further research will be
required before they are able to guide clinical intervention. These studies and
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genes are discussed in greater detail in Chapter 5 Section 5.1.2.
Regulation of E-cadherin by unspecific defects at the CDH1-locus may also
explain HDGC in some families. Under normal conditions CDH1 is
biallelically expressed (Gimelbrant, Hutchinson, Thompson, & Chess, 2007),
however in tumours occurring in patients with a pathogenic germline CDH1
variant, CDH1 expression is monoallelicly expressed or completely absent
(Pinheiro et al., 2010). Interestingly, in a study of germline RNA extracted from
peripheral blood lymphocytes from cancer-free, HDGC CDH1 variant-positive,
and HDGC variant-negative probands, CDH1 showed biallelic expression in
all cancer free samples, and irregular mono-allelic expression in 80% and 71%
of variant positive and negative probands, respectively (Pinheiro et al., 2010).
The study by Pinheiro et al. suggests that some sort of non-coding variant or
other yet to be identified regulatory element could be impairing the regulation
of E-cadherin in some CDH1 variant-negative families.
1.1.5 Next-Generation Sequencing (NGS)
Prior to the advent of NGS, human genomics was primarily concerned with
the characterisation of single genes and relied largely on linkage-analysis with
subsequent candidate gene selection. With NGS, it became possible to
sequence entire genomes and survey for genetic aberrations that may be
responsible for inherited syndromes, disease, and cancer. NGS has
revolutionised the field of genetics, creating a paradigm of using genetic
sequencing to address biological questions at a genome-wide scale.
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1.1.5.1 Advances in sequencing technologies
In 1977, Frederick Sanger developed the first rapid DNA sequencing technique
(Sanger, Nicklen, & Coulson, 1977). Known as the Sanger’s dideoxy
chain-termination sequencing method, this technique incorporates
fluorescently labelled chain-terminating dideoxynucleotides into DNA
extension reactions, that when separated by size, can be used to determine a
genetic sequence (Sanger et al., 1977). The dideoxy chain-termination method,
hereinafter referred to as Sanger sequencing, revolutionised genetics and was
the most widely used sequencing method for nearly 40 years.
In the mid 2000s, Sanger sequencing was exceeded by next-generation
sequencing technology (Mardis, 2008). Instead of inferring nucleotide identity
by fluorescent labels, NGS utilises pyrophosphate synthesis to detect
nucleotides as they are incorporated in real time (Metzker, 2010). In the first
NGS machines, libraries of DNA molecules were attached to beads that
underwent a water-in-oil PCR reaction. These DNA coated beads were
washed over a plate of microscopic wells only large enough to hold a single
bead, and were sequenced in parallel (Metzker, 2010). Later, several new
parallel sequencing techniques were developed. Of the new technologies,
bridge amplification excelled. For this, adapter bracketed DNA libraries are
passed over complementary oligonucleotides attached to a flow cell (Metzker,
2010). The single-stranded sequences are amplified in a solid phase PCR to
produce millions of dense double-stranded clusters that can be detected using
sensitive cameras (Metzker, 2010). NGS revolutionised the sequencing process
by using array-based systems that allow millions of small DNA fragments to
be sequenced in parallel, greatly increasing the yield of sequencing efforts.
NGS technology was initially used to study whole genomes, including both
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coding and non-coding regions. However, the amount of data generated by
whole-genome sequencing can be difficult to manage and is frequently
superfluous to requirements. Because of this, a variety of targeted sequencing
approaches that address defined regions of the genome have been developed.
Currently, there are two main techniques used to target specific regions of the
genome (Koboldt, Steinberg, Larson, Wilson, & Mardis, 2013). The first is by
PCR, typically involving multiplexed primer pairs that are designed to target
specific regions of DNA. Following amplification of targeted regions,
platform-specific adapters are added to each end of the PCR products to form
a library suitable for sequencing. The second approach involves hybrid
capture, for which probes are designed to bind selected regions of DNA and
are captured using magnetic beads. Hybrid capture is commonly used to
capture all known coding regions of the genome in an approach referred to as
’exome capture’ (Koboldt et al., 2013). Alternatively, a panel of probes can be
synthesised to target specific regions of DNA in a ’targeted panel.’ Targeting
NGS is an efficient strategy for uncovering pathogenic variants that are
attributable to rare hereditary syndromes, such as hereditary cancers, but are
limited to genes and variants that have previously been associated with risk.
Along with the advances in the sequencing technology and target enrichment
strategies, multiplexing has revolutionised the efficiency of sequencing.
Multiplexing allows for the pooling of multiple samples into a single
sequencing reaction, cutting the costs and time associated with separate
sequencing reactions (Elshire et al., 2011; Smith et al., 2010). For multiplexing,
unique sample-specific sequence indices are included in adapters used during
library preparation, making the origin of each strand of DNA identifiable.
Being able to trace DNA to a sample of origin enables the sequencing of
accumulated samples in a single sequencing reaction. Multiplexing is proving
to be the most effective way to classify recurrent variants in large cohorts,
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when large numbers of samples and regions of interest can be sequenced in a
single reaction.
1.1.5.2 Utilising NGS for HDGC gene discovery
A genomic era of research is developing rapidly. In particular, the field of
cancer genomics has been impacted profoundly by the application of NGS
technology (McKenna et al., 2010). NGS has accelerated the pace of gene
discovery while dramatically reducing the cost of data production, enabling
remarkable advances in our understanding of the somatic and germline
variant profiles of cancer genomes. Hence, there has been a rapid progression
from using traditional Sanger sequencing, to either targeted, or whole-genome
sequencing using these massively parallel sequencing platforms. There still
remains significant challenges in understanding HDGC, but our fundamental
understanding of which genes are frequently mutated in cancer cells, the
pathways that are impacted by these variants, and how these contribute to
cancer biology, will undoubtedly mature as a result.
Pathogenic germline variants in CDH1 are a well established cause of HDGC.
However, for approximately 60% of families that fit the clinical criteria for
HDGC, a genetic cause remains elusive (Hansford et al., 2015). NGS has
assisted in the identification of a small number of genes that may be
predisposing in some families (Section 1.1.4.3), however the majority of CDH1
variant-negative families are still unexplained. As the cost of sequencing
continues to drop, it is increasingly feasible to address some of the questions
surrounding HDGC. Families and populations who appear to be at a high-risk
of HDGC can be examined for genetic variants that may be predisposing to
disease.
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1.2 Thesis aims and outline
The principal aim of this thesis was to develop a greater understanding of the
genetic factors that increase diffuse gastric cancer risk. To address this, I have
used NGS and bioinformatic tools to identify predisposing germline variants
that are carried by gastric cancer patients. This thesis includes three results
chapters, each identifying and assessing predisposing germline variants in
different study groups, and providing distinctive insights into different
aspects of hereditary gastric cancer risk and management.
Chapter 3 describes the investigation of pathogenic germline CDH1 variants
as a cause of the high incidence of diffuse gastric cancer in New Zealand
Māori. This chapter examines both rare variants and common polymorphisms
in germline CDH1. In Chapter 3, I also discuss the impact genetic screening for
CDH1 variants has had on the New Zealand Māori gastric cancer population.
Chapter 4 explores pathogenic CDH1 variants as a cause of cancer in a cohort
of Chilean gastric cancer patients that presented with a striking family history
or early-onset disease. This chapter provides a direct insight into the
importance of screening for germline CDH1 variants, as well as the application
of HDGC testing criteria in identifying gastric cancer patients in a
high-incidence population such as Chile.
Chapter 5 expands the search for predisposing germline variants beyond
CDH1. In this chapter, whole-exome sequencing is used to identify rare
germline variants carried by CDH1 variant-negative diffuse gastric cancer
patients that fit the clinical criteria for HDGC. This chapter identifies variants
in genes that are associated with increased gastric cancer risk, as well as genes
that have not previously been linked to diffuse gastric cancer risk. The
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findings from Chapter 5 have implications for future HDGC studies and the
clinical screening and management of gastric cancer patients.
Finally, Chapter 6 discusses the results from the preceding chapters in relation
to the biggest challenges for improving the screening and management of






Agarose - AppliChem, USA
Agencourt AMPure XP beads - Beckman Coulter, USA
dsDNA High Sensitivity Assay Kit - Thermo Fisher, USA
Ethidium Bromide - Merck, USA
GF–1 Nucleic Acid Extraction Kit - Vivantis, Malaysia
Kapa Hotstart Readymix with dye - Kapa Biosystems, South Africa
Kapa HiFi Hotstart Readymix with dye - Kapa Biosystems, South Africa
Kapa Robust Hotstart Readymix with dye - Kapa Biosystems, South Africa
Kapa Universal Ladder - Kapa Biosystems, South Africa
MiSeq Reagent Nano Kit, v2 (300 cycles) - Illumina Inc., USA
MiSeq Reagent Nano Kit, v2 (500 cycles) - Illumina Inc., USA
MiSeq Reagent Kit v2 (500cycle) - Illumina Inc., USA
MiSeq Reagent Kit v3 (150cycle) - Illumina Inc., USA
MiSeq Reagent Kit v3 (600cycle) - Illumina Inc., USA
Nextera Expanded Exome Library Preparation Kit - Illumina Inc., USA
SALSA MLPA P083 CDH1 probemix (vC1) - MRC-Holland, Netherlands
Tris-ultrapure - Applichem, USA
TruSeq Exome Enrichment Library Preparation Kit - Illumina Inc., USA
Tween-20 - Sigma-Aldrich, USA
2.0.2 Equipment
ABI 3730xl DNA Analyser - Thermo Fisher, USA
Agilent 2100 Bioanalyzer - Agilent Technologies, USA
GelDoc Transilluminator - BioRad, USA
Illumina HiSeq 2000 - Illumina Inc., USA
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Illumina MiSeq - Illumina Inc., USA
Milli-Q Ultrapure Water Purification System - Millipore, USA
Nanodrop ND-1000 Spectrophotometer - Nanodrop Technologies, USA
QubitTM 2.0 Fluorometer - Invitrogen, USA
2.0.3 Software
4peaks (v.1.7.2) - http://nucleobytes.com/4peaks/
Bioanalyzer 2100 (v1.0) Expert Software - Agilent Technologies, USA
Coffalyser - MRC-Holland, Netherlands
Integrative Genomics Viewer (IGV),
http://software.broadinstitute.org/software/igv/
QuantityOne (v.4.6.5), BioRad, USA
R (v3.3.2), https://www.r-project.org/
2.0.4 Online tools
BLAST 2 Sequences - http://www.ncbi.nlm.nih.gov/tools/primer-blast/
CBioPortal - Gao et al. (2013), http://www.cbioportal.org/
PrimerBlast - NCBI, http://www.ncbi.nlm.nih.gov/
Primer3 - Untergasser et al. (2012), http://www.simgene.com/Primer3/
KEGG - Kanehisa Laboratories, Japan, http://www.kegg.jp/
Reactome - Croft et al. (2013), http://www.reactome.org/
2.0.5 Bioinformatic tools
AnnoVar (v.2015Dec14) - http://annovar.openbioinformatics.org/
Burrows-Wheeler Aligner (v0.7.7) - http://bio-bwa.sourceforge.net/
33
FastQC (v0.10.1) - http://bioinformatics.babraham.ac.uk/projects/fastqc/
Genome Analysis Toolkit (v3.2-2) - https://software.broadinstitute.org/gatk/
Picard (v1.109) - https://broadinstitute.github.io/picard/
SNPEff (v4.1) - http://snpeff.sourceforge.net/SnpEff.html
SNPSift (v4.1) - http://snpeff.sourceforge.net/SnpSift.html
Trimmomatic (v0.33) - https://github.com/timflutre/trimmomatic
2.0.6 In silico prediction tools
Condel - http://bg.upf.edu/fannsdb/
SIFT - http://sift.jcvi.org/
Polymorphism Phenotyping v2 (PolyPhen2) -
http://genetics.bwh.harvard.edu/pph2/
MutationAssessor (Release 3) - http://mutationassessor.org/r3/





Human Splicing Finder (v3.0) - http://www.umd.be/HSF3/
2.0.7 R packages
ggplot2 (v2.2.1) - (Wickham, 2016)
SNPassoc (v1.9.2) - (González et al., 2007)
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2.1 General laboratory protocols
2.1.1 DNA quantification
DNA and PCR products were quantified using either the NanoDrop ND-1000
Spectrophotometer (Nanodrop Technologies) or Qubit 2.0 Fluorometer
(Thermo Fisher). The Nanodrop utilises UV absorbance and compares the
ratio of absorbance between 260 nm and 280 nm (260/280) to quantify DNA.
In contrast, the Qubit uses fluorescence-based dyes to bind and quantify DNA.
2.1.1.1 NanoDrop
Tris-EDTA (TE) or mqH20 was used as a blank reading and to calibrate the
instrument before each use. Samples were quantified by loading 2 µL of
sample onto the NanoDrop pedestal and reading the absorbance. The purity
of the DNA was assessed by the A260/280 ratio.
2.1.1.2 Qubit
Samples were quantified using a Qubit dsDNA High Sensitivity Assay Kit and
assay tubes (Thermo Fisher). Qubit working solution was prepared by
diluting Qubit reagent 1:200 in Qubit buffer. Qubit standards were prepared
by mixing 190 µL of working solution with 10 µL of each standard in separate
assay tubes. 2 µL of the sequencing library was mixed with 198 µL of working
solution. All tubes were left to incubate at room temperature for 2 min. The




2% agarose gels were used for resolution of PCR products. The gels were
prepared by dissolving agarose powder (HydraGene) in 1 x Tris acetic acid
EDTA (TAE) buffer containing ethidium bromide (10 mg/mL). Gels were
submerged in 1 x TAE buffer containing ethidium bromide (10 mg/mL). 4 µL
of PCR products were mixed with 1 µL of 6 x DNA loading dye on a piece of
parafilm and loaded into the gel. 4 µL Kapa Universal Ladder (Kapa
Biosystems) was loaded as a size marker in each gel. Gels were run for up to
40 min at 90 V. The products were visualised and photographed under UV




PCR products were resuspended in 5 x their total volume of 100% ethanol
with 0.3 M sodium acetate, and transferred to a spin column and collection
tube. Samples were centrifuged for 1 min at 5000 x g and the supernate
discarded. The DNA was cleaned in two wash steps by adding 200 µL 70%
ethanol and centrifuging at 5000 x g for 1 min. Columns were then centrifuged
at 14000 x g for 3 min to dry the column, and transferred to a new collection
tube. 50 µL of warmed elution buffer (EB) was added to the column and left at
room temperature for 5 min. Finally, the column was centrifuged at 5000 x g
for 1 min. The eluted DNA was stored at 4◦C until used.
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2.1.3.2 Bead clean-up
DNA samples and sequencing libraries were cleaned with Agencourt AMPure
XP beads (Beckman Coulter) according to the manufacturer’s protocol. Briefly,
an aliquot of beads was taken and left to warm to room temperature for 30
min. Samples were resuspended in 1.8 x volume of Ampure beads, incubated
at room temperature for 15 min, and placed upon a magnetic stand until all the
beads had aggregated to one point. The supernatant was carefully removed
and discarded. The beads were washed twice in 200 µL of 70% ethanol and left
to air dry for 15-20 min. The samples were taken from the magnetic stand and
the DNA was resuspended in 40 µL of EB and transferred to a new tube.
2.1.4 Primer design
Primer sets were designed using the open source primer design software
Primer3 (http://simgene.com/Primer3) and checked for off target binding
using the online tool BLAST 2 Sequences
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). When designing
primers, consideration was given to the size, melting temperature, and
formation of hairpins. All primers were ordered from Integrated DNA
Technologies (IDT. Ltd., Singapore) and reconstituted in 1 x TE to a stock
concentration of 100 µM. Aliquots of primer stocks were further diluted with
ddH20 to a working solution of 10 µM. Primers were kept at -20 ◦C until use.
2.1.5 Sanger sequencing
Purified PCR products were sent for sequencing at the Genetic Analysis
Services (GAS; Department of Anatomy, University of Otago). Products were
37
sequenced using a capillary ABI 3730xl DNA Analyser (Thermo Fisher).
Samples were prepared for sequencing by combining 1 ng/100 bp/5 µL of
PCR product with 3.2 pM/5 µL in a total volume of 5 µL.
2.2 Māori case-control study
2.2.1 Cases
All New Zealand Māori diagnosed with gastric cancer (ICD10 C16), based on
histology reports sent to the New Zealand cancer registry (NZCR) between 1
February 2009 and 31 October 2013, were eligible for inclusion in this study.
As the time of registration for gastric cancer can be up to one year post
diagnosis, an additional method for identifying cases was used. For the
identification of additional controls, the pathology reports for all cancer
diagnosis that were sent to the New Zealand Cancer Registry (NZCR) for
confirmation, were also sent to the study centre, where gastric cancer cases
were identified. Ethnicity of each case was identified from the NZCR data that
assigned Māori ethnicity if the person had self-identified as Māori on a
previous health record. The clinician named on the pathology report was
contacted via letter or phone call for permission to contact the patient. Follow
up reminder letters were faxed to the clinician within a two week period.
When consent and contact details were provided, each case was contacted by
post. If no reply was received, two reminder letters were sent.
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2.2.2 Controls
Controls were block samples from the New Zealand electoral roll based on the
age of cases in 5-year age bands. In New Zealand, registration on the electoral
roll is compulsory for all people age 18 years and over. Māori can choose to
enrol on either the ’General’ or ’Māori’ electoral roll. All those who enrol on
the general electoral role are asked to self-identify whether they are Māori of
Māori descent. Māori controls were randomly chosen in equal numbers from
both rolls using the most recent 2008 and 2010 electoral rolls. Due to a large
number of non-responders, an additional database of Māori population-based
controls was used. A control cohort which had been established using the
same methods, whose recruitment period had ended approximately one year
before that of the current study, and whom more recent contact details were
available, were contacted. Controls were sampled from this additional
database, including both those who had, and had not, consented to take part
in the earlier study.
2.2.3 Exposure information
Consenting study participants were given the option of completing a
questionnaire with a trained interviewer face-to-face, returning it by mail, or
completing it over the telephone. The questionnaire comprised of sections on
childhood socioeconomic demographics, household crowding, parent and
sibling cancer history, occupational history, and life course exposures to health
behaviours, such as smoking and exposure to second hand smoke. Age was
defined as the age of diagnosis for cases and the time of interview for controls.
For current exposures, both cases and controls were asked to report their
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lifestyles for the past year including exercise frequency, alcohol intake, as well
as dietary intakes of red meat, white meat, fish and dried/salty food, and
servings of fruit and vegetables per week. Participants were also asked their
height and weight from which body mass index (BMI) was calculated.
Questions regarding diagnosis of diabetes, having ever been tested for H.
pylori, and diagnosed dyspepsia were also included.
2.2.4 Case pathology
Cases were matched to their National Health Index (NHI) number,
corresponding pathology reports, and information reported to the cancer
registry. Pathology reports were reviewed for information regarding tumour
pathology and details related to previous variant screening, prophylactic
gastroectomies and endoscopic screening. Tumour histology classified using
the WHO classification (Bosman et al., 2010) was aligned with the Lauren
classification (Lauren, 1965).
2.2.5 Collection of blood samples
For those completing the interview face-to-face, participants were given the
opportunity to accompany the interviewer to the nearest medical laboratory
for collection of a blood sample. For those unable to do this at the time of
interview, the laboratory staff came to the participants home to collect a
sample, or the collection kit was left with the participant to organise collection
of a sample at their convenience. Once blood samples were taken, they were
couriered directly to Canterbury Health Laboratories (Christchurch, New
Zealand). At the conclusion of the study collection period, blood samples were
sent to relevant institutions and testing facilities for assessment. Blood
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samples were used to assess a variety of gastric cancer associated risk factors,
including H. pylori serology, heritable genetic alterations, antioxidant levels,
and trace elements of heavy metals. The latter information is provided for
completeness; however, only the heritable genetic alterations are being
analysed as a part of this thesis.
2.2.6 Ethical approval
The study was granted ethics approval by the Multi-region Ethics Committee
(ref: MEC/08/08/102/AM03).
2.2.7 DNA extractions
Blood samples were kept frozen at -20◦C for short-term storage and -80◦C for
long-term storage. When a sample was required, the sample was thawed at
room temperature and an aliquot was taken. The aliquot of blood was kept on
ice until used.
Germline DNA was extracted from blood samples using a GF–1 Nucleic Acid
Extraction Kit (Vivantis) according to the manufacturer’s protocol. Briefly, 200
µL of whole blood was mixed with 200 µL of buffer and 20 µL of proteinase K,
and incubated at 65◦C for 15 min. Following this, 200 µL of absolute ethanol
was added and mixed, then the entirety transferred to a GF-1 spin column and
collection tube. The spin column and collection tube were centrifuged at 5,000
x g for 1 min, capturing DNA in the spin column. The DNA was washed by
adding 500 µL of wash buffer 1 to the spin column and centrifuging at 5000 x g
for 1 min. The DNA was then washed a second time by adding 500 µL of wash
buffer 2 to the spin column, and centrifuging at 5000 x g for 1 min. The column
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was washed and dried in a final wash step by adding 500 µL of wash buffer 2
to the spin column and centrifuging at 15,000 x g for 3 min. Finally, the spin
column was placed into a new collection tube and the DNA was eluted in 100
µL of elution buffer (EB) and centrifuged at 5,000 x g for 2 min. Eluted DNA
was stored at 4◦C for short-term storage and -20◦C for long-term storage.
2.3 CDH1 amplicon sequencing library design
To sequence all coding regions and the proximal promoter of the CDH1 gene, I
adapted a two-step PCR strategy used by New Zealand Genomics Limited
(NZGL; Dunedin, New Zealand) and Illumina, that uses two PCR reactions to
create a DNA library suited for sequencing on an Illumina MiSeq.
Targeted PCR reactions amplify the regions of interest in separate reactions.
These PCR reactions are then pooled and amplified in a second reaction using
primers designed to substitute for Illumina sequencing adapters. Both the
forward and reverse primers used in the second PCR reaction were designed
to contain unique indices, the sequences required for binding to an Illumina
flow cell, and the sequences required for the binding of Illumina MiSeq
extension primers. Each sample was amplified using a unique combination of
indices. These steps are summarised in Figure 2.1.
2.3.1 PCR 1: Amplicon specific primer design
Primers were designed to amplify each of the 16 exons and the proximal
promoter of CDH1. Each primer was designed with a targeted sequence and
18 bp of non-specific sequence. The targeted sequence was designed to be
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Index	  
Figure 2.1: Two-step PCR strategy for creating NGS amplicon sequencing
libraries. A schematic diagram of the two-step PCR strategy for generating
sequencing libraries. Locus specific primers amplify region of interest in the
first PCR reaction. PCR products are amplified in a second PCR reaction using
primers which substitute for Illumina sequencing adapters. The primers used
in the second PCR reaction contain unique indices and binding sites for
sequencing primers used by the Illumina MiSeq.
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Figure 2.2: Base diversity of first four sequenced bases. Diversity of the first
four bases sequenced for custom CDH1 amplicon sequencing libraries for the
(A) forward sequencing primers, and (B) reverse sequencing primers.
designed to act as the binding site for primers used in the second PCR
reaction. Each primer pair was designed to produce an amplicon less than 500
bp in length to fit within the capabilities of 500-cycle MiSeq reagent kits.
Fluorescence calibration for base calling occurs during the first four bases of
sequence during a MiSeq run. Consideration was given to the distribution of
bases in these positions to enable the best sequence quality possible. There are
two channels that need to fluoresce at each of these sites: G/T and A/C.
In total, 17 primer pairs were required to cover the coding regions and
proximal promoter of the CDH1 gene. Primers were designed to provide the
best possible distribution of bases in the first four read positions. Amplicon
specific primers are displayed in Appendix A.1. Figure 2.2 shows the
distribution of bases in the forward and reverse primers in the first four read
positions in each direction.
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2.3.2 PCR 2 : Adapter primer design
The primers used in the second reaction were designed as a substitute for the
adapters used in standard TruSeq library preparations. These primers were
based on the standard sequences used for Illumina TruSeq custom amplicon
sequencing, and contain the necessary primer binding sites for pair-end
dual-index sequencing.
The 3’ end of each adapter primer was complementary to the lagging strand of
the non-specific overhang sequence introduced to the products during the first
round of PCR amplification. This meant that any residual primers left after the
first PCR reactions would not bind and inhibit the primers used in the second
PCR reaction. Primers contain the sequences required for sequencing primers
to bind during the sequencing reaction and for flow cell binding.
The same 6 bp indices used in the TruSeq and short RNA sequencing kit
designed by Illumina were used for both the i7 (reverse) and i5 (forward)
adapters. These indices are designed to allow for two miss-incorporations per
index and still have enough redundancy to be unique compared to other
indices. In total, 20 different forward primers and 30 reverse primers were
designed and are listed in Appendix Table A.2 and A.3, respectively.
2.4 Amplicon sequencing and analysis
2.4.1 Amplicon specific PCR
Exonic regions were amplified in 10 µL PCR reactions. As there were large
numbers of reactions required to amplify all 17 amplicons, a pre-made Kapa
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Hotstart Ready Mix with Dye (Kapa Biosystems) was used to reduce the time
required for master mix preparation and handling of samples when visualising
products on an agarose gel. For negative controls mqH20 was substituted for
DNA. Amplicon specific PCR reactions were made as specified in Table 2.1.
Reagent Volume
mqH20 1.8 µL
10 µM forward primer 0.6 µL
10 µM reverse primer 0.6 µL
Kapa Hotstart readymix 5 µL
DNA (20 ng total) 2 µL
Total 10 µL
Table 2.1: Amplicon specific PCR mastermix.
PCRs reactions were amplified on a DNA Engine Thermal Cycler (BioRad).
The standard cycling conditions for PCR were are outlined in Table 2.2.
Temperature gradient PCRs for each of the primer pair were carried out using
control DNA. Annealing temperatures with the strongest product band and
absence of multiple banding were selected. Variations in annealing
temperature for each primer pair are stated in Appendix Table A.1.
Time Temperature Cycles
Initial denaturation 3 min 95◦C 1 x
Denaturation 14 sec 98◦C
Annealing 14 sec 64-66◦C 35 x
Extension 14 sec 72◦C
Final extension 1 min 72◦C 1 x
Table 2.2: PCR conditions for amplicon specific PCRs.
After PCR, products were run on a 2% agarose gels to verify successful
amplification and absence of contamination. Gels were prepared and run as
described in Section 2.1.2. As PCR products from the first reactions had the
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same 18 bp sequences on each end, they could be combined and amplified in a
second PCR reaction using primers targeting these sequences as priming sites.
In a UV treated hood, 2 µL of each amplicon product was combined into
sample-specific pools. To remove any residual primers in each reaction, 10 µL
of each sample specific pool was purified using Ampure XP beads (as
previously described in Section 2.1.3.2).
2.4.2 Adapter PCR
Unique combinations of forward and reverse adapter primers were used in the
second round of PCR reactions. Adapter combinations were cycled through
between runs to reduce the chance of contamination between sequential runs.
PCR reactions were made as described in Table 2.3.
Reagent Volume
mqH20 1.8 µL
10 µM forward primer 0.6 µL
10 µM reverse primer 0.6 µL
Kapa HiFi hotstart readymix 5 µL
DNA (2 ng total) 2 µL
Total 10 µL
Table 2.3: Amplicon specific PCR mastermix.
PCR conditions were optimised for complete amplification of all 17 amplicon
specific PCR products while limiting the number of cycles and required DNA
input. The standard cycling conditions for these PCR reactions are shown in
Table 2.4.
Post PCR, all amplicon libraries contained a unique index combination,
making each sample identifiable. Each reaction was visualised on a 2%
agarose gel to confirm adapter PCR amplification (Section 2.1.2). 5 µL of each
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Time Temperature Cycles
Initial denaturation 2 min 95◦C 1 x
Denaturation 14 sec 98◦C
Annealing 14 sec 68◦C 10 x
Extension 14 sec 72◦C
Final extension 1 min 72◦C 1 x
Table 2.4: Thermocycler conditions for adapter PCR of amplicon products.
post adapter PCR reaction was pooled into a single tube. 50 µL of the
combined sample libraries was purified using Ampure XP beads and the same
protocol described in Section 2.1.3.2.
2.4.3 Library preparation
Purified sequencing libraries were quantified using the Qubit. An Agilent 2100
Bioanalyzer (Agilent Technologies) was used to determine the average size of
the combined libraries. 500 pg of combined library was loaded into a Agilent
high sensitivity DNA chip (Agilent Technologies) and read using the
bioanalyzer. The Bioanalyzer 2100 Expert Software (v1.0; Agilent
Technologies) was used to determine the average size of each library.
Before sequencing, DNA libraries were denatured and diluted to an
appropriate concentration for loading. The library concentration was
converted to a nM amount using equation 2.1 and diluted to 4 nM with EB.
concentration (nM) =
DNA conc. (ng/ul) × 1× 106
average size (bp) × 656.4 (g/M)
(2.1)
Frozen aliquots of 200 µL 1.0 M NaOH were thawed at room temperature.
Once thawed, aliquots were diluted in 800 µL of mqH20 to make 1 mL of 0.2 M
NaOH. A fresh dilution of NaOH was made each time a library was made.
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DNA was denatured into single strand libraries by combing 5 µL of 4 nM
DNA library with 5 µL of freshly diluted 0.2 NaOH. This sample solution was
vortexed briefly and left to incubate at room temperature for 5 min. 10 µL of
denatured DNA was mixed with 990 µL of chilled HT1 buffer, resulting in a 20
pM denatured library at 1 mM NaOH.
For the best sequence quality, the MiSeq machine requires diversity within the
sequencing library, so no single base is over-represented, causing
overexposure and making cluster definition difficult. PhiX is a control virus
genome added to sequencing libraries to add diversity to sequencing libraries.
A 4 nM PhiX library was prepared by combining 2 µL of 10 nM stock PhiX
library with 3 µL 10 mM Tris-Cl with 0.1% Tween20. 5 µL of this library was
combined with 5 µL of 0.2 M NaOH and vortexed briefly. The template
solution was left to denature at room temperature for 5 min. A 20 pM library
was made by diluting 10 µL into 990 µL of pre chilled HT1 buffer.
Denatured 20 pM PhiX was added to sequencing runs at various
concentrations. In low diversity runs, PhiX made up 20% of the total run. For
libraries with high diversity, the proportion of PhiX was reduced to 5% of the
total run. In later runs, sequencing runs were shared with sequencing libraries
from other projects using the same library preparation strategy. The
proportion of PhiX was adjusted to compensate for the diversity of the
additional libraries added to the MiSeq run.
Sequencing libraries were loaded at various concentrations depending on the
version of reagents being used and complexity of the library. Loading varied
between 6-16 pM. Low diversity runs were loaded at a lower concentration





Reagent cartridges were stored at the recommended conditions of -20◦C.
Before being used, the reagent cartridge was removed from storage and
thawed in a room temperature water bath for approximately 2 hours. Once
thawed the cartridge was removed from the water bath, mixed by inverting
the cartridge multiple times, and visually inspected to make sure all reagents
were appropriately thawed. The cartridge was tapped on a bench top to
reduce air bubbles in the reagents and stored on ice until used.
2.4.4.2 Sample sheet
The MiSeq system required a sample sheet to control the reaction cycles
during sequencing and demultiplex the sequencing libraries post run. Due to
the indices in the custom primer adapters used in our library preparations, the
standard Illumina Experimental Manager (IEM) used for amplicon sequencing
was not suitable to make a sample sheet for our custom sequencing libraries.
Instead, a comma-separated values (CSV) formatted sample sheet was made.
The CSV sample sheet was designed to imitate sample sheets created by the
standard IEM software, and was loaded into the appropriate file location on
the MiSeq machine.
2.4.4.3 Sequencing
Prior to the sequencing run, the MiSeq system was rebooted to restore the
machine to its full memory. Post reboot, the MiSeq was cleaned with three
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cycles of a pre-run standby wash using 0.5% Tween. The flow cell was
removed from its storage buffer solution and rinsed rigorously with mqH20
and 100% ethanol, and then wiped clean. Once dry, the flow cell was loaded
into the MiSeq machine.
600 µL of library was loaded into the sample reservoir in the MiSeq reagent
cartridge and visually inspected to make sure it had moved to the bottom of
the well. The reagent cartridge and incorporation buffer were loaded into the
MiSeq machine and the sequencing run was started. Post run the MiSeq was
washed with 0.5% tween using the post run wash tray and wash bottle. The
wash tray, wash bottle, and flow cell were left in place until the MiSeq was
next used.
2.4.5 Quality checks
FastQC is a bioinformatic tool used for checking the quality of raw sequence
data generated by NGS. FastQC (version 0.11.2) was used for assessing the
quality of the fastq sequencing files. Fastq files were assessed for quality as
well as other parameters, including the GC content, N content, sequence
length distribution, duplication levels, overrepresented sequences, and Kmer
content.
2.4.6 Data processing and analysis
Processing of high throughput NGS data can be split into three major steps:
pre-processing, variant calling, and variant evaluation. Each step is necessary
for the identification of true genetic variants from a background of sequencing
artefacts and errors. A shell script was written in a text editor and was used
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for the step-wise processing of the raw fastq sequencing reads into annotated
variant call formatted (VCF) files. A schematic diagram of the sequencing
pipeline is shown in Figure 2.3 and is described in detail below.
2.4.6.1 Pre-processing
Data produced by high throughput sequencing technology produces raw
sequence data that is unable to be processed by evaluation tools immediately.
First, the data needs to be processed to prepare it for the variant calling. There
are three main steps for this pre-processing; trimming, mapping, and base
quality score recalibration (BQSR).
Demultiplexed fastq files were downloaded from the MiSeq and loaded onto
the local machine for processing. Fastq files were trimmed using Trimmomatic
(Bolger, Lohse, & Usadel, 2014). For trimming, adapters, amplicon specific
primers, and leading and trailing low quality bases were removed. A sliding
window of 4 bases was used to cut reads when average quality dropped below
Q20. Only reads with matching pair end reads were retained for further
processing.
Trimmed sequence reads were mapped to the reference human genome
(Hg19) using the Burrows-Wheeler Aligner (BWA) (H. Li & Durbin, 2009).
BWA relies on the Burrows-Wheeler transform algorithm for compression of
text rich sequences to increase alignment efficiency and reduce memory usage.
The BWA software comes with three algorithms: BWA-backtrack, BWA-sw, and
BWA-mem. The BWA-mem algorithm was selected as the most recent and best
aligner for long reads, and was used to produce a SAM formatted file.
Next, Picard tools (v1.109; http://broadinstitute.github.io/picard/) was used
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Figure 2.3: Summary of pre-processing and variant calling analysis of CDH1
amplicon sequencing data workflow. Fastq files for CDH1 amplicon
sequencing libraries were processed to produce analysis ready variant files for
annotation and filtering. BQSR, base quality score recalibration; INDELS,
insertions/deletions; SNPs, single nucleotide polymorphisms.
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to convert the SAM file to a BAM file and sort the reads by genomic
coordinates, soft-clip reads beyond the end of reference alignments, verify
mate-pair information, and set MAPQ scores for unmapped reads to 0.
Finally, the Genome Analysis Toolkit (GATK) BaseRecalibrator was used to
apply base quality score recalibration (BQSR) and adjust the quality scores of
of each base. BQSR applies machine learning to model per-base estimates of
error emitted by the sequencing machine and adjust the quality scores
accordingly. A machine learning model was applied to mapped reads based
on the data and known variants in the dbSNP and goldindel files to analyse
the patterns of covariation in the sequence dataset. The covariation was used
in a second pass of the data using the same known sites. Plots were generated
to evaluate the recalibration. The recalibration was then applied to the BAM
file to recalibrate base quality scores.
2.4.6.2 Variant calling
The GATK HaplotypeCaller was run for each BAM file to generate VCF files. A
bed file was used to restrict variant calling to the coding exons and splice
regions of CDH1. GATK GenotypeGVCFs was used to merge the VCF files and
annotate them with dbSNP (build 137).
2.4.6.3 Variant evaluation
The effect of variants were predicted using SnpEFF (Cingolani et al., 2012).
Annotations included information about how gene transcripts were affected
and the variant type. Variant calls were further annotated with population
frequencies from the Exome Aggregation Consortium (ExAc; (Lek et al.,
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2016)), NHLBI Exome Sequencing Porject (ESP6500;
http://evs.gs.washington.edu), and 1000 Genomes Project (1000 Genomes,
(1000 Genomes Project Consortium, 2010)). Sequence alignment files and
variant call files were visually inspected in Integrative Genomics Viewer (IGV,
(Robinson et al., 2011)).
FannsDB 1.0 Condel (v2.0) (González-Pérez & López-Bigas, 2011) was used to
predict the effect of missense variants. Condel incorporates predictions from
MutationAssessor (Reva, Antipin, & Sander, 2011) and FatHMM (Shihab et al.,
2013) to produce a single effect score and prediction. Notably, previous
versions of Condel incorporated predictions scores from five bioinformatic
tools, namely: SIFT (P. C. Ng & Henikoff, 2003), PolyPhen2 (Adzhubei et al.,
2010), MutationAssessor (Reva et al., 2011), Ensembl-variation (McLaren et al.,
2010), Multivariate Analysis of Protein Polymorphism (MAPP) (Stone &
Sidow, 2005) and LogR Pfam E-value (Clifford, Edmonson, Nguyen, &
Buetow, 2004). Although the latter tools are not incorporated into Condel v2.0,
they are still reported in result outputs and are included in these analyses.
The effect of splice site mutations were predicted using MaxEntScan (Yeo &
Burge, 2004), NNSplice (Reese, Eeckman, Kulp, & Haussler, 1997), and Human
Splicing Finder 3.0 (HSF) (Desmet et al., 2009).
Average coverage was used as check for successful sequencing of targeted
regions. Amplicon coverage was determined from sequence alignment files
using GATK’s DepthofCoverage tool. Coverage plots were generated and
visualised in the statistical platform R (v3.3.2; https://www.r-project.org/).
Amplicons with a coverage of less than 40 reads were identified and were
re-sequenced by NGS or Sanger sequencing.
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2.4.7 Validation of variants
DNA was re-extracted from blood samples using the protocol described in
Section 2.2.7. New primers were designed and checked for off target binding.
Primers used for sequencing validation are listed in Appendix Table A.4.
Pathogenic variants were validated in forward and reverse direction using
Sanger sequencing.
2.5 Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA) is a multiplex PCR
method used for the detection of abnormal copy numbers of DNA or RNA
sequences. MLPA uses a series of paired oligonucleotides, each pair specific
for one target. The pair of probes are hybridised against two target sequences
immediately adjacent to each other, and ligated together to form a single
product. Primer pairs are fluorescently labelled and contain a ’stuffer’
sequence of variable length. Ligated products are amplified in a subsequent
PCR reaction and separated using capillary electrophoresis. The amount of
fluorescence from PCR products is proportional to the amount of target DNA
present in the sample, making this technique suitable for quantitative
measurements.
2.5.1 MLPA methodology
Structural rearrangement were were analysed in cases without a clear
pathogenic CDH1 variants using a SALSA MLPA P083 CDH1 probemix (vC1;
MRC-Holland). These reactions were performed on a BioRad thermocycler
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Figure 2.4: Schmatic diagram of MLPA reaction. MLPA reaction showing the
hybridisation of probes to denatured DNA, ligation of probes to form single




Step 1: DNA denaturation 5 min 98◦C
Pause 25◦C
Step 2: Hybridisation reaction 1 min 95◦C
18 hours 60◦C




Step 4: PCR reaction 30 sec 95◦C




Table 2.5: Thermocycler programme for MLPA reactions.
with heated lid (105◦C) in thin-walled PCR tubes. Samples were left on the
thermocycler to maintain the required temperature when reagents were being
added. Thermocycler conditions are displayed in Table 2.5.
80 ng of DNA in 5 µL was denatured at 95◦C for 5 min, then cooled to 25◦C. 1.5
µL MLPA buffer and 1.5 µL probemix was added to each denatured DNA
sample and mixed gently. Samples were heated to 95◦C for one min, incubated
at 60◦C for 18 hours to allow probes to hybridise, and cooled to 54◦C. 3 µL
ligase buffer B, 25 µL of mqH2O and 1 µL of ligase were added to each sample
and mixed gently. Samples were incubated for 15 min at 54◦C , then 98◦C for 5
min. After ligation, 1 µL SALSA PCR-primers, 2 µL SALSA enzyme dilution
buffer, 15.75 µL mqH2O, 0.25 µL SALSA Polymerase and 5 µL of Polymerase
were added to each sample and the PCR reaction was started (PCR conditions,
35 cycles: 30 sec 95◦C; 30 sec 60◦C; 60 sec 72◦C). The reaction ended with a 20
min incubation at 72◦C. Post PCR, amplified products were stored in the dark
at 4◦C until fragment analysis.
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2.5.2 Analysis
10 µL of post-PCR samples were sent to the Genetic Analysis Service for
genotyping. Samples were genotyped on an ABI3730XL using LIZ-600 size
standard. The output for each MLPA reaction displayed a series of peaks
which corresponded to the amount of amplified ligated probe present for each
target region. Additionally, MLPA probe sets contain various control
fragments used to detect problems in the MLPA reactions. Internal quality
control fragments include: one nucleotide benchmark probe, used to compare
other control fragments to; four quantify fragments (Q-fragments), used to
measure whether sufficient DNA was added and ligation was successful; two
Denaturation fragments (D-fragments), used to measure whether DNA
fragments denature properly; and gender specific X and Y fragments, used to
identify sample gender to control for sample swapping.
Peak heights were analysed using the MRC-Holland software Coffalyser
(MRC-Holland). Standard presets for the P083 CDH1 (vC1) probemix were
used to identify peaks. Within each sample, targeted probe peaks were
compared to reference probe peaks to determine a relative probe ratio. This
relative probe ratio was compared to the average relative probe ratio in the
reference samples to determine a final ratio, which is known as the Dosage
Quotient (DQ). Copy number status was considered normal for probes with a
DQ greater than 0.7 and less than 1.3.
59
2.6 Chilean gastric cancer cohort
2.6.1 Study cohort
Cases were identified at various medical institutions in Chile between 2006
and 2017. Patients were consented and blood samples were taken at referring
institutions. Germline DNA was extracted and sent to our laboratory for
sequencing. The probands clinical details and family history were collected
and provided by the referring institution.
2.6.2 Amplicon sequencing and validation of rare variants
Germline CDH1 was sequenced by a combination of NGS and Sanger
sequencing. NGS and subsequent analysis was performed as previously
described in Section 2.4 and 2.4.6, respectively. Sanger sequencing was
performed as previously described in Section 2.1.5. Deleterious and rare
missense variants and were validated by Sanger sequencing as previously
described in Section 2.4.7.
2.7 Whole-exome sequencing
2.7.1 Case selection
Gastric cancer patients who had previously tested negative for pathogenic
CDH1 variants were considered for this study. Cases were evaluated for their
tumour histology, age at the time of diagnosis, and family history of cancer.
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Cases with the most striking family history of cancer, or an unusual
early-onset of diffuse gastric cancer, were selected for further sequencing.
2.7.2 Library preparation and sequencing
DNA samples were checked for integrity by agarose gel electrophoresis and
the nanodrop. Samples were quantified using the Qubit. Whole-exome
capture and sequencing was contracted to NZGL. Libraries were prepared and
sequenced in two separate batches: eleven samples were prepared with the
TruSeq Exome Enrichment library preparation kit (Illumina Inc.) and 2 x 100
pair-end sequenced on one lane of HiSeq 2000; and three samples were
prepared with the Nextera Expanded Exome library preparation kit (Illumina
Inc.) and 2 x 100 pair-end sequenced on one lane of HiSeq 2000. Sequence
reads were returned as FASTQ formated files for processing and analysis.
2.7.3 Data processing and analysis
Similar to the amplicon sequencing data produced by the Illumina MiSeq, the
data produced by the Illumina HiSeq requires bioinformatic processing before
variants can be identified and evaluated. The processing of whole-exome
sequencing data is more complex than amplicon sequencing data and requires
more computational power and processing steps to recalibrate the quality of
variant calls.
Pre-processing and variant calling of whole-exome sequencing data was
performed with the assistance of Dr. David Markie (University of Otago, New
Zealand). The pipeline showing the pre-processing and variant calling is
summarised in Figure 2.5. Notably, many of these steps are the same as those
61
used in the processing of the amplicon sequencing data (Section 2.4.6). These
steps are briefly outlined, while the steps which have been added or changed
to account for the complexity of whole-exome data are described in greater
detail.
2.7.3.1 Pre-processing
Fastq files were trimmed using Trimmomatic (Bolger et al., 2014). Adapters,
amplicon specific primers, and leading and trailing low quality bases were
removed. A sliding window of 4 bases was used to cut reads when average
quality dropped below Q20 and short reads (< 40 bases) were removed. Only
reads with matching pair end reads were retained for further processing.
BWA-mem and was used to map reads to the reference human genome and
produce SAM formatted files. Picard tools was used to convert the SAM file to
a BAM file and sort the reads by genomic coordinates, soft-clip reads beyond
the end of reference alignments, verify mate-pair information, and set MAPQ
scores for unmapped reads to 0. In an additional step compared to the
processing of the targeted amplicon sequencing data, duplicate reads were
removed using Picard tools. BQSR was applied to adjust the quality scores of
of each base and plots were generated to evaluate the recalibration.
2.7.3.2 Variant calling
The GATK HaplotypeCaller was used to generate VCF files from each BAM file.
Joint genotyping was done using GATK GenotypeGVCF in conjunction with an
additional 394 unrelated exome samples, which leveraged information from
all samples when calling the genotypes for the individual samples. These
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Figure 2.5: Summary of pre-processing and variant calling analysis for
whole-exome sequencing data. Fastq files were processed to produce analysis
ready variants for annotation and filtering.
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additional exomes were produced using the same sequencing and alignment
procedures.
Variant quality score recalibration (VQSR) was performed on the 14 exomes in
this study in combination with 394 exomes from unrelated subjects using
GATK VariantRecalibrator and ApplyRecalibration. VQSR is a statistical soft
filtering that is applied to the raw variant calls to filter false positives and
improve the accuracy of base calling by determining the probability that a
variant is real. An adaptive error model is built using a training set of variants
verified in the 1000 Genomes database to discover the properties of these
variants, including things such as strand bias, read position, mapping quality,
and haplotype score. This model is then applied to known and novel variation
discovered in the call set of interest to estimate the probability that each
variant in the call set is a true genetic variant or a machine/alignment artefact.
The filtering criteria are derived from the data itself and therefore it is
recommended that at least 30 exomes are used to empower VQSR. GATK
ApplyRecalibration uses a sensitivity thresholds to bin variants into tranches,
that establish thresholds indicating different levels of sensitivity relative to the
training sets. The higher tranches specify a more accurate call set than the
lower tranches, which are more sensitive and therefore contain more true
variants but also including more false positives. The values assigned to each
variant by VQSR acts as an estimate of the accuracy of that call by assigning a
relative ranking to help identify true variants.
2.7.3.3 Variant evaluation
ANNOVAR (v.2015Dec14; http://annovar.openbioinformatics.org/; Wang et
al., 2010) was used for the annotation of VCF files. Annotated variant files
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were then loaded into R and filtered successively for quality, location, and
frequency in population databases. In silico predictions for the missense
variants were performed using FannsDB 1.0 Condel (v2.0) (González-Pérez &
López-Bigas, 2011).
2.7.4 Validation of variants identified by whole exome sequencing
Prioritised variants were validated using Sanger sequencing. Primers were
designed as previously described in Section 2.1.4 and are shown in Appendix
Table A.5.
2.8 Declaration
The following people contributed to work described within this thesis.
Chapter 3
Blood samples, survey information, and clinical data was collected by research
nurse and clinical staff. All experimental work and analysis was completed by
the candidate.
Chapter 4
Clinical information and DNA samples were collected by numerous research
nurse and clinical staff from referring institutions. All experimental work and
analysis was completed by the candidate.
Chapter 5
Library preparation and whole-exome sequencing was contracted to NZGL.
Processing of raw reads was completed with the assistance of Dr. David
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Markie (University of Otago, Dunedin). All other analysis and experimental
work was completed by the candidate.
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Chapter 3
Germline CDH1 Variants as a Cause
of Gastric Cancer in Māori
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3.1 Introduction
While New Zealand as a whole is considered to be a country with a low
incidence of gastric cancer, New Zealand Māori have a notably elevated
incidence of gastric cancer compared to non-Māori, and are one of the few
populations worldwide with a higher incidence of the diffuse form of the
disease. Multiple Māori families have been diagnosed with pathogenic
germline CDH1 variants and the cancer syndrome HDGC, which predisposes
to early-onset diffuse gastric cancer. As part of a study examining the known
risk factors of gastric cancer in Māori, next-generation amplicon sequencing,
MLPA, and Sanger sequencing were used to search for variants in germline
CDH1. Our aim was to determine the prevalence of pathogenic CDH1 variants
in the Māori gastric cancer population, and understand what impact this is
having on the incidence of gastric cancer in New Zealand.
3.1.1 The Māori population
Originating from eastern Polynesia, Māori settlers migrated to New Zealand in
several waves of canoe voyage between 1200 and 1300 CE (Oliver, 1981). For
many centuries the Māori population lived as an isolated group, developing
characteristic cultures, language, and mythology. Māori were the only ethnic
population in New Zealand until Europeans first visited New Zealand in 1642,
with subsequent settlements beginning in the early 1800’s (Oliver, 1981).
Modern day New Zealand has a population of more than 4.5 million people
from diverse ethnic backgrounds. Although people can identify as multiple
ethnicities, 14.9% of the population (approximately 600,000 people) identified
as Māori in the most recent census (Statistics New Zealand, 2013a). Other
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major ethnic groups were European (74.0%), Asian (11.1%), and Pasifika
(7.4%) (Statistics New Zealand, 2013a). Māori are a comparatively young
population with a median age of just 23.9 years, an age much lower than that
of the non-Māori population (encompassing all other ethnic groups) of 38.0
years. Geographically, 86.0% of Māori live in the North Island of New
Zealand, with 23.8% of all Māori concentrated in New Zealand’s largest urban
centre, Auckland (Statistics New Zealand, 2013b).
Historically, the Māori population has experienced poorer health outcomes
than the general population (R. Harris et al., 2006a). Māori are overrepresented
in almost all poor health indicators, including high rates of cot death, glue ear,
teenage pregnancy, youth suicide, self injury, diabetes, stroke, pneumonia,
influenza, and mental health (R. Harris et al., 2006b; Ministry of Health, 2015).
The reasons for the disparities in these indicators and the overall poor health
of Māori involve a complex mix of socioeconomic, environmental, and lifestyle
factors. Understanding these complexities and identifying ways in which they
can be addressed is a primary concern for health research in New Zealand.
3.1.2 Cancer in New Zealand
Cancer is a substantial burden on the New Zealand health care system. In
2013, the New Zealand Cancer Registry received 22,166 new cancer
registrations for nearly 90 different cancer sites, an incidence of 335.5 new
registrations per 100,000 population (Ministry of Health, 2016b). Prostate
cancer was the most common registration type, making up 14.1% of the total
cancer burden. This was followed closely by colorectal cancer (13.9%), breast
cancer (13.7%), and melanoma (10.7%) (Ministry of Health, 2016b). In 2013
9,063 people died as the result of cancer, accounting for approximately one
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third of all deaths in New Zealand that year (Ministry of Health, 2016b).
Cancer related deaths were most commonly a result of lung cancer (18.3%),
colorectal cancer (13.8%), and prostate cancer (7.1%) (Ministry of Health,
2016b). The age-standardised mortality rate was 122.8 deaths per 100,000
population (Ministry of Health, 2016b).
When considering Māori and non-Māori as two separate groups, Māori
experience disproportionately high cancer registration and mortality rates. In
2013, the cancer registration rate was 1.3 times higher for Māori compared to
non-Māori (418.9 versus 328.2 per 100,000 population) (Ministry of Health,
2016b). Similar differences were seen in terms of mortality, for which the
age-standardised mortality rate was 1.7 times higher for Māori compared to
non-Māori (197.9 versus 116.0 per 100,000 population) (Ministry of Health,
2016b).
3.1.2.1 Gastric cancer
In 2013, the world age-standardised gastric cancer incidence in developed
countries was 14.4 per 100,000 population, almost three times the New
Zealand incidence of 5.4 per 100,000 population (Ferlay et al., 2015; Ministry of
Health, 2016b). In line with international trends, the overall incidence of
gastric cancer in New Zealand has fallen in recent decades (Ferlay et al., 2015;
Ministry of Health, 2016b). Since the 1980’s, the age-standardised incidence of
gastric cancer in New Zealand has approximately halved (Figure 3.1). A
similar trend is seen for the age-standardised mortality rate, which has also
halved since the 1980’s (Ministry of Health, 2016b). However, despite this
drop in the mortality rate, the survival outcomes for gastric cancer patients in


































































































































Figure 3.1: Age-standardised gastric cancer registration rate in New Zealand,
1980-2013. Age-standardised rate per 100,000 population; standardised to the
WHO world standard population. Data source: New Zealand Cancer Registry,
Cancer: New Registrations and Deaths.
in New Zealand is just 20%, much lower than the 60% 5-year survival for all
cancer sites combined (Service, 2006), but comparable to international rates of
gastric cancer (Fock, 2014).
While gastric cancer registration and mortality rates for both Māori and
non-Māori have declined for the last two decades, there are still clear
disparities between the two groups. The incidence of Māori gastric cancer has
consistently been 2-3 times higher than that of non-Māori (Figure 3.2).
Similarly, gastric cancer mortality rates mirror this pattern of inequity, and
have been up to three times higher for Māori compared to non-Māori
(Ministry of Health, 2016b). These trends are exemplified in the most recent
2013 NZCR data, for which the age-standardised gastric cancer incidence and
mortality rates were 3.3 (14.6 versus 4.4 per 100,000 population) and 3.5 (11.4
versus 3.3 per 100,000 population) times higher for Māori compared to
non-Māori, respectively (Ministry of Health, 2016b).




































































































































Figure 3.2: Age-standardised incidence of gastric cancer in New Zealand,
Māori and non-Māori, 1980-2013. Age-standardised incidence per 100,000
population; standardised to the WHO world standard population. Data
source: New Zealand Cancer Registry, Cancer: New Registrations and Deaths
non-Māori. Internationally it is widely accepted that intestinal-type gastric
cancer is more common than diffuse-type disease (histological subtypes
previously described in section 1.1.1.1). Although New Zealand Europeans
align with this trend and are predominately diagnosed with intestinal-type
gastric cancer, Māori do not, and are more commonly diagnosed with
diffuse-type disease (Biggar et al., 2011). Additionally, Māori are more likely to
be diagnosed with tumours in the distal stomach (43% Māori versus 26 %
non-Māori), and on average, develop gastric cancer approximately 10 years
younger that non-Māori (Signal et al., 2015). Together, these finding suggest
that there may be differing aetiological factors driving the high-incidence of
gastric cancer observed for Māori.
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3.1.3 Disparities in exposure to environmental risk
As described in Section 1.1.2, there are a number of risk factors that influence
gastric cancer risk. It is presumed that Māori experience a higher exposure to a
number of these risk factors and that these are contributing to their high
incidence of gastric cancer relative to non-Māori.
One of these risk factors is socioeconomic status, a well established
determinant of health. In New Zealand, socioeconomic status can be measured
by a series of indicators from census information, including: education,
income, employment status, occupation, living standards, wealth, deprivation,
and poverty (Robson, Purdie, & Cormack, 2010). In general, a lower
socioeconomic status is associated with an increased risk of cancer. Although
both Māori and non-Māori with low socioeconomic status are at a heightened
risk, Māori are highly over-represented in the most deprived deciles of all
socioeconomic indicators (Robson et al., 2010). In the 2002–2006 period, it is
estimated that a higher exposure to socioeconomic deprivation accounted for
27% of the disparity in cancer incidence between Māori and non-Māori
(Robson et al., 2010).
Another risk factor disproportionately experienced by Māori is H. pylori
infection. H. pylori is a well established gastric cancer risk factor which has
been shown to greatly increase risk. Although H. pylori infection rates have
declined across all ethnic groups in New Zealand, differences in infection
prevalence between different ethnic groups have increased. Currently the
prevalence of H. pylori infection is nearly double for Māori (35%) compared to
Europeans (18%) (McDonald, Sarfati, Baker, & Blakely, 2015). It is thought that
this difference may partially be explained by household overcrowding, which
is five times more common for Māori, and has been associated with increased
73
rates of H. pylori infection (Brown, 2000; Baker, Goodyear, Telfar Barnard, &
Howden-Chapman, 2006). H. pylori infection has also been linked to the
development of distal stomach cancer (Crew & Neugut, 2006; Forman &
Burley, 2006), which may explain the high rates of distally located tumours for
Māori.
The rates of smoking for both Māori and non-Māori have dropped in recent
years, however 2015/2016 New Zealand health survey data showed that the
proportion of Māori 15 years and over who were regular smokers was more
than double that of New Zealand Europeans (32.7% versus 14.1%,
respectively) (Ministry of Health, 2016a). While the direct risk of gastric cancer
caused by smoking has been debated, it is still considered a risk factor for
gastric cancer and has a series of co-morbidities. Of note, smoking is thought
to interact with H. pylori and increase the risk of gastric cancer more than what
would be expected for each risk factor alone (Forman & Burley, 2006).
Smoking is one of the leading modifiable risks to health.
3.1.3.1 Gastric cancer risk factors for Māori
The research in this thesis is an adjunct to a large population based
case-control study investigating the relationships between established risk
factors and gastric cancer for New Zealand Māori. Recently, a paper
presenting the methods and findings in relation to known gastric cancer risk
factors was published (Ellison-Loschmann et al., 2017). The full study includes
165 Māori gastric cancer cases, identified from the New Zealand Cancer
Registry between 1 February 2009 and 31 October 2013, and 480 controls
identified from the New Zealand electoral roll and matched to cases by 5-year
age band (Ellison-Loschmann et al., 2017).
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Results from this study confirmed the importance of a number of risk factors
identified in previous studies. Of note, being tested for H. pylori (OR 12.17,
95% CI 6.15-24.08), having diabetes (OR 2.03, 95% CI 1.32-3.14) or dyspepsia
(OR 2.61, 95% CI 1.70-4.01), sharing a bedroom (>2 people) in childhood (OR
3.30, 95% CI 1.95-5.59), and having a parent diagnosed with gastric cancer (OR
4.54, 95% CI 2.45-8.40) were all significantly associated with an increased risk
of gastric cancer. Being an ex-smoker (OR 2.26, 95% CI 1.44-3.54) and being
exposed to environmental tobacco smoke (OR 3.29, 95% CI 1.94-5.59) were
both significantly associated with gastric cancer risk, however being a current
smoker was not (OR 1.46, 95% CI 0.86-2.48). Apart for the highest quantile,
deprivation was not associated with an elevated risk of gastric cancer. There
were no significant associations between alcohol intake, red and white meat
consumption, or obesity and increased gastric cancer risk. Markedly, this
study noted nearly half of all cases in the cohort (49.7%) were of the
diffuse-type, almost double that of the intestinal-type.
3.1.4 HDGC in New Zealand
Familial gastric cancer in a kindred of Māori ethnicity was first reported in
1964 (Jones, 1964). In this pedigree of 98 family members (known as family A),
28 (28.6%) were affected by primary gastric carcinoma, with many at an early
age. While the clustering of gastric cancer in this family was consistent with
the dominant inheritance of a susceptibility gene with incomplete penetrance,
genetic linkage and sequencing technology was limited, making a search for a
genetic cause of the disease impossible.
Almost 30 years later, the genetic basis underlying the familial clustering of
gastric cancer in family A was discovered (Guilford et al., 1998). In a
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partnership between the family and scientists at the University of Otago,
genetic linkage analysis and meticulous genealogy records assembled by
family A were used to identify a conserved haplotype containing the
E-cadherin gene CDH1. Subsequent sequencing of the CDH1 gene identified a
heterozygous missense c.1008G>T variant in the last base of exon 7. RT-PCR
experiments revealed that the variant was deleterious and resulted in a 7-bp
insertion and a premature stop codon derived from an intronic sequence
between the normal splice donor site and an adjacent cryptic splice site
(Guilford et al., 1998). In this family, the proportion of individuals with the
c.1008G>T variant who were affected with disease provided a lifetime
penetrance estimate of approximately 70% (Guilford et al., 1998).
In addition to the c.1008G>T variant identified in family A, deleterious
variants in germline CDH1 were identified in two additional Māori families
with early-onset diffuse gastric cancer (also known as family B and C)
(Guilford et al., 1998). In family B, two nonsynonymous variants were
identified. The first was an insertion of a cytosine residue in a run of five
cytosines in exon 15 (c.2382_ 2386insC), that resulted in an E-cadherin
molecule lacking a section of its cytoplasmic domain (Guilford et al., 1998). An
additional missense variant (c.1409C>T) was identified in exon 10 of CDH1 in
the proband from this family. However, this variant did not segregate with the
disease phenotype and was not thought to be causative in this family
(Guilford et al., 1998). In family C, a c.2095C>T variant was identified in exon
13 of CDH1. This variant is an inactivating nonsense variant that results in an
E-cadherin peptide lacking its transmembrane and cytoplasmic domains
(Guilford et al., 1998). As a result of the identification of germline CDH1
variants in these families, further pathogenic CDH1 variants were identified in
similar families around the world, culminating in the description of a new
familial cancer syndrome - hereditary diffuse gastric cancer.
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In New Zealand genetic testing has been offered to families with history of
diffuse gastric cancer since the time variants were first discovered in 1997. For
those found to carry a predisposing variant, regular endoscopic screening and
total prophylactic gastrectomy have been offered since the year 1998. Between
the years of 1998 and 2008, 68 Māori carrying deleterious CDH1 variants were
identified in New Zealand (P. Guilford, personal communication). In more
recent years, testing for CDH1 variants has moved away from research labs
into clinical laboratories, making the exact number of Māori whom carry these
variants unknown.
3.1.5 Clustering of sporadic gastric cancer
Clustering of sporadic gastric cancers, for which no major high-penetrance
variants have been identified, appear to be due to a complex combination of
environmental and genetic factors. Environmental risk factors for gastric
cancer have been well established and when shared by a family group,
community, or ethnicity, may explain high rates of the disease. However,
common low-penetrance genetic variants could also be contributing to the
clustering of gastric cancer in these groups. Single nucleotide polymorphisms
(SNPs) are one type of common genetic variant, which through either a direct
genetic mechanism or by being in linkage disequilibrium with another variant,
have proven useful as markers for genetic risk. Accordingly, associations
between SNPs and gastric cancer risk have been established in various
variants and populations world-wide (Gonzalez, Sala, & Capellá, 2002;
Skierucha et al., 2016).
Genetic variants located in genes relating to several pathways critical for
gastric cancer progression have been identified through a series of candidate
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gene and genome wide association studies. SNPs have been identified in
genes related to: (1) cell-to-cell adhesion (CDH1); (2) protection against
invading pathogens (MUC1); (3) the inflammatory response (IL-1, IL-17, and
toll-like receptors); (4) the repair of DNA damage related to H. pylori (ERCC2,
XPA, XPC); (5) the metabolism of polycyclic aromatic hydrocarbons (EPHX1,
GSTT1, NAT2, SULT1A1); (6) the metabolism of xenobiotic chemicals (Cyp2e1);
and (7) further genes whose functions are not fully understood, for example
PSCA (Gonzalez et al., 2002; Skierucha et al., 2016).
Of particular interest are SNPs in close proximity to the CDH1 gene. Loss of
E-cadherin expression has been observed in diverse types of sporadic human
cancer, in particular, diffuse-type gastric cancer and lobular breast cancer
(Van Roy & Berx, 2008). Accordingly, SNPs in and in close proximity to CDH1,
may promote to the high incidence of sporadic gastric cancer and sporadic
diffuse gastric cancer in some populations. The most widely studied
polymorphism is CDH1 -160C>A (rs16260), where the A allele was found to
have reduced transcription factor binding strength, and reduced
transcriptional activity of the CDH1 gene (L. Li et al., 2000).
Associations between the rs16260 SNP and gastric cancer risk have been
inconsistent and sometimes contradictory (Jiang et al., 2015). Medina-Franco,
Ramos-De la Medina, Vizcaino, and Medina-Franco (2007) found that the
homozygous AA genotype had a significantly elevated risk for gastric cancer
in the Mexican population (OR = 6.5, 95% CI = 2.1–19.6). Al-Moundhri et al.
(2010) found a similar result in the Omani population (OR = 3.6, 95% CI =
1.1–11.8). Conversely, Wu et al. (2002) observed that the frequency of the AA
genotype was significantly lower in gastric cancer cases than controls in the
Taiwanese population (OR = 0.20, 95% CI 0.06–0.56). In a recent meta-analysis
of the rs16260 SNP, including 4218 cases and 5461 controls from 22 case-control
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studies, no association between the CDH1 -160C>A polymorphism and risk of
gastric cancer was found (Jiang et al., 2015).
When exclusively considering sporadic diffuse-type gastric cancer, there is
some evidence that the A allele increases disease risk. In an Italian case-control
study, the odds ratio associated with the A-allele was 2.27 (95% CI 1.16-4.44)
for CA heterozygotes and 7.84 (95% CI 2.89-21.24) for AA homozygotes
(Humar, Graziano, et al., 2002). Furthermore, this study noted that the age at
diagnosis was highest in CC homozygotes and lowest in AA homozygotes
(mean ages: CC=59, CA=52.6, AA=52.3 years), and that a three marker
haplotype containing the -160C>A polymorphism was significantly associated
with disease risk (Humar, Graziano, et al., 2002). As of yet, no studies have
examined the associations between SNPs at the CDH1 locus and gastric cancer
risk for the Māori population.
3.2 Results
HDGC is well documented in Māori families from New Zealand. However,
the contribution of germline CDH1 variants to overall high incidence of
diffuse gastric cancer in the Māori population is unknown. In this chapter, the
most recent data from the New Zealand Cancer Registry was examined to
identify differences in the presentation of gastric cancer between Māori and
non-Māori. Next, I used next-generation amplicon sequencing, MLPA, and
Sanger sequencing to identify germline CDH1 variants in a case-control cohort
of Māori gastric cancer patients and matched healthy controls. Variants were
evaluated and rare and potentially pathogenic CDH1 variants were validated
using Sanger sequencing. Pathology reports from cases were reviewed to
identify those who were likely to be members of HDGC families. Using this
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information, the contribution of HDGC families to the high incidence of
gastric cancer in the Māori population was estimated. Finally, associations
between common variants at the CDH1 locus and the development of sporadic
gastric cancer and sporadic diffuse gastric cancer in the Māori population
were analysed.
3.2.1 Characterisation of New Zealand cancer registry data
Data from the New Zealand Cancer Registry was acquired to examine the
trends for gastric cancer registrations for the years 2009-2013. During this
period there were 1,882 gastric cancer registrations, of which 379 (20.1%) were
Māori and 1,503 (79.9%) were non-Māori. For the early-onset 5-year age bands
15-19, 20-24, 25-29, and 35-39, there were markedly more gastric cancer
registrations for Māori than non-Māori (Figure 3.3a). For all age bands greater
than 45 years, there were more non-Māori gastric cancer registrations (Figure
3.3b).
The crude age-standardised registration rate of gastric cancer increased with
age for both Māori and non-Māori. However, in the crude number of
registrations there was a striking over-representation of early-onset gastric
cancer registrations which were absent from the non-Māori population (Figure
3.3c). For the early-onset age-bands, less than 45 years of age, the rate of
registration was 3.9 times higher for Māori compared to non-Māori. The
age-standardised registration rate peaked at the 80-84 age band for both Māori
(181.1 per 100,000 population) and non-Māori (56.6 per 100,000 population)
(Figure 3.3d). For this period, the relative risk for Māori was 3.29 (95% CI
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Figure 3.3: Crude gastric cancer registrations and age-adjusted incidence by
5-year age band, Māori and non-Māori, 2009-2013. Distribution of crude
gastric cancer registrations by 5-year age band for (a) early onset cases and (b)
all cases. Age-adjusted incidence by 5-year age band for (c) early onset cases




Germline CDH1 was sequenced for 94 cases and 200 healthy controls matched
for 5-year age band and gender. The case cohort comprised 50 (53%) males
and 44 (47%) females with an average age at diagnosis of 55.5 years (range
17–81 years). More than half of cases (53%) were classified as diffuse-type
gastric cancers, nearly double the number of cases classified as intestinal-type
gastric cancer (27%). Reflecting the large number of diffuse-type tumours,
exactly half of tumours (47 tumours; 50%) were poorly differentiated. In
contrast to earlier studies (Biggar et al., 2011) there were slightly more
tumours located in the proximal stomach (32%) than the distal stomach (21%).
Patients were most commonly diagnosed at an early stage when tumours were
still localised (28%). Full clinical details for cases are presented in Table 3.1.
Controls were cancer free at the time of blood draw and interview. The control
cohort comprised 104 (52%) males and 96 (48%) females with an average age
of 57.6 years (range 19–84 years).
3.2.2.1 Clinical features of early-onset gastric cancers
Frequency of clinical features distributed by age at diagnosis are shown in
Figure 3.4. Of particular interest is the proportion of early-onset gastric
cancers, defined as cases younger than 45 years of age at the time of diagnosis.
Of the 94 cases in the cohort, 21 (22.3%) were in this group. Twenty (95.2%) of
the early-onset cases were diffuse-type, while one (4.8%) was unspecified (Fig
3.4a). The earliest intestinal-type tumour was diagnosed in a patient aged 49
years. Tumour differentiation was most frequently unspecified (61.9%), while


















Well differentiated 4 4
Moderately differentiated 10 11










Lymph node involvement 20 21
Regional spread 7 7
Metastatic spread 13 14
NOS 28 30
Table 3.1: Characteristics of Māori case cohort. *Other subtype includes
intermediate type tumours described using the World Health Organization












Table 3.2: Characteristics of control cohort.
There did not appear to be any trend in the site of the early-onset cancers, of
which four (19.0%) were distal, six (28.6%) were proximal, and 12 (52.4%) were
unspecified (Fig 3.4c). Nearly half (47.6%) of these early-onset cancers were
still localised, although two (9.5%) had lymph node involvement, and five
(23.8%) had metastatic spread (Fig 3.4d).
3.2.2.2 Review of pathology reports
Pathology reports from all 94 patients were reviewed for information
regarding diagnosis and prior variant screening. Reports from 15 of the 94
cases described prophylactic gastrectomies or endoscopic screening as a part
of the clinical pathway, and/or noted the patient was a CDH1 carrier of a
pathogenic variant. As prophylactic gastrectomies and endoscopic screening
procedures are offered to CDH1 pathogenic variant carriers, these cases were
likely to be CDH1 pathogenic variant carriers who had elected for prophylactic









































































































































































































































































Figure 3.4: Frequency of clinical features by age at diagnosis of gastric cancer
in the Māori population. Distribution of (a) histological subtypes, (b) tumour
grade, (c) tumour site, and (d) tumour extent. NOS; Not Otherwise Specified.
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3.2.3 Sequencing libraries and data
Amplicon libraries were prepared for the 94 cases and 200 matched controls in
this study. All libraries were prepared the same way. First, 17 target sites were
amplified in separate PCR reactions and run on 2% agarose gels to check for
successful amplification (Figure 3.5a). Second, diluted pools of amplicon
products were amplified using a pair of primers that were designed to add
indices and sequences necessary for sequencing on an Illumina MiSeq (Figure
3.5b). Amplicon products were designed to fit within the capabilities of a 500
cycle MiSeq reagent kit. For each sequencing run, indexed libraries were
pooled and checked on a bioanalyzer to determine the average size of each
library (Figure 3.5c).
As a part of this PhD, multiple MiSeq sequencing runs were used to sequence
CDH1 amplicon libraries for different study cohorts. Data was generated from
a total of seven MiSeq runs. Basic details including the reagents and flow cell
used, loading density, number of reads obtained, percentage of reads which
passed filter, percentage of reads which aligned to PhiX, and percentage of
reads with a quality greater than Q30, are displayed in Table 3.3.
Five different sequencing runs were used to generate sequence data for the
Māori case and control samples relevant to this chapter. Two of these runs (run
one and run four) were used to generate short pair-end reads which were used
to optimise the library loading density and representation of each sample for
the long read runs. For samples with a low number of reads or low
representation of target amplicons, extra sample specific library was added.
Three full length runs (run two, three, and five) were used to generate pair-end
reads that were long enough to cover the full target regions: In run two, 87 case
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Figure 3.5: Preparation of CDH1 MiSeq Libraries. Exemplar library
preparation showing: (a) amplification of targeted CDH1 exon target sites; (b)
adapter PCR used for adding sequences necessary for sequencing on an


































































































































































































































































































































































































































samples were sequenced; and in run five, 192 control samples were sequenced.
Run five, six, seven, and eight were used for sequencing of samples in Chapter
4. Notably, in runs three, five, six, and seven, additional samples from other
projects within the lab were included in the sequencing run.
A negative control library was prepared and sequenced along side each set of
samples as a measure of contamination and erroneous reads. mqH20 was used
as the negative control and underwent the same library preparation method as
the DNA sample. The number of aligned reads identified in the negative
control library was compared to the lowest number of reads for each
amplicon. In all sequencing runs the number of reads identified in the
negative control sample were less than 1% of the lowest read depth for each
amplicon. Therefore there was a low likelihood of false positives caused by
erroneous reads or contamination between samples. Additionally, the Fisher
strand values and allele counts were used to assess each variant call to identify
any variant calls which had an abnormal distribution of reads. All variant calls
had expected allele ratios and Fisher strand values.
3.2.4 CDH1 variants
In total 26 different variants were identified across the case and control cohorts
(Table 3.4). Of these: 18 variants were located in the coding exons of the CDH1
gene (six synonymous, eight missense, three nonsense, and one frameshift);
five variants were located in the proximal promoter and 5’UTR; and three were
located in intronic splice sites. Table 3.4 shows the position of each variant,
allele frequencies in the case and control cohort, and allele frequencies from
major population databases. All rare variants (MAF < 0.05) were critically
reviewed to assess the clinical significance of variants identified in this study.
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The effects of missense and splice variants were predicted using in silico
prediction tools. The functional consequences of missense variants were
predicted using Condel, a bioinformatics tool for the evaluation of
nonsynonymous single nucleotide variants (SNVs) (González-Pérez &
López-Bigas, 2011). Condel incorporates two prediction tools
(MutationAssessor and FatHMM) to create a Condel pathogenicity score that
is used for variant classification. Condel also reports pathogenicity scores from
other prediction software, namely SIFT and PolyPhen2. The scores from each
prediction tool and the overall Condel score and variant classification are
shown in Table 3.5. Possible splice site alterations were predicted using
MaxEntScan, NNSplice and Human Splicing Finder (HSF) 3.0 and are shown
in Table 3.6.
Classification of variants reported in the public archive ClinVar are included in
the review of variants. ClinVar reports the clinical significance using the five
terms for Mendelian diseases recommended by the American College of
Medical Genetics and Genomics (ACMG) and the Association for Molecular
Pathology (AMP) (Richards et al., 2015). The five clinical significance values
are: (1) benign, (2) likely benign, (3) variants of uncertain significance (VUS),
(4) likely pathogenic, and (5) pathogenic, respectively.
3.2.4.1 Frameshift variants
c.2381_ 2386insC
Four cases diagnosed with diffuse gastric cancer, aged 17, 20, 26, and 44 years,
were found to carry a CDH1 c.2381_ 2386insC variant. This variant is located
in exon 15 of the CDH1 gene and has been shown to cause a truncated





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































al., 1998). CDH1 c.2381_ 2386insC is a well established pathogenic HDGC
variant in New Zealand and was first seen by Guilford et al. (1998), in one of
the three Māori families germline CDH1 variants were first identified in.
ClinVar classifies CDH1 c.2381_ 2386insC as pathogenic.
3.2.4.2 Nonsense variants
c.190C>T
The CDH1 c.190C>T variant was identified in four cases diagnosed with
diffuse gastric cancer, aged 24, 29, 48, and 61 years. This nonsense variant
causes the premature termination in the E-cadherin sequence by changing a
glutamine residue to a stop codon at codon 64 of the E-cadherin protein
(p.Gln64*). CDH1 c.190C>T was originally described by Guilford et al. (1999)
in a Māori family with a history of gastric cancer. In this family, the proband
was diagnosed with poorly differentiated, diffuse gastric cancer at age 22
years. The probands’ mother was also affected by diffuse gastric cancer and
had died of the disease aged 28 years. ClinVar classifies CDH1 c.190C>T as
pathogenic.
c.1792C>T
CDH1 c.1792C>T was identified in four cases diagnosed with diffuse gastric
cancer, aged 29, 20, 23, and 24 years. CDH1 c.1792C>T causes a nonsense
change (p.Arg598*) in exon in 12 of CDH1, resulting in a truncated E-cadherin
protein. The variant was first seen by Gayther et al. (1998) in a European
family in which two identical twins were both diagnosed with diffuse gastric
cancer. Later, Humar, Toro, et al. (2002) identified the same variant in a Māori
family from New Zealand. The European and Māori families are not known to
be related, and as of 2005, no further analysis of relatedness had been done
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(Suriano et al., 2005). ClinVar classifies CDH1 c.1792C>T as pathogenic.
c.2287G>T
Four cases diagnosed with diffuse gastric cancer were found to carry a CDH1
c.2287G>T variant. These cases were aged 31, 39, 41, and 50 years at the time
of diagnosis. The CDH1 c.2287G>T variant is a nonsense change (p.Glu763*)
located in exon 14 which truncates the protein in the cytoplasmic domain.
CDH1 c.2287G>T has previously been described in a HDGC family in New
Zealand (Charlton et al., 2004; Guilford, Humar, & Blair, 2010). ClinVar
classifies CDH1 c.2287G>T as pathogenic.
3.2.4.3 Missense variants
c.88C>A
The germline c.88C>A CDH1 variant was identified in one healthy control,
aged 56 years. This variant causes a proline to threonine substitution at codon
30 of the E-cadherin protein (p.Pro30Thr). Between species, the proline residue
is weakly conserved and there is only a small physiochemical difference
between proline and threonine. Condel predicts c.88C>A is deleterious. This
variant is present at low frequencies in ExAc (MAF 0.00094), 1000 Genomes
(MAF 0.0004), and ESP6500 (MAF 0.0010) variant databases. ClinVar classifies
CDH1 c.88C>A variant as likely benign.
c.1214A>G
CDH1 c.1214A>G was identified in one healthy control aged 74 years. CDH1
c.1214A>G causes an asparagine to serine substitution at codon 405
(p.Asn405Ser), located in the cadherin three domain of extracellular
E-cadherin. The asparagine residue is moderately conserved across species































































































































































































































































































































































































































































































































































Condel predicts this variant to be neutral. CDH1 c.1214A>G has been seen at a
low frequency in the ExAc variant database (MAF 0.00003), but was absent
from both the 1000 Genomes and ESP6500 databases. ClinVar classifies CDH1
c.1214A>G as a variant of unknown significance.
c.1409C>T
CDH1 c.1409C>T was identified in three cases and four controls in this study.
The three cases varied in age and cancer morphology and were diagnosed
with intestinal-type, unspecified-type, and diffuse-type gastric cancer, aged 71,
66, and 21 years, respectively. Of note, the case diagnosed with diffuse-type
disease carried a second rare frameshift variant (c.2381_ 2386insC), a well
documented HDGC variant. Controls identified to carry this variant were
aged 35, 57, 59, and 74 years.
CDH1 c.1409C>T causes a threonine to isoleucine at codon 470 of the
E-cadherin protein (p.Thr470Ile). The threonine residue is highly conserved
between species and there is a moderate physicochemical difference between
threonine and isoleucine. Condel predicts CDH1 c.1409C>T to be damaging.
This variant is rare in ExAc database (MAF 0.00003) and is absent from the
1000 Genomes and ESP6500 databases. ClinVar classifies CDH1 c.1409C>T as
likely benign.
This variant has previously been described in a Māori family affected with
early-onset diffuse gastric cancer alongside a deleterious c.2381_2386insC
CDH1 variant (Guilford et al., 1998). In this family, the second variant
segregated with the disease while CDH1 c.1409C>T did not, suggesting that
the c.1409C>T substitution was not the primary cause of disease in this family
(Guilford et al., 1998). As homozygosity for deleterious CDH1 variants is
embryonic lethal, the co-occurrence of c.1409C>T with another pathogenic
variant argues against its pathogenicity. Furthermore, as this variant was
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found in an additional four currently healthy controls, it is likely this variant
may be more common in the Māori population than other populations,
making the identification of this variant in cases unremarkable.
c.1774G>A
The CDH1 c.1774G>A variant was identified in one case diagnosed with
diffuse gastric cancer aged 57 years and one control aged 64 years. CDH1
c.1774G>A causes an alanine to threonine substitution at codon 592 of the
E-cadherin protein (p.Ala592Thr.) The alanine in this position is not well
conserved between species and there is another rare substitution (c.1774G>T;
ExAc MAF 0.00042) in the same position. CDH1 c.1774G>A was predicted to
be neutral by Condel and is classified as benign and likely benign by ClinVar.
CDH1 c.1774G>A has been reported at low frequencies in the ExAc (MAF
0.0032), 1000 Genomes (MAF 0.0012), and ESP6500 (MAF 0.0045) variant
databases.
CDH1 c.1774G>A has previously been identified in a Swedish cancer family
(Jonsson, Bergh, Stattin, Emmanuelsson, & Grönberg, 2002). In the Swedish
family, the variant was found in two male siblings, both with prostate cancer.
A sister with breast cancer did not carry the variant. Structural analysis from
in vitro (Keller et al., 2004) and in silico studies (Suriano, Seixas, Rocha, &
Seruca, 2006) do not support a pathogenic classification for CDH1 c.1774G>A.
c.1849G>A
CDH1 c.1849G>A was identified in one case diagnosed with intestinal-type
gastric cancer, age 77 years. CDH1 c.1849G>A causes an alanine to threonine
substitution at codon 617 (p.Ala617Thr), in the fifth extracellular repeat of the
E-cadherin protein. The c.1849G>A variant is present at low frequencies in the
ExAc (MAF 0.00423), 1000 Genomes (MAF 0.0144) and ESP6500 (MAF 0.0160)
databases, and is almost exclusive to the African population (MAF
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approximately 0.05). CDH1 c.1849G>A is predicted to be neutral by Condel
and is classified as benign by ClinVar.
CDH1 c.1849G>A was first reported by Risinger, Berchuck, Kohler, and Boyd
(1994) in a sample of endometrial cancer tissue. Later, Ascaño et al. (2001)
reported a germline variant in a diffuse gastric cancer patient of
African-American decent. Similarly, El-Husny et al. (2016) also noted a
germline variant in a diffuse gastric cancer patient of African-American
decent. In vitro assays examining the p.Ala617Thr variant in Chinese hamster
ovary cells did not show increased motility or invasiveness as a result of the
CDH1 c.1849G>A variant, but did observe a significant reduction of cellular
adhesion (Suriano et al., 2003).
c.2195G>A
CDH1 c.2195G>A was identified in one case diagnosed with diffuse gastric
cancer aged 38 years. CDH1 c.2195G>A causes a missense arginine to
glutamine at codon 732 of the E-cadherin protein (p.Arg732Gln). CDH1
c.2195G>A is located in a highly conserved residue, which is located at the
intracellular border of the cytoplasmic domain of the E-cadherin protein. The
variant was absent from population databases and was predicted to be
damaging by Condel.
The c.2195G>A variant has previously been identified in two HDGC families
of European decent (Kaurah et al., 2007; Brooks-Wilson et al., 2004). In silico
analysis of p.Arg732Gln predicted this missense change to cause a new
acceptor splice site in the E-cadherin protein (Kaurah et al., 2007). RT-PCR
analysis of RNA extracted from white blood cells and a gastrectomy specimen
of a p.Arg732Gln variant carrier showed a complex splicing and deletion of 32
base pairs at the start of exon 14 (Kaurah et al., 2007).
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c.2329G>A
CDH1 c.2329G>A was identified in one case diagnosed with a gastric cancer of
an unspecified type aged 81 years. CDH1 c.2329G>A causes an aspartic acid to
asparagine substitution at codon 777, in cytoplasmic tail of the E-cadherin
protein (p.Asp777Asn). The aspartic acid residue is highly conserved and
there is only a small physicochemical difference between aspartic acid and
asparagine. CDH1 c.2329G>A is present at low frequencies in the ExAc (MAF
0.00013) and ESP6500 (MAF 0.0001) variant databases. Condel predicts CDH1
c.2329G>A to be deleterious, however ClinVar describes the variant as likely
benign.
CDH1 c.2329G>A has been reported in a families with prostate (Jonsson et al.,
2002), breast (Tung et al., 2016), and colon cancers (Kraus et al., 2015). CDH1
c.2329G>A has also been identified in an individual from a healthy, ancestrally
diverse cohort using cancer susceptibility gene panel testing (Bodian et al.,
2014).
c.2556G>T
CDH1 c.2556G>T variant was identified in two controls age 62 and 68 years.
CDH1 c.2556G>T causes a glutamic acid to aspartic acid at codon 852 in the
cytoplasmic domain of the E-cadherin protein (p.Glu852Asp). The glutamic
acid is weakly conserved between species and there is only a small
physicochemical difference between glutamic acid and aspartic acid. CDH1
c.2556G>T is rare in variant databases and is only reported in the ExAc
database (MAF 0.00002). Condel predicts this variant to be neutral. CDH1
c.2556G>T has not been described in any published literature.
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Positiona Variant MaxEntScan NNSplice HSF 3.0
68835801 c.387+5G>A 9.80→ 7.88 0.99→ 0.64 100→ 99.0
68867187 c.2440-6C>G 10.9→ 9.85 0.98→ 0.95 84.3→ 80.8
Table 3.6: Splice site prediction scores. MaxEntScan: splice site if >= 3;
NNSplice: splice site if >= 0.95; HSF 3.0: splice site if >= 65. HSF, Human
Splice Finder. aReference sequence for variant position is Hg19.
3.2.4.4 Intronic splice variants
c.387+5G>A
One case, diagnosed with intestinal gastric cancer aged 77 years, and three
controls, aged 39, 47, and 67 years were identified to carry a CDH1
c.387+5G>A variant. In silico models predict CDH1 c.387+5G>A to weaken,
but not disrupt, the nearby natural donor site of intron 3. CDH1 c.387+5G>A
was not recorded in the ESP6500 or 1000 Genomes databases but was seen at a
very low frequency in the ExAc database (MAF 0.00001). The guanine
nucleotide that is altered is not conserved across species. There have been no
RNA or functional studies examining the effects of this variant. ClinVar
classifies CDH1 c.387+5G>A as likely benign.
c.2440-6C>G
CDH1 c.2440-6C>G was identified in two controls aged 59 and 66 years. In
silico models predict CDH1 c.2440-6C>G to weaken the nearby acceptor site of
intron 15. CDH1 c.2440-6C>G is present at low frequencies in the ExAc (MAF
0.00180), 1000 Genomes (MAF 0.00002), and ESP6500 (0.0021) variant
databases. ClinVar classifies CDH1 c.2440-6C>G as benign or likely benign.
The CDH1 c.2440-6C>G variant has been controversially discussed in the
literature. More et al. (2007) first described CDH1 c.2440-6C>G in a patient
with diffuse gastric cancer. The authors identified an unusual splicing pattern
by gel electrophoresis of RT-PCR products and classified the CDH1
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c.2440-6C>G variant as disease causing. Later, two groups could not confirm
the unusual banding in others with the CDH1 c.2440-6C>G variant using
RT-PCR analysis and Sanger sequencing analysis (Grodecká et al., 2014;
Molinaro et al., 2014). Analysis of a heterozygous SNP in mRNA from blood
cells from a CDH1 c.2440-6C>G variant carrier demonstrated that both alleles
are transcribed (Grodecká et al., 2014).
3.2.4.5 5’ UTR and promoter variants
c.-276T>C (-152T>C)
CDH1 c.-276T>C was detected in one control aged 64 years. CDH1 c.-276T>C
is not described in the three variant databases used in this study but does has a
SNP ID (rs34149581). This variant has previously been identified in a
case-control study for which no risk of developing breast cancer was detected
(Lei et al., 2002). Additionally, transient transfection experiments using
reporter constructs with the CDH1 c.-276T>C variant did not significantly
decrease transcriptional activity compared to the wild-type construct (Lei et
al., 2002).
c.-176C>T (-52C>T)
CDH1 c.-176C>T was identified in two controls aged 69 and 71 years. This
variant is seen at a low frequency in the 1000 Genomes database (MAF 0.0018),
but was not reported in the ExAc or ESP6500 databases. CDH1 c.-176C>T has
been reported in a first degree relative of a sporadic gastric cancer patient, but
was not seen in the affected patient (Garziera et al., 2013).
c.-71C>G
CDH1 c.-71C>G was identified in three healthy controls aged 60, 64, and 73
years. CDH1 c.-71C>G is reported at low frequency in the 1000 Genomes
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variant database (MAF 0.0056) and is classified as benign and likely benign in
ClinVar. CDH1 c.-71C>G has previously been reported in both sporadic gastric
cancer cases and healthy controls and was not thought to affect gene
expression (Avizienyte, Launonen, Salovaara, Kiviluoto, & Aaltonen, 2001).
3.2.4.6 Summary of rare variant classification
Evidence supporting the classification of the variants identified in this cohort
was varied and sometimes contradicting. Using all available information, the
pathogenicity of variants were evaluated in accordance with ACMG/AMP
guidelines.
In summary, five variants (c.190C>T, c.1792C>T, c.2195G>A, c.2287G>A, and
c.2381_ 2386insC) were classified as pathogenic; two variants (c.1214A>G and
c.2556G>T) were classified as variants of uncertain significance; and ten
variants (c.-276T>C, c.-176C>T, c.-71C>G, c.88C>A, c.387+5G>A, c.1409C>T,
c.1774G>A, c.1849G>A, c.2329G>A, and c.2440-6C>G) were classified as
benign or likely benign. Notably, both variants of uncertain significance
variants were predicted to be neutral by Condel and were exclusively
identified in controls aged greater than 60 years.
3.2.5 Validation of variants
All rare and pathogenic variants identified using our NGS amplicon
sequencing were validated using Sanger sequencing. For validation, germline
DNA was re-extracted from blood samples, amplified using new primer sets,
and Sanger sequenced. 100% of variants identified by NGS were validated
successfully. An example of the pathogenic variants identified in this cohort
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are shown in Figure 3.6. Sanger sequence of all pathogenic, rare missense, and
rare splice site variants are shown in Appendix B.
3.2.6 MLPA
MLPA is a method used for the identification of abnormal copy numbers of
DNA sequences. In this study MLPA was used to screen samples for large
genomic deletions or duplications of the CDH1 gene that may have been
missed by our PCR based amplicon sequencing approach. MLPA was used to
screen samples from the 77 cases who did not carry a clear pathogenic
germline CDH1 variant, and ten samples from healthy controls. Samples from
healthy controls were assumed to have a normal copy number and were used
as reference samples. No positive control was included as a sample from an
individual with a known large genomic deletion or duplication was not
available.
The dosage quotient and standard deviation of probes for test and reference
sample are shown in Appendix C tables C.1 and C.2. For 8/10 reference
samples (80%), the standard deviation of both reference and test probes were
less than 0.10 and had DQ values ranging between 0.85-1.15 for both target
and reference probes. Two reference samples (Y357 and Y638) showed
considerable variation and had probes with a standard deviation larger than
0.10. Because of this, they were excluded from further analysis. For test
samples the standard deviation of reference probes ranged between 0.04-0.15.
DQ values ranged between 0.76-1.24 and were considered to be normal.








Figure 3.6: Validation of pathogenic CDH1 variants. Forward orientated
chromatograms of the five different pathogenic variants identified in the
Māori gastric cancer cohort.
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3.2.7 Characteristics of pathogenic CDH1 variant carriers
Clinical characteristics of the 17 cases carrying a clear pathogenic germline
CDH1 variant were reviewed and are displayed in Table 3.7. Cases were
diagnosed between the age of 17-61 years. All cases with pathogenic germline
CDH1 variants were diagnosed with diffuse-type gastric cancer. 15/17 (88.2%)
cases were diagnosed with early-stage localised tumours. These 15 pathogenic
variant carriers were the same cases as those who were likely diagnosed as a
result of HDGC familial cancer screening (Section 3.2.2.2). The remaining two
cases with pathogenic variants were diagnosed with late-stage metastatic
disease. There was no indication from the pathology reports these latter two
cases had CDH1 pathogenic variants identified at the time of diagnosis. The
degree of differentiation and stage of these 17 tumours were mostly
unspecified, however tumours for which this information was specified were
all described as poorly differentiated (3/17, 17.6%) and were identified in the
proximal stomach (3/17, 17.6%).
3.2.8 Frequency of pathogenic CDH1 variants
Overall, pathogenic CDH1 variants were identified in 17/94 (18.1%) of the
total gastric cancer case cohort and 17/50 (34.0%) of diffuse gastric cancers
(Figure 3.7). The proportion of cases with a pathogenic CDH1 variant that
were aged less than 45 years at diagnosis was 14/21 (66.7%). Only 3/73 (4.1%)
of cases with pathogenic variants were aged 45 years and over. The average
age of diagnosis for pathogenic variant carriers was 33.2 years (range 17-61),
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CDH1 mutation 
No CDH1 mutation 
Figure 3.7: Frequency of pathogenic CDH1 variants by age at diagnosis of
gastric cancer in the Māori gastric cancer cohort. Red, CDH1 pathogenic
variant positive; blue, CDH1 pathogenic variant negative.
3.2.9 The impact of HDGC screening
Our raw data shows that approximately 18% (17/84) and 34% (17/50) of
Māori gastric cancer and diffuse gastric cancer cases, respectively, were caused
by pathogneic germline CDH1 variants. However, these figures are skewed by
the impact of familial HDGC screening and the incomplete penetrance of
pathogenic germline CDH1 variants, for which without the increased
surveillance via endoscopic screening and elected prophylactic surgery
available to pathogenic germline CDH1 variant carriers, it is likely the 15 cases
identified as a result of prior genetic screening would have presented with
late-stage disease.
Accounting for the length of time Māori HDGC families have been screened
for pathogenic germline CDH1 variants in New Zealand (since the first
families were identified in 1998), the number of Māori identified with a
pathogenic germline CDH1 variant between 1998 and 2008, and a penetrance
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estimate of 70% between the age of 20-70 years, we estimate that in the absence
of familial HDGC screening, pathogenic germline CDH1 variants would
account for 6% (95% CI 0.9-11.3) and 13% (95% CI 2.4-23.9) of all advanced
Māori gastric cancer and diffuse gastric cancer, respectively.
3.2.10 Associations between CDH1 polymorphisms and sporadic
gastric cancer
Multiple studies have examined common variants in and around the CDH1
locus for associations with various cancer types. Notably, associations between
common CDH1 variants and risk for sporadic gastric cancer have been
inconsistent. Here, variant calls generated by direct amplicon sequencing to
investigate associations between common CDH1 variants and both sporadic
gastric cancer and sporadic diffuse gastric cancer in the Māori population.
Four common CDH1 variants (MAF > 0.05) were covered by our NGS
amplicon sequencing: rs16260, rs28372783, rs3743674, and rs1801552. The
rs16260 (-160C>A) and rs28372783 (-74A>C) SNPs are both located in the
proximal promoter of the CDH1 gene. rs16260 has been shown to reduce its
transcriptional efficiency of CDH1 in vitro while the effect of the rs28372783
SNP is unknown (L. Li et al., 2000). rs3743674 (c.48+6T>C) is located in the
donor splice site of intron 1 and is not known to have an effect on the
transcription or translation of the CDH1 gene (Avizienyte et al., 2001).
rs1801552 (c.2076T>C) is a synonymous variant (p.Ala692Ala) located in exon
13 of the of CDH1 gene and is thought to be silent (Risinger et al., 1994).
After removing the 17 cases that carried pathogenic germline CDH1 variants,
there were 77 sporadic gastric cancer cases in this study. These sporadic cases
comprised 43 males and 34 females, and had a mean age of 69.1 years (range
107
28-81 years.) Of the sporadic cases, 34 were diffuse-type, and had a mean age
of 54.9 years (range 28-81 years). All 200 sequenced controls were included in
the association analysis (previously described in Section 3.2.2). Odds ratios,
95% confidence intervals (CI), and p-values for trend associations for the
case-control study were obtained by conditional logistic regression analysis
and adjusted for age. Associations between cases and control samples were
tested using co-dominant, dominant, recessive, and over-dominant association
models.
The frequencies of all SNPs were in Hardy-Weinberg equilibrium for the case
and control groups (p > 0.134). Overall, there were no significant associations
between the four SNPs tested and sporadic gastric cancer risk (Table 3.8) or
sporadic diffuse gastric cancer (Table 3.9), for any of the association models
tested. The only association to approach significance was for the promoter
SNP rs3743674 when tested for an association with sporadic diffuse gastric
cancer using a dominant model (OR 2.25 (95% CI 0.98-5.18); p = 0.064).
Notably, the rs16260 A allele, which has been shown to decrease the
transcriptional activity of CDH1, was not significantly associated with risk of
sporadic gastric cancer or sporadic diffuse gastric cancer in this study (p >
0.152).
3.3 Discussion
To our knowledge, this is the first study that has examined the frequency of
gastric cancers that are attributable to germline CDH1 variants in a specific
ethnic group. In keeping with previous studies (Biggar et al., 2011;
Nevalainen, Laurén, & Gavin, 1988), a high proportion of diffuse gastric
cancers was observed in our Māori gastric cancer cohort. Overall, pathogenic
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SNP Model Genotype Controls Cases Odds Ratio (95% CI) p-value Adjusted
n (%) n (%) p-value
rs16260 Codominant CC 135 (67.5) 58 (75.3) 1
-160C>A CA 62 (31.0) 18 (23.4) 0.65 (0.35-1.20)
AA 3 (1.0) 1 (1.3) 0.73 (0.07-7.23) 0.376 1.000
Dominant CC 135 (67.5) 58 (75.3) 1
CA-AA 65 (32.5) 19 (24.7) 0.66 (0.36-1.20) 0.163 0.652
Recessive CC-CA 197 (98.5) 76 (98.7) 1
AA 3 (1.5) 1 (1.3) 0.83 (0.08-8.12) 0.869 1.000
Overdominant CC-AA 138 (69.0) 59 (76.6) 1
CA 62 (31.0) 18 (23.4) 0.66 (0.36-1.21) 0.170 0.680
rs28372783 Codominant AA 157 (78.5) 59 (76.6) 1
-73A>C AC 40 (20.0) 15 (19.5) 1.01 (0.50-1.91)
CC 3 (1.5) 3 (3.9) 3.18 (0.61-16.63) 0.399 1.000
Dominant AA 157 (78.5) 59 (76.6) 1
AC-CC 43 (21.5) 18 (23.4) 1.11 (0.59-2.10) 0.747 1.000
Recessive AA-AC 197 (98.5) 74 (96.1) 1
CC 3 (1.5) 3 (3.9) 3.20 (0.62-16.63) 0.176 0.705
Overdominant AA-CC 160 (80.0) 62 (80.5) 1
AC 40 (20.0) 15 (19.5) 0.94 (0.48-1.84) 0.859 1.000
rs3743674 Codominant TT 163 (81.5) 69 (89.6) 1
c.48+6T>C CT 36 (18.0) 7 (9.1) 0.48 (0.20-1.13)
CC 1 (0.5) 1 (1.3) 2.02 (0.12-33.32) 0.175 0.700
Dominant TT 163 (81.5) 69 (89.6) 1
CT-CC 37 (18.5) 8 (10.4) 0.53 (0.23-1.19) 0.107 0.416
Recessive TT-CT 199 (99.5) 76 (98.7) 1
CC 1 (0.5) 1 (1.3) 2.21 (0.13-36.43) 0.584 1.000
Overdominant TT-CC 164 (82.0) 70 (90.9) 1
CT 36 (18.0) 7 (9.1) 0.47 (0.20-1.12) 0.072 0.288
rs1801552 Codominant CC 65 (32.5) 23 (29.9) 1
c.2076T>C TC 105 (52.5) 37 (48.1) 1.05 (0.57-1.93)
TT 30 (15.0) 17 (22.1) 1.66 (0.77-3.58) 0.377 1.000
Dominant CC 65 (32.5) 23 (29.9) 1
TC-TT 135 (67.5) 54 (70.1) 1.19 (0.67-2.11) 0.560 1.000
Recessive CC-TC 170 (85.0) 60 (77.9) 1
TT 30 (15.0) 17 (22.1) 1.62 (0.83-3.15) 0.165 0.660
Overdominant CC-TT 95 (47.5) 40 (51.9) 1
TC 105 (52.5) 37 (48.1) 0.87 (0.51-1.47) 0.599 1.000
Table 3.8: Associations between sporadic gastric cancer and common variants
at the CDH1 locus. Allele frequencies of four CDH1 variants in sporadic
gastric cancer cases and control subjects and the odd ratios (ORs) for
co-dominant, dominant, recessive and over-dominant models. P-values were
corrected using the Bonferroni correction. CI, Confidence Interval; OR, Odds
Ratio; SNP, Single Nucleotide Polymorphism.
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SNP Model Genotype Controls Cases Odds Ratio (95% CI) p-value Adjusted
n (%) n (%) p-value
rs16260 Codominant CC 135 (67.5) 26 (78.8) 1
-160C>A CA 62 (31.0) 7 (21.2) 0.59 (0.24-1.44)
AA 3 (1.5) 0 (0.0) 0 (0.00-0.00) 0.294 1.000
Dominant CC 135 (67.5) 26 (78.8) 1
CA-AA 65 (32.5) 7 (21.2) 0.56 (0.23-1.37) 0.185 0.740
Recessive CC-CA 197 (98.5) 33 (100) 1
AA 3 (1.5) 0 (0.0) 0 (0.00-0.00) 0.318 1.000
Overdominant CC-AA 138 (69.0) 26 (78.8) 1
CA 62 (31.0) 7 (21.2) 0.60 (0.25-1.30) 0.152 0.608
rs28372783 Codominant AA 157 (78.5) 22 (66.7) 1
-73A>C AC 40 (20.0) 9 (27.3) 2.02 (0.853-4.90)
CC 3 (1.5) 2 (6.1) 4.64 (0.68-31.49) 0.131 0.524
Dominant AA 157 (78.5) 22 (66.7) 1
AC-CC 43 (21.5) 11 (33.3) 2.25 (0.98-5.18) 0.064 0.256
Recessive AA-AC 197 (98.5) 31 (93.9) 1
CC 3 (1.5) 2 (6.1) 3.93 (0.60-25.96) 0.181 0.724
Overdominant AA-CC 160 (80.0) 62 (80.5) 1
AC 39 (19.5) 9 (27.3) 1.89 (0.78-4.54) 0.167 0.668
rs3743674 Codominant TT 163 (81.5) 29 (87.9) 1
c.48+6T>C CT 36 (18) 4 (12.1) 0.63 (0.20-1.96)
CC 1 (0.5) 0 (0.0) 0 (0.00-0.00) 0.653 1.000
Dominant TT 163 (81.5) 29 (87.9) 1
CT-CC 37 (18.5) 4 (12.1) 0.62 (0.20-1.92) 0.390 1.000
Recessive TT-CT 199 (99.5) 33 (100) 1
CC 1 (0.5) 0 (0.0) 0 (0.00-0.00) 0.683 1.000
Overdominant TT-CC 164 (82.0) 29 (87.9) 1
CT 36 (18.0) 4 (12.1) 0.63 (0.21-1.96) 0.411 1.000
rs1801552 Codominant CC 65 (32.5) 8 (24.2) 1
c.2076T>C TC 105 (52.5) 20 (60.6) 1.52 (0.63-3.71)
TT 30 (15.0) 5 (15.2) 1.16 (0.34-3.92) 0.620 1.000
Dominant CC 65 (32.5) 8 (24.2) 1
TC-TT 135 (67.5) 25 (75.8) 1.44 (0.61-3.40) 0.401 1.000
Recessive CC-TC 170 (85.0) 28 (84.8) 1
TT 30 (15.0) 5 (15.2) 0.88 (0.31-2.50) 0.805 1.000
Overdominant CC-TT 95 (47.5) 13 (39.4) 1
TC 105 (52.5) 20 (60.6) 1.44 (0.65-1.98) 0.343 1.000
Table 3.9: Associations between sporadic diffuse gastric cancer and common
variants at the CDH1 locus. Allele frequencies of four CDH1 variants in
sporadic diffuse gastric cancer cases and control subjects and the odd ratios
(ORs) for co-dominant, dominant, recessive and over-dominant models.
P-values were corrected using the Bonferroni correction. CI, Confidence
Interval; OR, Odds Ratio; SNP, Single Nucleotide Polymorphism.
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germline CDH1 variants were identified in 17/94 (18%) of the total case cohort
and 17/50 (34%) of diffuse gastric cancers. The proportion of cases with a
pathogenic CDH1 variant aged less than 45 years at the time of diagnosis was
14/21 (67%). Only 3/73 (4%) of cases with pathogenic germline CDH1 variants
were aged 45 years and over. No pathogenic germline CDH1 variants were
identified in 200 healthy controls, nor were any associations between common
variants at the CDH1 locus and sporadic gastric cancer. After adjusting for the
effect of CDH1 screening, an estimated 6% of all advanced gastric cancer and
13% of all advanced diffuse gastric cancers carry pathogenic germline CDH1
variants . This study demonstrates that inherited genetic predisposition to
gastric cancer is an important cause of cancer, and a major contributor to the
high incidence of early-onset diffuse gastric cancer in the Māori population.
3.3.1 The impact of familial gastric cancer screening
In New Zealand, familial gastric cancer genetic screening has been offered
since 1998 when pathogenic germline CDH1 variants were first identified in
three Māori kindred (Guilford et al., 1998). For pathogenic variant carriers,
endoscopic screening and total prophylactic gastrectomy have been available
since the early 2000s. Some pathogenic variant carriers elect to undergo
regular endoscopic screening to identify early-stage foci before the cancer
progresses. However, foci can be small and hard to identify making screening
imperfect (van der Post et al., 2015). Currently, total prophylactic gastrectomy
is the only option available to completely eliminate the risk associated with an
inherited pathogenic CDH1 variant. While the mortality rate associated with
total prophylactic gastrectomy is approximately 1%, there are still major
morbidities associated with this procedure (van der Post et al., 2015).
111
The impact of prior CDH1 variant screening was apparent in the case cohort in
this study. Almost all of the cases (15/17; 88.2%) with pathogenic CDH1
variants were identified as a part of the clinical pathway for HDGC variant
carriers. Interestingly, the two cases which did not appear to know about their
pathogenic CDH1 variants (Y616 and Y670), both presented with advanced
metastatic disease. Y670 carried a known HDGC variant (c.2287G>T) that has
previously been documented in New Zealand (Charlton et al., 2004). As CDH1
c.2287G>T had been identified in a Māori kindred from New Zealand prior to
this study, it is a tragedy that this case was not diagnosed sooner. It is unclear
if case Y670 knew about their risk as a part of a known HDGC family and had
declined screening, or did not know about their risk of being a pathogenic
variant carrier. Y616 carried a missense c.2195G>A pathogenic variant, which
to our knowledge, has not previously been documented in New Zealand, but
has been documented in a HDGC families of European decent (Kaurah et al.,
2007; Brooks-Wilson et al., 2004).
Our data also highlights the importance of the identification and proper
clinical management of those with pathogenic CDH1 variants. The 15 cases
that were identified as a result of genetic screening were all still alive five years
post diagnosis, while the two cases that were not identified, both died shortly
after diagnosis (data not shown). It is almost certain that without intervention
the majority of cases that were identified as a result of genetic testing would
have presented with advanced diffuse gastric cancer and died. Although there
is risk of missing early lesions with endoscopic screening, and there is a high
level of morbidity associated with total prophylactic gastrectomy, as seen here,
the outcomes for both procedures are typically better than the prognosis
associated with the late detection of tumours.
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3.3.2 CDH1 c.2195G>A: a new HDGC variant in New Zealand
Of particular interest is case Y616, who was found to carry a pathogenic CDH1
c.2195G>A variant. Due to the lack of cancer diagnoses in their first degree
relatives, and no reference to any of the procedures normally available to
pathogenic CDH1 variant carriers, it appears this case did not know they were
a pathogenic CDH1 variant carrier. The apparent lack of family history in this
family could be explained by two main hypotheses. The first is that the
c.2195G>A variant has a low penetrance in this family. The second is that the
variant recently arose de novo in this individual or a recent ancestor.
If the CDH1 c.2195G>A variant was present in the family of Y616 for multiple
generations and has been shared by a large number of family members, there
is a significant deviation from the expected presentation of disease in this
family. Current estimates of the cumulative risk of developing diffuse gastric
cancer by the age of 80 years is 70% for men (95% CI 59%-80%) and 56% for
women (95% CI 44%-69%) (Hansford et al., 2015). However, previous
estimates of disease penetrance for variant carriers have ranged between 40%
and 83%, depending on gender and ethnicity (Kaurah et al., 2007; Pharoah,
Guilford, Caldas, International Gastric Cancer Linkage Consortium, &
International Gastric Cancer Linkage Consortium, 2001). Evaluation of CDH1
variant penetrance in large families from more recent studies are lower
(Kaurah et al., 2007), suggesting that family ascertainment for HDGC may
have skewed early estimates. The vast majority of individuals with truncating
CDH1 variants had a family history of diffuse gastric cancer, however as
sequencing is becoming more freely available, families that deviate away from
the expected pattern of disease are emerging. Recently, a series of studies have
reported pathogenic CDH1 variants in individuals with no family history of
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diffuse gastric cancer (Huynh & Laukaitis, 2016; Lajus & Sales, 2015; Xie et al.,
2011).
Alternatively, the c.2195G>A variant could have arisen de novo in case Y616 or
a very recent ancestor, explaining why there was no history of disease in the
family. Haplotype analysis of the two European families with the same
c.2195G>A variant found that the three haplotypes markers that were most
tightly linked to the c.2195G>A variant were identical, however, the two
markers flanking each side of these markers were different (Kaurah et al.,
2007). Because the variant could either have arisen independently in these two
families, or as an ancient variant with differing haplotypes as a result of two
separate recombination events, the results from this analysis were inconclusive
(Kaurah et al., 2007).
Already, three variants (c.1137G>A, c.1565+1G>A, and c.1792C>T) have been
found in multiple families from seemingly unrelated backgrounds and have
been proposed as CDH1 variation hotspots (Hansford et al., 2015). Strikingly,
including the c.2195G>A variant, all four of these hotspot sites are located in
cytosine-guanine (CpG) dinucleotide sites. CpG dinucleotides are known to be
a hotspot for variants in the human genome. This hypermutability is related to
its role as the major site of cytosine methylation, with the attendant risk of
spontaneous deamination of 5-methylcytosine (5mC) to thymine (Cooper &
Youssoufian, 1988). Recurrence of germline variants at CpG sites have been
reported for a number of genetic syndromes. For example, germline variants
in the methyl-CpG binding protein 2 gene MECP2 is causative of Rett
syndrome, a neurodevelopmental disorder characterised by loss of acquired
skills after a period of normal development in infant girls, are most common
in CpG hotspots (Wan et al., 1999). The identification of CDH1 c.2195G>A in
our geographically and ethnically distant cohort of New Zealand Māori,
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supports the notion that CDH1 c.2195G>A a de novo variant in a variant
hotspot. Regardless of the history of this variant, the family of Y616 can now
be screened for this pathogenic variant.
3.3.3 A high number pathogenic CDH1 variants in the Māori
gastric cancer population
Founder variants have been identified as a common cause of cancer in some
populations. Of note is the Ashkenazi Jewish population, for which
approximately 2% of the general population carry one of three founder
variants in the tumour suppressor genes BRCA1 and BRCA2 (Levy-Lahad et
al., 1997). Deleterious variants in BRCA1 and BRCA2 are associated with an
increased risk of both breast and ovarian cancer (King, Marks, & Mandell,
2003). Subsequently, approximately 12% of breast cancers (Warner et al., 1999)
and 29-40% (Modan et al., 2001; Moslehi et al., 2000) of ovarian cancers in the
Ashkenazi Jewish population are attributable to these specific variants.
Similarly, a founder variant in CDH1 has previously been linked to an
increased incidence of gastric cancer in Newfoundland Canada (Kaurah et al.,
2007). Interestingly, Newfoundland has an elevated incidence of gastric cancer
compared to the Canadian average and the regions these families come from
are the highest-risk areas within the province (Kaurah et al., 2007; McLaughlin
et al., 2006). As of yet, the overall contribution of pathogenic CDH1 variants to
the high incidence of gastric cancer has not been determined.
It is unclear why the prevalence of pathogenic CDH1 variants is so high in the
Māori gastric cancer population. Similar to the common variant seen in
Newfoundland, pathogenic CDH1 variants could have arisen as founder
variants prior to the Māori migration to New Zealand. However, the relatively
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high number of distinct CDH1 variants (5 pathogenic variants in this study
alone) suggests that rather than being an illustration of a simple genetic
bottleneck, it is possible CDH1 variants may have provided a selective
advantage to pathogenic variant carriers in ancestral Māori populations.
One possible explanation is that some CDH1 variant carriers may have some
innate resistance to infection with Listeria monocytogenes (L. monocytogenes), a
food-born pathogen that can cause gastroenteritis, meningitis, and miscarriage
in pregnant women (da Silva Tatley, Aldwell, Dunbier, & Guilford, 2003;
Hamon, Bierne, & Cossart, 2006). The bacteria is normally internalised into
epithelial cells by a process requiring the binding of the bacterial protein
internalin-A (InlA) to the N-terminus of the E-cadherin protein (Hamon et al.,
2006). Notably, some truncating E-cadherin variants produce short soluble
N-terminal peptides containing the InlA binding site, which have been shown
in vivo to act as decoy receptors for invading L. monocytogenes (da Silva Tatley
et al., 2003). Additionally, previous work has shown L. monocytogenes takes
advantage of junctional remodelling and exposed E-cadherin to adhere and
invade epithelial cells (Pentecost, Otto, Theriot, & Amieva, 2006). Conceivably,
deleterious CDH1 variant carriers may have less functional E-cadherin
available for bacterial adherence and subsequent invasion. Alternatively, some
CDH1 variants may interfere with the dynamics of L. monocytogenes
internalisation by misregulating the dynamics of the actin cytoskeleton
necessary for actin assembly at the bacterial entry site.
3.3.4 Conclusions
In conclusion, these results show pathogenic germline CDH1 variants are a
major contributor to the high incidence of early-onset diffuse gastric cancer
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seen in the Māori population. The importance of screening for predisposition
to gastric cancer was also apparent in this study group. We speculate that
some CDH1 variants could have provided an evolutionary advantage, which
may explain the high number of pathogenic variants seen in this cohort.
Routine sequencing of germline CDH1 should be considered for all Māori who
present with diffuse gastric cancer to enable genetic testing and early
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Chile is a country with a high incidence of gastric cancer. In this country, a
high prevalence of environmental risk factors is causing a high number of
early-onset and familial gastric cancer cases in Chile. Consequently, the
suggestion that some cases may be hereditary is often ignored. Currently,
there is no formal clinical genetic screening available for gastric cancer patients
in Chile. Despite the lack of screening, hereditary gastric cancers are expected
to explain a small but important portion of cases. Our aim was to identify
pathogneic variants in germline CDH1 carried by early-onset and familial
gastric cancer patients from Chile and highlight the importance of genetic
screening in high-incidence countries.
4.1.1 Chile
Occupying the narrow strip of land between the Andes mountains and the
Pacific Ocean, Chile is one of South America’s largest countries. Chile has been
populated by several tribes of Native Americans since 3000 B.C. (Collier &
Sater, 2004). Chile was conquered and colonised by Spain in the 16th century,
but later attained its independence in 1818 (Collier & Sater, 2004). Currently,
Chile has a population of approximately 18 million people, 40% of whom are
located in Chile’s capital city, Santiago (de la Jara et al., 2015).
There are three main ethnic groups in Chile: European, Mestizo, and Mapuche
(Fernández, 2005). European are the largest ethnic group, accounting for 59%
of the total population. The European group is primarily made up of
individuals with Croatian, French and Italian ancestry, but also includes those
of German, English, and Polish decent. Mestizo are the second largest ethnic
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group and account for 25% of the population. Mestizo includes those with
mixed European and Amerindian heritage. The Mapuche are third largest
ethnic group and are the main indigenous population of Chile. Approximately
9% of the population identify as Mapuche, the majority of whom are located in
the south-central region of the country. Collectively, Mapuche refers to a
wide-ranging ethnicity composed of various groups that share a common
social, religious and economic structure (Crow, 2013). The remaining 7% of the
Chilean population is made up of several small ethnic groups, namely
Africans, Aymara, Rapa Nui, Likan Antai, Colla, Yagan, Kawesqar, and
Quechua (Fernández, 2005).
4.1.2 Gastric cancer in Chile
In Chile, an estimated 35,000 people are diagnosed with cancer every year
(Goss et al., 2013; de la Jara et al., 2015). The age-adjusted incidence rates of
cancer are 226.1 and 180.0 per 100,000 population, for males and females,
respectively (Vallebuona et al., 2011). Notably, the burden of cancer related
mortality in Chile has grown consistently for the past several decades: 8.4% in
1960, 12.1% in 1970, 15.8% in 1980, and 18.1% in 1990 (de la Jara et al., 2015). In
2011, approximately 24% of deaths in Chile were cancer related (de la Jara et
al., 2015).
Gastric cancer is of particular concern for the Chilean population. The IARC
estimated incidence of gastric cancer in Chile is 15.6 per 100,000 population,
much higher than most countries worldwide (Ferlay et al., 2015). For example,
the IARC estimated incidence of gastric cancer in New Zealand is just 2.9 per
100,000 population (Ferlay et al., 2015). Additionally, gastric cancer is the main











































































































































































Figure 4.1: Countries with high gastric cancer incidence and mortality rates.
The 25 countries with the highest IARC estimated gastric cancer incidence and
mortality rates. A low incidence country, New Zealand, is shown for
comparison. Data acquired from: https://www.iarc.fr/.
died as a results of this disease, a rate of 13.8 per 100,000 population (Ferlay et
al., 2015). Strikingly, there was a significant increase in the number of
diffuse-type tumours diagnosed in Chile between 1986-1995 and 1996-2005
(46% versus 62%, respectively, p < 0.001) (Tapia et al., 2010).
Similar to other indigenous populations groups, the Mapuche people are
known to have a higher incidence of gastric cancer than the general
population (Caglevic, Silva, Mahave, Rolfo, & Gallardo, 2016). The
age-standardised incidence of gastric cancer for Mapuche has been reported to
be as high as 47.2 and 28.1, per 100,000 males and females, respectively (Heise,
Bertran, Andia, & Ferreccio, 2009). Higher mortality rates have been observed
in the south-central region of Chile where the Mapuche people historically
settled and diffuse-type tumours account for 55% of tumours (Heise et al.,
2009; Tapia et al., 2010).
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4.1.2.1 High exposure to environmental risk
As previously described in Section 1.1.2, there are a series of environmental
risk factors that influence gastric cancer risk. High levels of a number of these
risk factors are thought to be contributing to the high rates of gastric cancer in
Chile (de la Jara et al., 2015).
H. pylori infection is recognised as the principal risk factor for gastric cancer in
Chile (Caglevic et al., 2016). The prevalence of H. pylori infection is reported to
be as high as 73% in adults and 18% in children (Jaime, Villagrán, Serrano,
Cerda, & Harris, 2013). Diets high in salt are thought to facilitate H. pylori
infection and contribute to the high incidence of disease. The average adult
salt intake in Chile is estimated to be 10.4 grams per day, almost double the
WHO recommended intake of 5.0 grams per day, and significantly higher than
British adults who, on average, consume 8.1 grams per day (Crovetto & Uauy,
2013; López-Rodríguez, Galván-García, & Muzzo, 2009; Sadler et al., 2011). It
is suggested H. pylori and a high salt intake may synergise to promote the
development of gastric cancer (Caglevic et al., 2016).
Obesity is another risk factor thought to contribute to the high incidence of
gastric cancer in Chile. It is estimated that up to 20% of all cancers in Chile are
obesity related (de la Jara et al., 2015). Recent statistics show that 67% of the
Chilean population are overweight and 25% are obese (de la Jara et al., 2015).
Moreover, it is estimated that 88% of the population lead a sedentary lifestyle
that contributes to obesity (de la Jara et al., 2015).
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4.1.2.2 Screening for gastric cancer in Chile
Chile has taken steps to reduce the burden of gastric cancer by introducing a
gastric cancer screening programme. In 1995, the Chilean Ministry of Health
started an endoscopic-based screening pilot programme in Santiago. For the
1996–2006 period, the pilot screened 10,284 individuals, during which time 190
gastric cancers were identified (8.5 per 100 000 population, per year). On
average, 70 gastroscopies were required to identify one gastric cancer. One
third of these cancers were early stage and the average 5-year survival rate of
those diagnosed with gastric cancer via screening was 40%. In 2006, the
Ministry of Health initiated a nationwide gastric cancer detection programme
that focused on symptomatic individuals. It guaranteed endoscopic
examination for any patient older than 40 years of age that experienced
epigastric pain lasting more than 15 days, heavy bleeding, anaemia, weight
loss of unknown origin, general feeling of weakness, tiredness, loss of
appetite, or dysphagia. History of gastrectomy and family history of gastric
cancer are also taken into consideration but do not automatically lead to
screening. Additionally, unless endoscopic examination is normal, H. pylori
eradication is recommended for individuals with duodenal or stomach ulcers,
atrophic gastritis, lymphoma, gastric cancer, or a family history of gastric
cancer. Genetic testing is not a part of standard care for those that appear to
have a strong family history or early-onset of disease.
4.1.3 Hereditary gastric cancer in Chile
During the last decade there has been increased awareness of the importance
of identifying individuals with inherited cancer syndromes. Chile is a country
with good health standards and reliable services, but does not have an
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extensive clinical genetics programme (Castillo Taucher, 2015). In 2015, there
were 30 clinical geneticists in Chile, the majority of which resided in Santiago
(Castillo Taucher, 2015). Based on the WHO recommendation of having one
clinical geneticist per 100,000 population, Chile should have had
approximately 170 clinical geneticist’s at this time (Castillo Taucher, 2015).
Pathogenic variants in CDH1 are known to predispose to hereditary gastric
cancer and may be responsible for some of early-onset and familial gastric
cancer cases in Chile. To our knowledge, prior to this study, there have not
been any pathogenic variants in germline CDH1 in gastric cancer patients from
Chile. Identification of pathogenic variants in CDH1 in high-risk individuals
will improve awareness of hereditary gastric cancer syndromes and highlight
the importance of genetic testing HDGC families in Chile.
4.2 Results
In this chapter, next-generation amplicon sequencing was used to identify
variants in germline CDH1 in a series of Chilean gastric cancer probands with
either a striking early-onset and/or family history of gastric cancer. Germline
CDH1 variants were evaluated, and rare and potentially pathogenic variants
were validated using Sanger sequencing. I then screened the family of
probands with pathogenic CDH1 variants to determine carrier status.
4.2.1 Characterisation of Chilean cohort
Germline CDH1 was sequenced in 51 Chilean probands diagnosed with
gastric cancer between 2006 and 2017. Study inclusion criteria consisted of
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having early-onset gastric cancer or a striking family history of gastric cancer.
DNA samples and clinical details were collected by the referring institutions.
Clinical details from the proband cohort are summarised in Table 4.1. The
cohort consisted of 27 males (53%) and 24 females (57%). The average age of
diagnosis was 47.8 years (range 17-80 years). The majority of probands (74.5%)
were diagnosed with diffuse gastric cancer, while a small proportion were
diagnosed with intestinal-type cancer (21.6%), and no subtype was recorded
for two probands (3.9%). Tumour stage was defined according to TNM
classification (Strong, D’Amico, Kleinberg, & Ajani, 2013) and were near
evenly distributed across the four stages. Two thirds of cases (66.7%) were
poorly differentiated. Tumour location was not recorded.
The history of cancer in the proband’s family was also collected and is
summarised in Table 4.2. Family history data included the cancer type and age
at diagnosis for first, second and third degree relatives. Many of the probands
had a striking family history of gastric cancer and/or breast cancer. Four
probands are a part of families with five or more extended family members
that had been diagnosed with gastric cancer. Eight probands had one or more
family members diagnosed with breast cancer, four of whom also had multiple
gastric cancers diagnosed in their families. Remarkably, one proband in the
Chilean study cohort had an additional eight family members who have been
diagnosed with gastric cancer.
Unfortunately the subtype of gastric and breast cancers in the extended family
of probands were not recorded. Because of this, I was unable to determine if
many of these probands would have met the clinical criteria for HDGC testing
(van der Post et al., 2015). Twenty-eight probands were diagnosed with diffuse
gastric cancer less than 40 years of age, or were diagnosed with diffuse gastric






















Well differentiated 4 7.8
Moderately differentiated 13 25.5
Poorly differentiated 34 66.7
Table 4.1: Characteristics of Chilean gastric cancer probands. The stage of
tumours are defined by TNM staging. Tumours graded as poorly
differentiated include signet ring cell carcinomas. NOS, Not otherwise
specified.
gastric cancer, fitting the most recent clinical criteria for HDGC. The other 23
probands in this study had a family history of gastric and/or breast cancer,
however without the subtypes of the cancers diagnosed in the proband’s
extended family, the probands could not be accurately compared to the HDGC
testing criteria.
4.2.2 Sequencing libraries and data
DNA samples from Chilean probands arrived in small groups over three
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Proband meets clinical criteria for HDGC testing
Yes 28 54.9
No 23 45.1
Table 4.2: Summary of family history data collected for Chilean probands. The
number of family members with gastric cancer and the number of gastric
cancers diagnosed under 50 years of age include the study proband. The 2015
IGCLC guidelines are were used to define HDGC testing criteria (van der Post
et al., 2015).
timely testing of these samples, sequence data was generated across multiple
MiSeq runs and by Sanger sequencing. Sequencing libraries for these samples
were prepared and tested the same way as previously described in Section
3.2.3. Sequencing libraries were included in MiSeq runs five, six, seven, and
eight (previously described in Chapter 3 Table 3.3). PCR products for Sanger
sequencing were prepared using primers listed in Appendix A.4.
4.2.3 CDH1 variants
In total, 11 different germline CDH1 variants were identified across the 51
Chilean probands (Table 4.3). Of these, eight variants were located in the
coding exons of CDH1 (six synonymous, one missense, and one nonsense),
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two variants were located in the proximal promoter, and one was located in an
intronic splice site. Table 4.3 shows the position of each variant, the minor
allele frequency in this series of probands, and allele frequencies from major
population databases. To assess the clinical significance of variants identified
in this cohort, all rare non-synonymous variants (MAF < 0.05) were reviewed.




Proband 6 was found to carry a CDH1 c.1531C>T variant. This variant causes
the premature termination of the E-cadherin protein by changing a glutamine
residue to a stop codon at codon 511 (p.Gln511*). Proband 6 was was
diagnosed with advanced diffuse gastric cancer aged 23 years. Proband 6 did
not have a family history of gastric cancer or lobular breast cancer. CDH1
c.1531C>T has reported as pathogenic variant in ClinVar.
4.2.3.2 Missense variants
c.88C>A
Proband 17 was was found to carry a CDH1 c.88C>A variant. The proband
was diagnosed with advanced diffuse gastric cancer aged 59 years. The
probands father and paternal grandfather were also diagnosed with gastric
cancer, aged 65 and 51 years, respectively. CDH1 c.88C>A causes a proline to
threonine substitution at codon 30 of the E-cadherin protein (p.Pro30Thr). The
proline residue is weakly conserved between species and there is only a small
































































































































































































































































































































































































































































































































































































c.88C>A is deleterious. CDH1 c.88C>A is present at low frequencies in ExAc
(MAF 0.00094), 1000 Genomes (MAF 0.0004), and ESP6500 (MAF 0.0010)
variant databases. ClinVar most frequently classifies this variant as likely
benign. Notably, this variant was also identified in one healthy control in the
Māori cohort (Section 3.2.4.3).
4.2.4 Frequency of pathogenic CDH1 variants in probands
Proband 6 was the only proband found to carry a pathogenic CDH1 variant.
As a patient diagnosed with diffuse gastric cancer aged 23 years, Proband 6
fits the criteria for CDH1 screening (van der Post et al., 2015). With the possible
exception of Proband 17, none of the other 28 probands fitting CDH1 testing
criteria, or the other 23 probands who lacked enough detailed family history to
apply the clinical criteria for HDGC, carried a pathogenic CDH1 variant.
Overall, patogenic variants in germline CDH1 were identified in 3.6% (1/28) of
probands who met HDGC testing criteria and 2.0% (1/51) of all probands in
this study.
4.2.5 Inheritance of CDH1 c.1531C>T (p.Gln511*) in the family
of Proband 6
A further eight family members of proband 6 were sequenced to determine
carrier status of the pathogenic c.1531C>T (p.Gln511*) variant. Of these eight
family members, five were found to carry the same pathogenic variant (Figure
4.2a). The proband’s sibling (IV4; age 19 years), mother (III4; age 45 years),
maternal cousin (IV1; age 20 years), maternal aunt (III2; age 44 years), and
maternal grandmother (II7; age 66 years), were all found to carry the
c.1512C>T variant (Figure 4.2b). The proband’s maternal grandfather (II6;
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aged 70 years), father (III5; age 44 years), and maternal cousin (IV2; age 23
years) were also tested, but were homozygous for the reference allele (Figure
4.2c). Chromatograms showing the variant site for all eight family members
are shown in Appendix E. Variants were also independently validated by
clinical services in Chile.
Further members of proband 6’s extended family could also carry the
pathogenic variant (Figure 4.2a). The half-sibling of the proband (IV3) has a
50% chance of carrying the pathogenic variant but is currently too young for
genetic testing. If the c.1512C>T variant was inherited from either of the the
proband’s maternal great-grandparents (I3 and I4), the maternal grand-aunts
and grand-uncles of the proband (I8-I13) may also be at risk. Both maternal
great-grandparents are deceased and died of unrelated causes. I3 died as a
result of respritory problems aged 75 years, while I4 died as a result of bladder
intervention age unknown.
The five probands that were found to carry the pathogenic CDH1 c.1512C>T
variant are now receiving counselling.
4.3 Discussion
Chile has some of the world’s highest gastric cancer incidence and mortality
rates. High levels of environmental risk are largely to blame, while the
possibility of genetic predisposition is generally ignored. In this study,
next-generation amplicon sequencing was used to sequence germline CDH1 in
a series of 51 Chilean gastric cancer probands with striking early-onset or
familial gastric cancer, 28 of whom fit the clinical criteria for HDGC. Overall, I
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Figure 4.2: Analysis of proband 6 family members. (a) Family tree showing
the extended family of Proband 6. (b) Exemplar Sanger sequence of the
c.1531C>T variant. (c) Exemplar Sanger sequence of homozygous reference
allele. Both Sanger sequences are shown in the forward direction.
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additional eight family members of the affected proband identified a further
five pathogenic variant carriers. To our knowledge, this is the first pathogenic
CDH1 variant to be reported in Chile and one of a handful of HDGC families
with a confirmed pathogenic CDH1 variant to be identified in South America.
4.3.1 A low rate of variant detection
The frequency of cases that fulfil HDGC testing criteria and carry a pathogenic
variant in germline CDH1 varies between populations with high or low gastric
cancer incidence (Oliveira, Seruca, & Carneiro, 2009). To illustrate this,
Oliveira, Seruca, and Carneiro (2009) analysed the frequency of pathogenic
CDH1 variants in families fulfilling the criteria for HDGC from regions with
low, moderate, and high incidence of gastric cancer. Overall the frequency of
germline CDH1 alterations in countries with a low-incidence of gastric cancer
was approximately 40% in HDGC families, and 20% in isolated patients with
diffuse gastric cancer under the age of 35 years. In contrast, in moderate and
high-incidence countries, the frequency of pathogenic CDH1 variants was less
than 20% both in HDGC families and isolated patients with diffuse gastric
cancer less than 35 years of age (Oliveira, Seruca, & Carneiro, 2009). The
detection rate of pathogenic variants in germline CDH1 in HDGC and
early-onset diffuse gastric cancers from the high-incidence countries of
Portugal, Japan, and South Korea, range between 8% and 15% (S. Kim et al.,
2013; Oliveira, Ferreira, et al., 2004; Yamada et al., 2011).
In the current study, 3.6% (1/28) of probands whom meet the 2015 clinical
criteria for HDGC (van der Post et al., 2015) and 2.0% (1/51) of all probands in
this study were found to carry a pathogenic pathogenic variant in germline
CDH1. The frequency of pathogenic variants reported here are noticeably
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lower than those published in the aforementioned high-incidence populations.
There are a series of reasons that may explain this difference. Firstly, although
large deletions in CDH1 are rare (Oliveira, Senz, et al., 2009), I can not exclude
the possibility that some of these probands carry a large deletion in CDH1
which may have been missed by our amplicon sequencing. Secondly, the 2015
criteria used to define HDGC cases in this study are broader than those used
in earlier studies. By broadening the clinical criteria for HDGC, probands were
included in this analysis whom would not have been included if an older
version of HDGC criteria were used. For example, if the 2010 HDGC CDH1
screening criteria (Fitzgerald et al., 2010) were used to define those tested,
6.7% (1/15) of probands would carry a pathogenic CDH1 variant. Thirdly, 11
probands in this study were diagnosed with intestinal-type gastric cancer.
Intestinal-type gastric cancer is not a part of HDGC and is not caused by
pathogenic CDH1 variants. These intestinal-type cases do not affect the
frequency of pathogenic variants in probands that fit HDGC testing criteria in
this study, however if all 11 intestinal-type cases were removed from the
overall cohort, 2.5% (1/40) of all probands in this study would carry a
pathogenic variant.
4.3.2 The importance of genetic screening in high-incidence
countries
Pathogenic CDH1 variant carriers have an extreme risk of developing diffuse
gastric cancer and lobular breast cancer. Consequently, the identification of
CDH1 variants in probands and subsequently in their relatives, is of great
importance. Unfortunately, CDH1 variants have incomplete penetrance,
making it hard to distinguish hereditary cancer families from sporadic
early-onset cases or familial clusters without genetic testing.
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It is thought that environmental factors are driving the overall high incidence
of gastric cancer in Chile. Accordingly, environmental factors are likely
causing some early-onset cases and sporadic family clusters, which mask true
hereditary gastric cancer families. Until the prevalence of environmental
factors is reduced, the detection of true hereditary gastric cancer families will
be difficult and will return high rates of negative results. Despite this, I stress
the importance of screening individuals that meet HDGC testing criteria. As
seen in this study, by identifying one individual with a pathogenic CDH1
variant, I was able to screen and identify an additional five family members
that are at an extreme risk of diffuse gastric cancer. These family members are
now receiving additional targeted care to mitigate disease risk and will
undoubtedly have a better prognosis than if they were to present with
late-stage disease.
In high-incidence populations such as Chile, there will be large numbers of
patients diagnosed with compelling family histories and clinical features.
Twenty-three of the probands in this study were not diagnosed with diffuse
gastric cancer and/or did not have enough detailed family history to show
they met the clinical criteria for HDGC. It is likely that if detailed clinical
records and family histories were available, some of these cases would not
have met HDGC testing criteria and would not typically be offered CDH1
screening. In particular, patients diagnosed with intestinal-type gastric cancer
or those that present with a family history of intestinal-type gastric cancer are
not likely to benefit from CDH1 variant screening. To prevent
resource-consuming testing of patients that are unlikely to carry pathogenic
variants, detailed clinical features and family history of cancer should be
collected and considered before genetic testing. For families with a variety of
cancer types and/or subtypes, screening of other cancer predisposition genes




Overall, our results show pathogenic germline CDH1 variants were not a
common cause of gastric cancer in a series of Chilean probands. I show the
importance of screening CDH1 in cases who meet the clinical criteria for
HDGC, and if a pathogenic variant is identified, their extended family. This
study is also a reminder that a detailed family history of cancer should be
collected for gastric cancer patients, and that CDH1 screening need not be
offered to those diagnosed with intestinal-type gastric cancer. I stress the
importance of applying the HDGC criteria to identify those that may be at risk
and provide them with appropriate genetic testing. This research is relevant to
the development of clinical guidelines for screening germline CDH1 in Chile,









Pathogenic variants in germline CDH1 explain approximately 40% of cases
that fit the clinical criteria for HDGC. An explanation for the remaining 60% of
HDGC cases remains largely elusive. In this chapter, whole-exome sequencing
was used to examine HDGC patients that did not carry pathogenic CDH1
variants and identify variants that may be increasing diffuse gastric cancer
risk.
5.1.1 Discovery of cancer predisposing genes
More than 100 cancer predisposition genes have been identified over the last
three decades (Rahman, 2014). Since the year 1990, at least one new cancer
predisposition gene has been identified each year (Rahman, 2014).
Genome-wide linkage analysis has been the most successful strategy for gene
identification, leading to the discovery of 60 high-risk cancer predisposition
genes in the 1990s (Rahman, 2014). Candidate gene studies have also been
utilised for gene discovery, but with less success (Rahman, 2014). More
recently, the field of cancer genomics has been impacted by the application of
next-generation sequencing (NGS) technology that has accelerated the pace of
gene discovery while dramatically reducing the cost of sequencing.
Although there have been many important breakthroughs in the identification
of cancer predisposition genes, the missing heritability of many familial cancer
syndromes suggests that more cancer predisposition genes remain to be
discovered. Next-generation whole-genome and whole-exome sequencing
studies are ideally suited for the identification of high-risk genes. As with
other common complex conditions, identification of low- and
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moderate-penetrance genes will be challenging and will require large
collaborative efforts.
5.1.2 Genetic predisposition to gastric cancer
On average familial clustering of gastric cancer occurs for approximately 10%
of cases, but has been reported to be as high as 39% in some populations
(Yaghoobi et al., 2010). Hereditary gastric cancer syndromes, where inherited
germline variants are predisposing to a heightened risk of developing gastric
cancer, are thought to account for between 1-3% of all gastric cancers (Section
1.1.2).
HDGC is the most common hereditary gastric cancer syndrome. Pathogenic
germline variants in the E-cadherin gene CDH1 are well documented and
explain approximately 40% of HDGC cases (Hansford et al., 2015). An
explanation for the remaining 60% of HDGC cases remains largely elusive. A
small number of additional HDGC predisposition genes have been proposed,
but still require further validation. There is also emerging evidence that other
cancer predisposition syndromes may commonly present with the same
characteristics as HDGC.
5.1.2.1 Additional genes implicated in HDGC
As previously outlined in Section 1.1.4.3, further to germline CDH1 variants,
three studies have proposed a total of five additional HDGC genes, specifically
CTNNA1 (Majewski et al., 2013), MAP3K6 (Gaston et al., 2014), INSR (Donner,
Kiviluoto, Ristimäki, Aaltonen, & Vahteristo, 2015), FBXO24, (Donner et al.,
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2015), and DOT1L (Donner et al., 2015). These genes and the studies which
proposed them are discussed in detail below.
Pathogenic germline variants in α-catenin (CTNNA1) were first described by
Majewski et al. (2013) in a Dutch family with several cases of diffuse gastric
cancer over four generations. In this family, a truncating germline CTNNA1
variant was identified in two family members diagnosed with diffuse gastric
cancer, and four first degree relatives that had intramucosal signet ring cells
identified during endoscopic screening. Cases with the CTNNA1 variant
developed diffuse gastric cancer late in life (generally > 50 years of age),
suggesting this variant has a low to moderate penetrance. α-catenin was
detectable in normal epithelial structures, but was completely absent in the
tumour cells from two affected family members. Additionally, α-catenin
expression was lost in foci of signet ring cells detected in biopsy samples
obtained from a first-degree relative that carried the CTNNA1 variant.
α-catenin is involved in the cell-adhesion complex and facilitates adhesion and
communication between neighbouring epithelial cells. As previously
described in Section 1.1.4, α-catenin binds and secures interaction between
β-catenin, E-cadherin, and the actin cytoskeleton. Through its interactions
with the adherens junction, α-catenin directly regulates the assembly and
organisation of actin-filaments within the cell-adhesion complex (Gall &
Frampton, 2013; Sun, Zhang, & Ma, 2014). CTNNA1 is mutated in a variety of
cancer cell lines and primary tumours, and loss of α-catenin expression has
been reported in sporadic gastric cancers (Bignell et al., 2010; Shiozaki et al.,
1994). In animal models, loss of α-catenin induces hyperproliferation and
impaired apoptosis in skin cells (Vasioukhin, Bauer, Degenstein, Wise, &
Fuchs, 2001). In addition to the family described by Majewski et al. (2013),
germline variants in CTNNA1 have been discovered in a small number of
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additional HDGC families, supporting it’s inclusion as an HDGC gene, and
highlighting the importance of the adherens junction complex in HDGC
(Hansford et al., 2015; Schuetz et al., 2012).
Gaston et al. (2014) first described germline variants in MAP3K6 in a large
family from Maritime Canada with a history of gastric cancer. This family
presented with many features associated with HDGC, but with late onset of
disease (generally greater than 50 years of age). In this family, four affected
cases and five of 27 currently unaffected relatives harboured a truncating
MAP3K6 variant. A somatic mutation in MAP3K6 and hypermethylation of
MAP3K6 were detected in tumour DNA from two variant carriers. In
screening of an additional 115 individuals from unrelated CDH1
variant-negative gastric cancer families, four additional MAP3K6 variants (one
truncating and three missense variants) were identified. It is noteworthy that
in this family, the MAP3K6 variant did not completely segregate with disease
in this family and appears at a moderate frequency in the ExAc database (MAF
0.005), suggesting that this variant may be low penetrance.
MAP3K6 encodes a serine/threonine protein kinase that forms a component of
protein kinase-mediated signal transduction cascades (Iriyama et al., 2009).
The encoded kinase participates in the regulation of vascular endothelial
growth factor expression, apoptosis, and inflammation (Iriyama et al., 2009).
MAP3K6 is known to act as a tumour suppressor gene in epithelial cells and is
mutated in some gastric tumours and gastric cancer cell lines (Zang et al.,
2011). Further evidence of cancer risk will be required for MAP3K6 to be
considered a putative HDGC gene.
Donner et al. (2015) studied a family in which there there were six cases of
diffuse gastric cancer over two generations. Exome sequencing was used to
identify shared rare deleterious variants in two cases that were then Sanger
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sequenced in a third affected family member. Three candidate variants were
shared by all three cases: INSR p.Glu1313Lys, FBXO24 p.Arg81Pro, and
DOT1L p.Pro1146Leu. Analysis of tumour samples from these three family
members did not show loss of heterozygosity for any of the candidate genes,
and screening of an additional 26 gastric cancer patients with a confirmed or
suspected family history of diffuse gastric cancer did not identify any
additional variants in INSR, FBXO24, and DOT1L.
Of particular is the INSR variant. INSR encodes a transmembrane insulin
receptor that is activated by insulin, IGF-I, and IGF-II (Ebina et al., 1985). INSR
belongs to the tyrosine kinase growth factor receptor family and functions as
an enzyme that transfers phosphate groups from ATP to tyrosine on
intracellular proteins (Arcidiacono et al., 2012). Metabolically, INSR plays a
key role in insulin signalling and is primarily involved in glucose metabolism.
INSR has been implicated in the regulation of cellular growth and
differentiation, and under degenerate conditions, is thought to contribute to
cancer progression (Ebina et al., 1985; Malaguarnera et al., 2012; Taniguchi,
Emanuelli, & Kahn, 2006). Similar to MAP3K6, more evidence will be required
before INSR, DOTL1, or FBXO24 can be confirmed as HDGC genes.
5.1.2.2 Gastric cancer as a part of other cancer predisposition
syndromes
Gastric cancer is a part of a number of other familial cancer syndromes
(previously described in detail in Section 1.1.3.4). Accordingly, some studies
have reported families who meet the clinical criteria for HDGC and carry
pathogenic variants in genes that are more strongly associated with other
cancer types.
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In a study of CDH1 variant-negative HDGC probands, Hansford et al. (2015)
used a NGS targeted panel approach to identify pathogenic variants in genes
known to be associated with hereditary cancer syndromes, for which gastric
cancer is a part of the wider tumour spectrum. Overall 11% of CDH1
pathogenic variant-negative HDGC probands carried candidate germline
variants in other cancer predisposition genes. Specifically, the authors
identified truncating variants in ATM, BRCA2, CTNNA1, MSR1, PALB2,
PRSS1, SDHB, and STK11 (Hansford et al., 2015).
Similarly, Sahasrabudhe et al. (2016) used a combination of whole-exome
sequencing, targeted amplicon sequencing of candidate genes, and genotyping
of specific variants, to identify causal variants in known DNA damage repair
genes. Overall, 6.5% (2/31) of cases in this study that fitted the clinical criteria
for HDGC carried a pathogenic variant in either PALB2, RAD51C, or BRCA1
(Sahasrabudhe et al., 2016), genes that are more associated with breast cancer
risk. Strikingly, a further 9/331 (2.8%) patients with sporadic gastric cancer
were found to have pathogenic variants in PALB2, RAD51C, or BRCA1.
Some studies have also noted pathogenic germline variants in cancer
predisposition genes in unselected gastric cancer cases. In a study of the
germline variants in data generated by The Cancer Genome Atlas (TCGA), Lu
et al. (2015) reported 11% of gastric cancer cases carried rare truncating
variants in the tumour suppressor genes ATM, BRCA2, BRIP1, EME2, PALB2,
and XRCC2. Interestingly, the authors also reported a bimodal distribution for
age of onset in their gastric cancer cohort and an association between
pathogenic ATM variants and early-onset gastric cancer (p < 0.05), an
observation that has also been reported by others (Helgason et al., 2015;
Huang et al., 2015). Cancer predisposition syndromes that are characterised by
variants in these genes are described in detail in Section 1.1.3.4.
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5.1.3 Overlap of somatic and germline cancer genes
Lauren’s classification of gastric cancer is largely based on histological
assessment of glandular formation in the intestinal-type versus early loss in
cell-to-cell adhesion in the diffuse-type (Lauren, 1965). As previously
described in Section 1.1.1.1, in addition to histological classification, recent
molecular profiling of gastric tumours found four specific molecular profiles
with unique mutational signatures: Epstein-Barr virus (EBV)-positive,
microsatellite instable (MSI), chromosomal instable (CSI), and genomically
stable (GS) (Bass et al., 2014). Of particular interest is the GS subtype, which
was enriched for diffuse-type tumours with poor cell differentiation and
defective cell adhesion (Bass et al., 2014). As HDGC is characterised by
diffuse-type tumours, it is logical to consider that the genes frequently
mutated in the GS subtype may also be genes that are important in the
development of hereditary diffuse gastric cancer risk
Analysis of the GS tumours found that CDH1 was somatically mutated in up
to 37% of cases (Bass et al., 2014; Chen et al., 2015; Wang et al., 2014; Wong et
al., 2014). Furthermore, pathway enrichment analysis using the genes that
were most frequently altered by mutations, hyper-methylation, and copy
number changes, found that the adherens junctions, focal adhesions, and
WNT signaling pathways were over-represented. Of note, the genes CTNNA1,
CTNNA2, and CTNNB1 were all frequently mutated in GS tumours. Together,
these findings highlight the importance of the adherens junction complex and
cell adhesion in the diffuse gastric cancer (Wang et al., 2014). Unexpectedly,
aberrations in Rho signalling were also enriched in GS tumours. Ras homolog
gene family, member A (RhoA), encoded by the gene RHOA, was reported to
be mutated in up to 25.3% of GS tumours (Bass et al., 2014; Wang et al., 2014).
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Additionally, fusions involving Rho-family GTPase-activating proteins
(RhoGAPs) were reported in approximately 15% of GS tumours (Bass et al.,
2014).
RhoA is a member of the Rho GTPase family, which belongs to the Ras
superfamily of small GTP-binding proteins (Wennerberg, Rossman, & Der,
2005). RhoA is a multifunctional protein that, through the action of various
effector proteins, regulates a range of biological functions including actin
organisation, intracellular transport, cell migration, cell cycle, cell
proliferation, cell adhesion, oncogenic transformation, and tissue repair
(Ridley et al., 2003; Thumkeo, Watanabe, & Narumiya, 2013). RhoA exists in
two states: active GTP-bound and inactive GDP-bound. The activity state of
RhoA is regulated by a group of activating guanine exchange factors (GEFs),
that control the change of GTP to GDP, and two groups of deactivators,
GTPase activating proteins (GAPs) and guanine dissociation inhibitors (GDIs),
that increase the rate of GTP hydrolysis and inhibits the release of GDP,
respectively (Ridley et al., 2003).
RHOA mutations are highly enriched in GS tumours, but have also been
identified in EBV-positive and MSI tumours at a lower frequency, suggesting
there may be some overlap between molecular subtypes (Bass et al., 2014;
Chen et al., 2015; Wang et al., 2014; Wong et al., 2014). Somatic RHOA
mutations in gastric tumours show clustering in the GTP domains and effector
binding regions of the protein. Functional characterisation of two hotspot
mutations (p.Tyr42Cys and p.Leu57Val) has shown that these mutations result
in abnormal RHOA proteins that promote evasion from anoikis (Wang et al.,
2014).
Regulation of Rho signalling was further implicated as a key regulator of
carcinogenesis of diffuse-type tumours by the discovery of recurrent genomic
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Figure 5.1: The Rho-GTPase activation cycle. Regulation of small RhoGTPases
(RhoA; red) by guanine nucleotide exchange factors (GEFs; green) and
GTPase-activating proteins (GAPs; orange). GEFs replaces GDP with GTP to
activate the signalling function of the GTPase. Conversely, GAPs stimulate
hydrolysis of GTP into GDP to inactivate the GTPase. Guanine dissociation
inhibitors (GDIs) inhibit the release of GDP. Abbreviations: GAP,
GTPase-activating protein; GEF, guanine exchange factor; GDI, gaunine
dissociation inhibitors; GDP, Guanosine diphosphate; GTP, Guanosine
triphosphate; P, phosphate.
fusions between CLDN18 and two different RhoGAPs (ARHGAP26 and
ARHGAP6) in the GS subtype (Bass et al., 2014). CLDN18 is a component of
tight junction adhesion structures and has a role in maintaining cell polarity
and cell signalling (Morita, Furuse, Fujimoto, & Tsukita, 1999). Functional
analysis of CLDN18-ARHGAP26 showed that this fusion inhibits RhoA and
impairs epithelial integrity by reducing cell–cell and cell–extracellular matrix
adhesion (Yao et al., 2015). As RhoGAPs function to convert the active GTP
form of RhoA to its inactive GDP form, it is plausible that the fusion with
CLDN18, a membrane protein highly expressed in stomach, may result in
increased presence of these ARHGAPs in proximity to the cell membrane,
increasing GTPase activity and inactivation of RhoA at cell junctions.
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Furthermore, RHOA mutations do not overlap with CLDN18-ARHGAP
fusions, suggesting they may have similar roles in the carcinogenic process
(Bass et al., 2014).
Hypothetically, mutations in guanine exchange factors, that normally activate
RhoA, may prevent the normal activation of RhoA effector proteins.
Mutations in these guanine exchange factors may thereby cause a similar effect
to CLDN18-ARHGAP fusions and mutated RHOA, and inhibit or impair
effective RhoA signalling. Somatic nonsynonymous mutations in guanine
exchange factors (e.g., VAV1, VAV3, and ARGEF13) have been identified in
both diffuse- and intestinal-type tumours, suggesting they may be important
in tumourgenesis (Kakiuchi et al., 2014).
5.2 Results
Approximately 60% of gastric cancer patients who meet clinical criteria for
HDGC testing do not carry a pathogenic variant in germline CDH1. It is
probable that a proportion of these patients carry a predisposing variant in
another gene. In this chapter, whole-exome sequencing was used to search for
germline variants that may be predisposing to diffuse gastric cancer in a series
of CDH1 variant-negative HDGC patients.
5.2.1 Study cohort
Our whole-exome sequencing cohort comprised fourteen diffuse gastric
cancer patients from twelve different families (Table 5.1). Ten of the 14 cases
have one or more family members that have been diagnosed with gastric
cancer or breast cancer. Unfortunately, the subtypes of the majority of breast
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and gastric cancers in the extended family members of these cases could not be
verified. Cases that were confirmed were all lobular breast cancers or diffuse
gastric cancers. All patients in this study had previously tested negative for
germline CDH1 variants and meet one of the clinical criteria for HDGC CDH1
screening (van der Post et al., 2015). Eleven patients were single probands
from HDGC families, and three patients were from the same family (Family 9).
Family 9 is an Ecuadorian family in which three siblings were diagnosed with
diffuse gastric cancer aged 32, 53, and 56 years. The average age of the cases in
this study at the time of diagnosis was 37 years (range 22-56 years).
5.2.2 Characterisation of exome sequencing data
Sequence data was generated on an Illumina HiSeq in two sequencing runs.
The first run sequenced 11 patients in October 2013. The remaining three
patients were not available at that time, therefore they were sequenced
separately in July 2014. Basic read and mapping information is shown in Table
5.2.
For the first run, eleven libraries were prepared using TruSeq Exome
Enrichment Library Preparation Kit and were sequenced on one lane of an
Illumina HiSeq. There was considerable difference in the representation of
these twelve libraries. The total number of reads ranged between 10.6 million
and 39.6 million per sample. The number of on-target reads ranged between
6.0 million and 39.4 million reads per sample, and the average depth of
sequencing at target regions ranged between 7.8 and 52.0 reads.
For the second run, three libraries were prepared using a Nextera Exome
Enrichment Library Preparation kit and also sequenced on one lane of an
Illumina HiSeq. Compared to the libraries on run one, the representation for
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Patient Description Family
X3279 Diagnosed with diffuse gastric cancer aged 33 years. Sister
diagnosed with gastric cancer (unspecified type) age 35
years. Mother diagnosed with abdominal carcinoma age
78 years.
1
X5799 Diagnosed with diffuse gastric cancer aged 50 years.
Father diagnosed with gastric cancer (unspecified type)
aged 30 years, uncle diagnosed with gastric cancer
(unspecified type) aged 62 years, sister diagnosed with
cervical cancer aged 55 years, and grandfather diagnosed
with prostate cancer aged 81 years.
2
X7045 Diagnosed with diffuse gastric cancer aged 36 years. Aunt
diagnosed with breast cancer (unspecified type).
3
X7223 Diagnosed with diffuse gastric cancer aged 32 years. Two
sisters diagnosed with diffuse gastric cancer aged 28 and
36 years, one brother diagnosed with diffuse gastric cancer
aged 40 years, mother diagnosed with gastric cancer
(unspecified type) aged 41 years, and uncle diagnosed
with gastric cancer (unspecified type) aged 55 years.
4
X8288 Diagnosed with diffuse gastric cancer aged 22 years. No
reported history.
5
X8289 Diagnosed with diffuse gastric cancer aged 31 years. No
reported history.
6
X8706 Diagnosed with diffuse gastric cancer aged 36 years. No
reported history.
7
X8744 Diagnosed with diffuse gastric cancer aged 31 years. Sister
diagnosed with diffuse gastric cancer aged 33 years.
8
Y128 Diagnosed with diffuse gastric cancer aged 32 years. Two
siblings diagnosed with diffuse gastric cancer aged 53 and
56 years.
9
Y129 Diagnosed with diffuse gastric cancer aged 53 years. Two
siblings diagnosed with diffuse gastric cancer aged 32 and
56 years.
9
Y130 Diagnosed with diffuse gastric cancer aged 56 years. Two
siblings diagnosed with diffuse gastric cancer aged 32 and
53 years.
9
Y712 Diagnosed with diffuse gastric cancer aged 45 years.
Previously diagnosed with bilateral breast cancer
(unspecified type). Father diagnosed with gastric cancer
(age unspecified).
10
Y713 Diagnosed with diffuse gastric cancer aged 29 years.
Father diagnosed with pancreatic cancer aged 55 years.
11
Y714 Diagnosed with diffuse gastric cancer aged 36 years. Aunt
diagnosed with breast cancer aged 60 years.
12
Table 5.1: Exome sequencing study cohort. Patient identifier, description, and
family identifier for each study participant. The vertical line highlights the
three siblings from Family 9.
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these three libraries were much more even. The total number of reads ranged
between 89.1 million and 90.9 million per sample. The number of on-target
reads ranged between 54.4 million and 56.2 million per sample, and the
average depth of sequencing at target regions ranged between 63.6 and 66.3
reads.
5.2.3 Variant filtering
Exome data was filtered to identify rare variants that may be of significance
for diffuse gastric cancer (Figure 5.2). Before filtering there were 1,001,969
variant sites (894,699 SNPs and 107,270 indels). First, variant sites were filtered
for quality by removing variants that did not pass variant quality score
recalibration (VQSR). An additional hard filter was used to remove low
coverage variant (< 5 reads), that are difficult to interpret and more prone to
bias. Variants were then filtered for effect, where synonymous, intragenic, and
intronic variants were removed, retaining only nonsense, missense, frameshift,
and splice site variants. Finally, variant sites were filtered for rarity by
removing variants which were common (MAF > 0.001) in any of the three
major population databases (ESP6500, 1000 Genomes, and ExAc). Post
filtering there were 2,227 rare variants (2,022 SNPs and 205 indels).
5.2.4 Prioritising variants
Following variant filtering, the list of 2,227 variant sites was examined to
identify genes with a potential role in the carcinogenesis of diffuse gastric
cancer. Although 224 genes contained multiple rare variants, as with many
small scale exome-sequencing based studies, there was no single gene or
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Figure 5.2: Schematic diagram of variant filtering, prioritisation, and
evaluation of variants. Variants were filtered for quality, location, and
frequency in population databases. Variants which were identified in focus
areas, or were shared by all three members of Family 9 were prioritised for
further evaluation. Abbreviations: ESP6500, Exome Sequencing Project; ExAc,




ACP1, ACTB, ACTG1, ACTN1, ACTN2, ACTN3, ACTN4, AFDN, BAIAP2,
CDC42, CDH1*, CREBBP, CSNK2A1, CSNK2A2, CSNK2B, CTNNA1*, CTNNA2*,
CTNNA3, CTNNB1*, CTNND1, EGFR*, EP300, ERBB2*, FARP2, FER, FGFR1,
FYN, IGF1R, INSR*, IQGAP1, LEF1, LMO7, MAP3K7, MAPK1, MAPK3, MET*,
NECTIN1, NECTIN2, NECTIN3, NECTIN4, NLK, PARD3, PTPN1, PTPN6,
PTPRB, PTPRF, PTPRJ, PTPRM, RAC1, RAC2, RAC3, RHOA*, SMAD2, SMAD3,
SMAD4*, SNAI1, SNAI2, SORBS1, SRC, SSX2IP, TCF7, TCF7L1, TCF7L2,
TGFBR1*, TGFBR2*, TJP1, VCL, WAS*, WASF1, WASF2, WASF3, WASL, YES1
Frequently mutated in sporadic gastric cancer2
APC*, ARID1A*,ASTN1, BNC2, CDH1*, CTNNA2, CTNNB1, DCLK1, DLGAP2,
EPB41L3, ERBB2, ERBB4, GLI3, KRAS, LRFN5, MACF1, MUC6, NRG2, OPRK1,
PIK3CA, PTPRC, RASA1, RHOA, RIMS2, RNF43, SMAD4*, SPTA1, SYNE1,
TGFBR2*, THBS1, THSD7B, TLR4, TP53*, TSHZ3, WDFY4, ZIC4
Homologous recombination and non-homologous end-joining3
ATM*, BABAM1, BARD1, BLM*, BRCA1*, BRCA2*, BRCC3, BRE, BRIP1A*,
DCLRE1C, DNTT, EME1, FAM175A, FEN1, LIG4, MRE11, MUS81, NBN*,
NHEJ1, PLAB2*, POLD1*, POLD2, POLD3, POLD4, POLL, POLM, PRKDC,
RAD50, RAD51, RAD51B, RAD51C*, RAD51D*, RAD52, RAD54B, RAD54L,
RBBP8, RPA1, RPA2, RPA3, RPA4, SEM1, SSBP1, SYCP3, TOP3A, TOPBP1,
UIMC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6
Previously proposed to cause HDGC or gastrointestinal tumours4
AKAP12, AKR7A3, APC*, ARID1A*, ATM*, BCL2L10, BMPR1A*, BRCA1*,
BRCA2*, CASP10, CDH1*, CDKN2A*, CFTR, CHEK2*, CTHRC1, CTNNA1*,
DOT1L, EPCAM, FAT4, FBXO24, FHIT, FOXF1, GAB2, GREM1, HSPA5, IDH1,
IDH2, ITIH2, MAP3K6, MCCC1, MLH1*, MSH2*, MSH3, MSH6*, MSR1,
MUTYH*, PALB2*, PMS1, PMS2*, PRR5, PRSS1*, PSCA, PTEN*, PXN, SCARF2,
SCG5, SDHB, SDHC, SDHD, SLC22A4, SMAD4*, SPINK1, STK11*, TGFBR2*,
TP53*
Guanine Exchange Factors5
ABR, AKAP13, ARHGEF1, ARHGEF10, ARHGEF10L, ARHGEF11, ARHGEF12,
ARHGEF15, ARHGEF16, ARHGEF17, ARHGEF18, ARHGEF19, ARHGEF2,
ARHGEF26, ARHGEF3, ARHGEF33, ARHGEF35, ARHGEF37, ARHGEF38,
ARHGEF39, ARHGEF4, ARHGEF40, ARHGEF5, ARHGEF6, ARHGEF7,
ARHGEF9, CDC42*, ECT2, FGD1, FGD2, FGD3, FGD4, GNA13, ITSN1, KALRN,
MCF2, MCF2L, NET1, NGEF, OBSCN, PLEKHG2, PLEKHG5, PREX1, RAC1*,
RAC2*, RAC3*, RASGRF2, RHOA*, RHOB, RHOBTB1, RHOBTB2, RHOC,
RHOD, RHOF, RHOG, RHOH, RHOJ, RHOQ, RHOT1, RHOT2, RHOU, RHOV,
SOS1, SOS2, TIAM1, TIAM2, TRIO, VAV1, VAV2, VAV3
Table 5.3: Candidate genes for the five focus areas. 1Gene list downloaded
from KEGG, accession number hsa04520. 2Genes list curated from Bass et al.
(2014), Chen et al. (2015), Wang et al. (2014), and Wong et al. (2014). 3Gene list
downloaded from KEGG, accession numbers hsa03450 and hsa03450. 4Gene
list curated from Donner et al. (2015), Gaston et al. (2014), Hansford et al.
(2015) and Majewski et al. (2013). 5 Gene list downloaded from Reactome,
accession number R-HSA-194849.3. *Gene a part of multiple lists.
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list of variant sites to a manageable size for a comprehensive evaluation, two
strategies were used. The first was the prioritisation of variants in genes
involved in specific cellular functions (focus areas), and the second was the
prioritisation of variants which were shared by all three members of Family 9.
5.2.4.1 Focus areas
After a review of published literature, I identified five focus areas that I believe
to be important for the carcinogenesis of diffuse gastric cancer. The focus areas
were: (1) genes involved in the adherens junctions, (2) genes which are
frequently mutated in sporadic gastric cancers, (3) genes involved in DNA
homologous recombination and non-homologous end-joining, (4) genes which
have previously been implicated in hereditary gastrointestinal cancers and
HDGC, and (5) guanine exchange factors involved in RhoA regulation. A
candidate gene list encompassing the genes important to these five focus areas
was curated from recent publications and online databases (Table 5.3). In total,
I identified 258 candidate genes, 21 of which were common to two or more
focus areas.
Using the candidate gene list, I prioritised 25 variants (one frameshift variant,
one nonsense variant, and 23 missense variants) in 22 different candidate
genes for further consideration (Table 5.4). Three different variants were
identified in one candidate gene (SYNE1: c.14273T>C, c.6254T>C, and
c.4427C>T), and two different variants in another (AKAP12: c.3925A>G and
c.4383T>G). Variants in genes previously proposed to cause gastrointestinal
cancers (focus area 4) were most common and made up ten of the 25 short
listed variants. Variants in guanine exchange factors (focus area 5) were least
common and only contributed three variants to this prioritised list. Of note,
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three of these focus area variants were shared by multiple members of Family
9 (SYNE1 c.6254T>C, 2/3 family members; LMO7 c.3823C>T, 3/3 family
members; and IGF1R c.2683C>T, 3/3 family members).
In addition to the nonsense and frameshift variants in PMS1 and ATM,
respectively, 7/32 missense variants were predicted to be deleterious by
Condel (Table 5.5). Four of the deleterious variants were in genes that have
previously been proposed to increase gastric cancer risk (APC, ATM, PMS1,
and TP53), while three were in genes that had not previously been associated
with gastric cancer risk (FARP2, FGD4, and LMO7).
5.2.4.2 Variants shared by Family 9
Variants that were shared by all three affected members of Family 9 were also
short listed for further evaluation. There were no rare nonsense or frameshift
variants shared by these individuals, however there were 37 rare missense
variants. The effect of these variants were predicted using Condel (Table 5.6).
Variants in the genes MRPS22, SRP72, ANK2, NADKD1, ZNF474, MLL5, PLEC,
OR51A7, TRIM66, LMO7, and TMPRSS6 were predicted to be deleterious. The
function of these genes were investigated for a potential link to the
carcinogenesis of diffuse gastric cancer.
The most compelling gene and variants in the aforementioned gene list was
LMO7 c.3823C>T. LMO7, a candidate gene which belonged to focus area 1
(adherens junction). The cellular function of LMO7 discussed in detail in
Section 5.2.5.2. IGF1R is also a candidate gene (focus area 1), and the
c.2683C>T variant was shared by all three members of Family 9. However, the





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































suggesting it was not likely to contribute to the diffuse gastric cancers in this
family.
5.2.5 Evaluation of prioritised variants
We identified nine variants which were of functional and/or biological interest
with consideration of the predicted effect and known biological function. The
nine different variants included six variants in genes previously associated
with an increased risk cancer risk (APC c.4088A>T, ATM c.1157delG, MUTYH
c.56G>A, PALB2 c.574G>A, PMS1 c.697C>T, TP53 c.713G>A), and three
variants in novel candidate diffuse gastric cancer predisposition genes (FARP2
c.124A>G, FGD4 c.1562A>G, and LMO7 c.3823C>T). Patient X8706 carried a
deleterious variants in both FARP2 and ATM. The variant in LMO7 was shared
by the three siblings from Family 9 (Y128, Y129, and Y130). Although there
were multiple different variants in SYNE1 and AKAP12, they were not
considered for further analysis as none of these variants were predicted to be
deleterious. The nine genes and the specific variants identified in this study
are evaluated in detail below.
5.2.5.1 Variants in known cancer risk genes
APC c.4088A>T
APC encodes a tumour suppressor involved in cell adhesion, cell migration,
organisation of the actin and microtubule networks, as well as spindle
formation and chromosome segregation (Barth, Näthke, & Nelson, 1997).
Variants in APC are causative of a series of autosomal dominant
APC-associated polyposis conditions including FAP, attenuated FAP, and
GAPPS (previously described in Sections 1.1.3 and 1.1.3.4, respectively). The
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penetrance of colonic adenomatous polyposis and colon cancer is nearly 100%
in FAP families, and approximately 70% in attenuated FAP families (Neklason
et al., 2008). The penetrance of gastrointestinal polyps and cancer in GAPPS
families is currently unknown. APC is known to be frequently mutated in
sporadic gastric cancers, however less than 3% of APC pathogenic variant
carriers develop gastric cancer (Iwama et al., 2004).
The APC c.4088A>T variant substitutes a lysine for an isoleucine at codon 1363
of the APC protein (p.Lys1363Ile). The lysine residue is highly conserved
across species and there is a moderate physicochemical difference between
lysine and isoleucine. APC c.4088A>T is present in population ExAC
databases (MAF 0.0001). To our knowledge, APC c.4088A>T variant has not
been reported in anyone with an APC-related syndrome. Condel predicts this
missense change to be deleterious. ClinVar currently describes APC c.4088A>T
as a variant of uncertain significance.
ATM c.1157delG
ATM encodes a 350kD kinase involved in DNA double-stranded break-repair,
activation of cell-cycle checkpoints, and induction of apoptosis (Savitsky et al.,
1995). Biallelic pathogenic variants in ATM cause ataxia-telangiectasia (A-T), a
syndrome characterised by immune deficiency, progressive dysfunction of the
cerebellum, and an increased risk of cancer (McKinnon, 2004; Savitsky et al.,
1995). Lymphomas and leukemias are most common for A-T cases less than 20
years of age, however adults are susceptible to both lymphoid tumours and a
variety of solid tumours including breast, liver, gastric, and esophageal
carcinomas (Rothblum-Oviatt et al., 2016).
It has also been shown that pathogenic monoallelic ATM variants increase
breast cancer risk (Bernstein et al., 2006). Furthermore, it is suggested
monoallelic ATM variants increase risk of colorectal, gastric, and pancreatic
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cancers (Bernstein et al., 2006; Renwick et al., 2006; D. Thompson et al., 2005).
The estimated penetrance of breast cancer in three hereditary breast cancer
families with a monoallelic truncating ATM variants was approximately 60%
by 70 years of age (Chenevix-Trench et al., 2002). Recently, a series of
population based studies have shown a significant enrichment of deleterious
germline ATM variants in gastric cancer patients, affirming pathogenic ATM
variants increase gastric cancer risk (Helgason et al., 2015; Huang et al., 2015).
ATM c.1157delG causes a frameshift variant which is predicted to cause an
early truncation of the ATM protein. This variant has not been reported in any
literature, population databases, or ClinVar. According to the ACMG/AMP
guidelines for the interpretation of sequence variants (Richards et al., 2015), as
ATM c.1157delG causes a frameshift and early truncation of the ATM protein it
is classified as pathogenic.
MUTYH c.56G>A
MUTYH encodes a DNA glycosylase involved in repair of oxidative DNA
damage. Pathogenic variants in the MUTYH gene cause an autosomal
recessive form of FAP known as MUTYH-associated polyposis (MAP)
(Cheadle & Sampson, 2007). MAP is caused by biallelic pathogenic variants in
germline MUTYH and is characterised by an extreme lifetime risk of colorectal
cancer (almost 100% penetrance) (Cheadle & Sampson, 2007). Although
monoallelic variants are not thought to cause high penetrance MAP, it has
been proposed monoallelic MUTYH variants may act as low-penetrance
susceptibility modifiers for colorectal cancer risk (Morak, Laner, Bacher,
Keiling, & Holinski-Feder, 2010). Patients with MAP do not appear to have a
rate of gastric cancer any higher than the general population (Cheadle &
Sampson, 2007; Vogt et al., 2009).
The MUTYH c.56G>A variant replaces arginine with glutamine at codon 19 of
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the MUTYH protein (p.Arg19Gln). The arginine residue is moderately
conserved and there is a small physicochemical difference between arginine
and glutamine. The glutamine amino acid residue is found in multiple
mammalian species, suggesting that this missense change does not adversely
affect protein function. MUTYH c.56G>A is present in the ExAC database
(MAF 0.00006) and has been reported in an individual with breast cancer and
individuals who had previously been referred for Lynch syndrome testing
(Out et al., 2012; Tricarico et al., 2011; Yurgelun et al., 2015). Condel predicts
the effect of this missense change to be neutral. ClinVar classifies MUTYH
c.56G>A as a variant of uncertain significance.
PALB2 c.574G>A
PALB2 is important for genome maintenance and repair of DNA double
stranded breaks (Rahman et al., 2007). Biallelic variants in PALB2 are causative
of hereditary Fanconi anemia and are associated with a high-risk of breast
cancer (Fernandes et al., 2014). Monoallelic or heterozygous germline variants
in PALB2 have been implicated in a small number of hereditary breast and
pancreatic cancers, and are associated with a moderate cancer risk (Fernandes
et al., 2014). Recently pathogenic germline variants in PALB2 were also
identified in a series of studies that examined germline DNA from gastric
cancer patients (Hansford et al., 2015; Lu et al., 2015; Sahasrabudhe et al.,
2016). The frequent discovery of deleterious variants in PALB2 in gastric
cancer patients suggests that they may increase gastric cancer risk.
PALB2 c.574G>A causes a valine to isoleucine substitution at codon 192 of the
PALB2 protein (p.Val192Ile). The lysine residue is weakly conserved across
species and there is only a small physicochemical difference between valine
and isoleucine. PALB2 c.574G>A variant is predicted to be neutral by Condel
and has not been reported in the literature, population databases, or ClinVar.
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According to the ACMG/AMP guidelines for the interpretation of sequence
variants (Richards et al., 2015), PALB2 c.574G>A is a variant of uncertain
significance.
PMS1 c.697C>T
PMS1 has been commonly associated with Lynch Syndrome (syndrome
described in Section 1.1.3.4), although a robust link between deleterious PMS1
variants and cancer risk is yet to be established. On re-examination of the only
Lynch syndrome family which has been described with a deleterious PMS1
variant, a pathogenic MSH2 variant was also discovered (Nicolaides et al.,
1994). MSH2 is also involved in DNA mismatch repair, and segregation
analysis showed that only the MSH2 variant co-segregated with colon cancer
in the Lynch syndrome family (Liu et al., 2001). Additional analysis of a large
series of Lynch syndrome families failed to find any PMS1 variants and
PMS1−/− mice did not show any cancer phenotype (Prolla et al., 1998).
PMS1 c.697C>T causes a truncating p.Gln233* variant. PMS1 c.697C>T is rare
in the ExAc population database (MAF 0.00003), but is absent from ClinVar
and, to our knowledge, has not been reported in any cancer families. Given
there is no irrefutable evidence PMS1 is a cancer predisposition gene, this
nonsense variant is unlikely to be of consequence.
TP53 c.713G>A
Sometimes described as the guardian of the genome, TP53 is tumour
suppressor gene that plays a role in apoptosis, cell-cycle regulation, genomic
stability, and inhibition of angiogenesis (Bieging, Mello, & Attardi, 2014;
Levine, 1997). TP53 is frequently mutated in human cancers, and pathogenic
germline variants in TP53 are causative of Li-Fraumeni syndrome (Malkin et
al., 1990; Varley, 2003). Although sarcomas, brain tumours, leukemias, breast
cancers, and adrenal cortical carcinomas are typically recognised as
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Li-Fraumeni syndrome-associated tumours, gastric cancer is also a part of the
wider tumour spectrum (Bouaoun et al., 2016). The frequency of gastric cancer
in families carrying pathogenic TP53 variants ranges from 1·8% to 4·9%, and
up to 40% of families with a pathogenic TP53 variant will present with at least
one gastric cancer diagnosis (Bouaoun et al., 2016; Masciari et al., 2011). It
remains unclear if Li-Fraumeni is associated with a particular histological
subtype of gastric cancer.
The c.713G>A variant replaces cysteine with tyrosine at codon 238 of the TP53
protein (p.Cys238Tyr). The cysteine codon is highly conserved across species
and there is a large physicochemical difference between cysteine and tyrosine.
The cysteine residue at codon 238 is involved in coordinating a zinc ion in the
DNA-binding domain of the TP53 protein. TP53 c.713G>A has been reported
in individuals with Hodgkin’s disease and breast cancer (Alsner, Yilmaz,
Guldberg, Hansen, & Overgaard, 2000; Nichols et al., 2003). In vitro studies
have shown that this missense change results in significantly decreased
transactivation activity of TP53, and that it may act in a dominant negative
fashion to reduce the transactivation activity of the wild-type allele (Monti et
al., 2011). Additionally, other amino acid substitutions at this codon have been
reported in families with Li-Fraumeni syndrome, all of which have also been
described as severe deficiency alleles (Monti et al., 2011). ClinVar classifies
TP53 c.713G>A as likely deleterious.
5.2.5.2 Variants in novel candidate diffuse gastric cancer genes
The novel candidate diffuse gastric cancer genes FARP2, FGD4, and LMO7
were examined in CBioPortal (Gao et al., 2013) for additional evidence FARP2,
FGD4, and LMO7 are involved in diffuse gastric cancer carcinogenesis.
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Individual somatic mutations have been found throughout the coding regions
of all three genes for various cancer types, including gastric cancer. However,
none of these genes are frequently mutated in gastric cancer, nor were these
specific mutations enriched in diffuse-type tumours.
FARP2 c.124A>G
FARP2 was identified as a candidate gene in the adherens junction pathway
(focus area 1). FARP2 encodes a guanine nucleotide exchange factor that is
thought to be important for the remodelling of the actin-cytoskeleton
(Fukuhara et al., 2004; Toyofuku et al., 2005). FARP2 activates Rac1 and Cdc42
in response to upstream signals, thereby regulating processes such as neuronal
axon guidance and bone homeostasis (Toyofuku et al., 2005). Motivated by the
abundant expression of FARP2 in neurons in the adult brain, functional studies
of FARP2 have primarily focused on its role in the regulation of neuronal
development and morphology (Kawakita et al., 2003; Kubo et al., 2002). How
the GEF activity of FARP2 is regulated remains poorly understood (He, Kuo,
Rosche, & Zhang, 2013). FARP2 is moderately expressed in the stomach (GTEx
Consortium, 2015). There are no studies implicating FARP2 as a cancer
predisposition gene.
FGD4 c.1562A>G
FGD4 was identified as a candidate gene with Rho guanine exchange factor
activity (focus area 5). FGD4 encodes a protein known to be expressed in the
nervous system where it regulates cell myelin production and facilitates the
attachment of the actin cytoskeleton to the cell membrane (Y. Kim et al., 2002).
Pathogenic variants in FGD4 are known to cause autosomal recessive
Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system,
characterised by progressive weakness and atrophy (Delague et al., 2007).
FGD4 is highly expressed in the stomach (GTEx Consortium, 2015). There is
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no prior evidence that FGD4 is associated with gastric cancer risk.
LMO7 c.3823C>T
LMO7 encodes a widely expressed protein-protein recognition module that is
characterised by its PDZ and LIM domains. LMO7 is an important protein in
the adherens junction (focus area 1), that in conjunction with α-actin, is known
to connect the E-cadherin-catenin and nectin-afadin complexes (B. Harris &
Lim, 2001; Kadrmas & Beckerle, 2004; Ooshio et al., 2004). The nectin-afadin
complex is involved in the activation of Cdc42 and Rac small G proteins, that
are known to enhance the formation of adherens junctions through
reorganisation of the actin cytoskeleton (Ooshio et al., 2004). LMO7 is
exclusively located at the apical surface of epithelial cells and is thought to
assist in the formation and maintenance of epithelial architecture (Ooshio et
al., 2004). LMO7 is highly expressed in the stomach (GTEx Consortium, 2015).
LMO7 is not known to be important to the carcinogenesis of gastric cancer, but
has previously been implicated as a cause of hereditary breast cancer in
humans and lung cancer in mice (Kainu et al., 2000; Tanaka-Okamoto et al.,
2009).
5.2.6 Summary of prioritised variants
After the in-depth evaluation of the nine prioritised variants (APC c.4088A>T,
ATM c.1157delG, FARP2 c.124A>G, FGD4 c.1562A>G, LMO7 c.3823C>T,
MUTYH c.56G>A, PALB2 c.574G>A, PMS1 c.697C>T, and TP53 c.713G>A), I
concluded that both the ATM c.1157delG and TP53 c.713G>A variants were
deleterious and most probably predisposed to the diffuse gastric cancers
diagnosed in patients X8289 and Y712, respectively. The APC c.4088A>T,
PALB2 c.574G>A, and MUTYH c.56G>A variants are variants of unknown
171
significance and will need to be reviewed again in light of future data. There
was no evidence to suggest the nonsense PMS1 variant increases cancer risk.
All three variants in the novel candidate diffuse gastric cancer genes FARP2
(c.124A>G), FGD4 (c.1562A>G), and LMO7 (c.3823C>T) are compelling
candidates for further studies. As LMO7 is a gene important for cell-cell
adhesion and the c.3823C>T variant in this gene is shared by all three
members of Family 9, it is a particularly interesting candidate for functional
studies. Further evidence will be required before any of these novel candidate
diffuse gastric cancer genes are considered as HDGC predisposition genes.
Further evidence supporting the inclusion of these genes as HDGC genes
includes the re-occurrence of deleterious germline variant in these genes in
further diffuse gastric cancer families, loss of heterozygosity in tumour
samples, and functional in vitro analyses showing variants in these genes can
induce cancer phenotypes.
As pathogenic variants in genes which are associated with increased cancer
risk have clinical implications for the patients in the current study, I
successfully validated each of the six variants I identified in genes associated
with cancer risk using Sanger sequencing (Figure 5.3). Furthermore, as the
variants in novel candidate diffuse gastric cancer genes may be of interest to
future studies, I also attempted to validate these variants. The FARP2
c.124A>G variant carried by patient Y8289 and the LMO7 c.3823C>T variant
carried by patients Y128 and Y130 were validated successfully (Figure 5.4).
Due to insufficient sample however, I was unable to validate the FGD4 variant
carried by patient Y713 and the LMO7 variant carried by Y129 with Sanger
sequencing. Given the depth and quality of NGS reads for these variants, it is
highly likely that these variants are real.
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X5799 PALB2 c.574G>A 
X8289 ATM c.1157delG 
Y712 TP53 c.713G>A 
Y8706 APC c. 4088A>T 
Y7045 PMS1 c.697C>T 







Figure 5.3: Validation of variants in genes associated with increased cancer
risk. Sanger sequence validation of (a) Y8706 APC c.4088A>T, (b) X8289 ATM
c.1157delG, (c) X3279 MUTYH c.56G>A, (d) X5799 PALB2 c.574G>A, (e) Y7045
PMS1 c.697C>T, and (f) Y712 TP53 c.713G>A. Sanger sequences for a,c,d,e, and
f are shown in the forward direction. Due to a repetitive sequence upstream of
the ATM variant, Sanger sequence for (b) (ATM c.1157delG) is shown in
reverse direction.
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Y128 LM07 c.3823C>T b 
c Y130 LM07 c.3823C>T 
Y8289 FARP2 c.124A>G a 
Figure 5.4: Validation of variants in candidate HDGC genes. Sanger sequence
validation of (a) Y8289 FARP2 c.124A>G, (b) Y128 LMO7 c.3823C>T, and (c)




In this study, whole-exome sequencing was used to search for deleterious
variants in 14 diffuse gastric cancer patients that meet the clinical criteria for
HDGC, but did not carry a pathogenic germline variant in CDH1. Variants in
these cases were filtered and then prioritised for further evaluation. I
identified pathogenic variants in ATM and TP53, two genes that are not
associated with clinical HDGC, but are known to increase gastric cancer risk.
Additional variants of interest were identified in FARP2, FGD4, and LMO7,
genes that are important in the coordination of the actin cytoskeleton and/or
cell adhesion, two cellular functions which are known to be dysregulated in
diffuse-type gastric tumours (Bass et al., 2014). Until now, FARP2, FGD4, and
LMO7 were not previously associated with diffuse gastric cancer risk.
5.3.1 Pathogenic variants in ATM and TP53
Two patients in this study were found to carry deleterious variants in ATM
and TP53, two genes associated with a moderate-risk of gastric cancer. Patient
X8289 was diagnosed with early-onset diffuse gastric cancer (diagnosis at age
36 years) and carries the ATM variant, whereas patient Y712 was diagnosed
with bilateral breast cancer and diffuse gastric cancer (diagnosis at age 45
years) and carries the TP53 variant.
As previously described, monoallelic loss-off-function variants in germline
ATM are most commonly associated with a moderately increased risk of breast
cancer, but are also associated with an increased risk of various other cancer
types, including gastric cancer. Unfortunately, our understanding of the
gastric cancer risk associated with deleterious ATM variants is still
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developing. Thus far, studies have shown that deleterious ATM variants
increase gastric cancer risk more than a four-fold (OR 4.74, 95% CI 3.0–7.4)
(Helgason et al., 2015) and that ATM variant carriers are diagnosed with
gastric cancer at a significantly earlier age than non-carriers (Helgason et al.,
2015; Lu et al., 2015). Additionally, ATM is known to be frequently mutated in
gastric cell lines and some gastric tumours (Zhang et al., 2004). To date, no
studies have found an association between deleterious ATM variants and a
particular subtype of gastric cancer, or estimated the cumulative incidence of
gastric cancer in ATM variant carriers (Helgason et al., 2015).
Similar to pathogenic ATM variant carriers, gastric cancer is diagnosed
significantly earlier in TP53 variant carriers than non-carriers in the general
population (Masciari et al., 2011). Furthermore, although gastric cancer is not
typically associated with TP53 variants, gastric cancers make up 1.8-4.9% of all
cancers diagnosed in Li-Fraumeni syndrome families (Malkin et al., 1990;
Masciari et al., 2011). Little is known about the pathological features of these
cancers, however, both intestinal- and diffuse-type gastric cancer have been
diagnosed in Li-Fraumeni syndrome families, suggesting that these variants
are not associated with a specific histological subtype (Masciari et al., 2011).
Notably, before patient Y712 was diagnosed with gastric cancer, she had
previously been diagnosed with bilateral breast cancer. The identification of a
pathogenic TP53 variant in a patient with a history of multiple malignancies
and breast cancer is not unusual. Breast cancer is the most common tumour
type in women with Li-Fraumeni syndrome and the frequency of pathogenic
TP53 variants in early-onset breast cancers patients (aged less that 30 years at
diagnosis) ranges from 1-7% (Gonzalez et al., 2009; Lalloo et al., 2006;
Mouchawar et al., 2010). Strikingly, half of all Li-Fraumeni syndrome patients
will develop at least one Li-Fraumeni syndrome-associated cancer by the age
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of 30 years. Furthermore, approximately one third of Li-Fraumeni syndrome
cancer patients will develop multiple primary cancers over their lifetime
(Sorrell, Espenschied, Culver, & Weitzel, 2013).
As a result of our study and the identification of the deleterious variants in
ATM and TP53, both patient X8289 and Y712, and their families, will receive
genetic counselling. The management guidelines for both TP53 and ATM
variant carriers recommend comprehensive annual physical examination,
screening for breast cancer from an early age, and to consider risk-reducing
prophylactic mastectomy (Bevers et al., 2009; Daly et al., 2010). Additionally,
pathogenic ATM variant carriers are advised to consider options for pancreatic
cancer screening (Bevers et al., 2009; Canto et al., 2013). As gastric cancer is not
a common malignancy associated with either ATM or TP53, neither set of
management guidelines for variant carriers recommends endoscopic screening
for variant carriers. Despite this, emerging evidence suggests that pathogenic
variants in these genes increase the risk of early-onset gastric cancers,
therefore I suggest that pathogenic variant carriers may benefit from regular
endoscopic screening from an early age.
There is some evidence that gastric cancer is more prevalent in Li-Fraumeni
syndrome families from Asian populations compared to Caucasian
populations (Ariffin et al., 2015; I. Kim et al., 2005; Yamada et al., 2007).
Although there are both genetic and environmental differences between Asian
and Caucasian populations, one possible explanation for this difference is that
there is a synergistic effect between pathogenic TP53 variants and H. pylori
infections. H. pylori is an environmental risk factor that is known to be more
common in Asian populations (Miwa, Go, & Sato, 2002). Both in vitro and in
vivo studies have shown that H. pylori infections can cause DNA damage and
promote the expression of genes in DNA repair pathways, including ATM and
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TP53 (Kalisperati et al., 2017; Koeppel, Garcia-Alcalde, Glowinski,
Schlaermann, & Meyer, 2015; Toller et al., 2011). It is possible that by having a
mutated TP53 or ATM, the DNA damage response is not as effective in
responding to H. pylori induced DNA damage. Consequently, pathogenic
variant carriers may accumulate mutations caused by H. pylori and have a
higher risk of tumour formation. Currently no studies have directly assessed
H. pylori infection related carcinogenesis in families with ATM or TP53
variants. If the risk of gastric cancer associated with H. pylori is higher for
those with a pathogenic ATM or TP53 variant, targeted screening and
eradication of H. pylori may reduce the burden of gastric cancer.
5.3.2 Evidence LMO7 is a tumour suppressor
In addition to variants in genes previously associated with cancer risk, I
identified three rare variants in candidate genes which were predicted to be
deleterious. Of particular interest, the LMO7 c.3823C>T variant was predicted
to be deleterious and was shared by all three members of Family 9. LMO7 has
previously been implicated as a tumour suppressor in both lung cancer in mice
and breast cancer in humans (Kainu et al., 2000; Tanaka-Okamoto et al., 2009).
In a study by Tanaka-Okamoto et al. (2009), LMO7-deficient mice developed
irregular epithelial lesions in their terminal respiratory bronchioles, that
tended to progress to lung adenocarcinoma (Tanaka-Okamoto et al., 2009).
LMO7-deficient epithelial cells developed a protruding phenotype which
characteristically associated with in-folding of the basement membrane. The
cumulative incidence of lung cancer in LMO7−/− and LMO7+/− mice was 22%
and 13%, respectively. Notably, it took more than 90 weeks for LMO7−/− mice
to develop lung cancer, suggesting that LMO7 acts as a tumour-suppressor,
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and that secondary events are required for carcinogenesis (Tanaka-Okamoto et
al., 2009). LMO7 expression has been shown to be inversely correlated with the
development and prognosis of human lung adenocarcinoma (Nakamura et al.,
2011), supporting its role as a potential tumour suppressor in humans.
Tanaka-Okamoto et al. (2009) propose a model for how LMO7 deficiency could
be inducing lung adenocarcinoma. In their model, LMO7 is localised to the
apical membrane of normal epithelial cells, and controls the spread of
epithelial sheets by balancing tension between apical and basal cell surfaces.
In epithelial cells lacking functional LMO7, it is proposed that the forces in the
apical and basal cell surfaces are unbalanced, causing the basement membrane
of epithelial cells to begin in-folding and form apical protrusions. Due to
limited space in the epithelial plane, some epithelial cells may disrupt
epithelial surface integrity and be displaced laterally. Tanaka-Okamoto et al.
(2009) conclude that, in addition to cancer-promoting events, displaced LMO7
deficient cells may progress to lung adenocarcinoma.
The model proposed by Tanaka-Okamoto et al. (2009) is strikingly similar to a
proposed model for the initiation of diffuse gastric cancer in pathogenic CDH1
variant carriers (Humar & Guilford, 2008). In the Humar and Guilford model,
multifocal SRCC are initiated in CDH1 variant carriers when loss of E-cadherin
leads to the loss of cell-cell adhesion and mitotic spindle orientation in gastric
epithelial cells. It is hypothesised that when these cells divide, a proportion of
daughter cells are displaced outside of the epithelial plane into the lamina
propria, a proportion of which undergo an EMT and acquire the ability to
invade surrounding tissues (Humar & Guilford, 2008). Although neither
model has been proven correct, the similarities between the models are clear.
LMO7 may have a role in maintaining epithelial integrity and protecting cells
from invasion of microbes and extracellular toxins. In a study by Lim, Kim,
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and Kim (2003), E-cadherin expression was decreased in gastric cells cultured
with H. pylori. In contrast, the expression of LMO7, as well as other genes that
regulate cell–cell adhesion and the cell–extracellular matrix, were
up-regulated (Lim et al., 2003). The importance of this upregulation is yet to be
established, however, the upregulation of LMO7 in response to a known
gastric cancer risk factor is of interest. It may be that increased LMO7
expression is a compensatory mechanism for decreased E-cadherin, in which
LMO7 stabilises cells in response to decreased cell-cell adhesion. Alternatively,
over expression of LMO7 may lead to disruption of intracellular signaling, cell
differentiation, or cell adhesion, and contribute to the carcinogenic process.
5.3.3 Whole-exome sequencing studies for the identification of
variants which predispose to diffuse gastric cancer
The exome represents less than 2% of the genome and contains approximately
85% of known disease-related variants (Van Dijk, Auger, Jaszczyszyn, &
Thermes, 2014). Whole-exome sequencing is a cost-effective way to identify
variants in the exome and has been extremely successful in the discovery of
variants and genes important in hereditary disorders (Van Dijk et al., 2014). In
this study whole-exome sequencing was utilised to search for variants that
may increase diffuse gastric cancer risk.
While sequencing exomes from patients with a salient family history or
early-onset of cancer facilities the identification of novel variants, their
discovery among the tens of thousands of variants in an exome can be
overwhelming and difficult to interpret. Population based variant databases
such as ESP6500, ExAC, and 1000 Genomes are useful in providing
population-specific allele frequencies that can assist filtering for rare variants.
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However, even after the exclusion of common variants, there are often still too
many variants to conclusively identify causative variants. Therefore,
additional filtering and prioritising strategies are required.
The small scale of the current whole-exome sequencing study meant it was not
well powered for the statistical based discovery of re-occurring rare variants
that predispose to diffuse gastric cancer (Lee, Abecasis, Boehnke, & Lin, 2014).
To combat this, two separate strategies were used. The first was the
prioritisation of variants in genes from focus areas. The second was the
prioritisation of variants that were shared by all three members of Family 9.
Naturally, both of these strategies have limitations that have been minimised
in the current study.
Candidate gene studies are most notably limited by the extent of knowledge
available on the disease of interest. Because of limited knowledge, candidate
gene studies have a significant risk of overlooking potentially causative
variants in genes that are not currently implicated in disease pathways. In the
current study, I minimised the risk by using broad focus areas to identify
candidate genes. Focus areas were identified from current literature regarding
diffuse gastric cancer carcinogenesis, and included a breadth of genes that are
not currently known to increase diffuse gastric cancer risk.
The prioritisation of variants shared by all three members of Family 9 also has
a risk of overlooking potentially causative variants. By electing to only
evaluate variants shared by all three family members, I did not address the
possibility that one or more of these family members were a sporadic case, or
that the exome sequencing may not have covered a specific locus in all three
family members. Therefore, variants of interest may have been missed.
However, as variants in disease pathways would have been identified in our
focus areas, even a single member of Family 9 with a variant in any gene
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related to one of our selected disease pathways would still have been
identified by our analyses.
One of the main limitations of whole-exome sequencing compared to
whole-genome sequencing is the limited coverage of variants outside the
coding regions. Intronic and intergenic regions are known to encompass a
large number of disease associated variants (Manolio et al., 2009). Notably,
most GWAS loci lie in non-coding regions and results from the Encyclopedia
of DNA Elements (ENCODE) Project suggest that many non-coding regions
have important biological functions (Lee et al., 2014). Despite this limitation,
the relative cost effectiveness and focus on a high-value portion of the genome
suggest that exome sequencing will remain an important experimental
approach for the identification of rare variants. As more intronic and
intergenic variants are associated with disease, future studies will need to
consider whole-genome sequencing as a way to capture variation in these
areas.
Additional issues also remain persistent in whole-exome sequencing studies
including strand bias, the level and variability of coverage across target
regions, and false positive calls (Bertier, Hétu, & Joly, 2016). Many of these
issues stem from low sequencing depth and the subsequent processing steps
undertaken to generate and process variant calls. To minimise the impact of
these factors in the current study, the GATK best practise guidelines were
followed using the most up-to-date bioinformatic tools.
The current study was unable to definitively identify any rare variants that
increase gastric cancer risk outside of known cancer predisposition genes.
Ideally, if tumour samples were available, loss of heterozygosity would be
looked for in patients with rare variants in novel candidate genes.
Furthermore, if a large series of CDH1 variant-negative HDGC cases were
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available, novel candidate genes could be sequenced to identify further
variant carriers. If variants in these genes were found in any large families,
segregation analysis could be carried out to determine penetrance of candidate
variants. Functional in vitro assays will also be useful for establishing whether
any of these rare variants disrupt protein structure, trafficking, or signalling.
5.3.4 Conclusions
In conclusion, whole-exome sequencing is a powerful tool for the
identification of novel variants in HDGC CDH1 variant-negative patients. In
our study I identified pathogenic variants in ATM and TP53, two genes that
are not associated with HDGC, but are known to increase gastric cancer risk.
Additional variants of interest were identified in FARP2, FGD4, and LMO7,
genes which are linked to cellular processes that may be important in diffuse
gastric cancers carcinogenesis. In particular, I believe LMO7 is an interesting
candidate for further studies. It is clear from this study and other HDGC
studies that there is no other common gene for HDGC, but many families may
carry private variants in genes rarely associated with disease. Identifying such









Although the identification of a predisposing variant does not directly remove
the associated risks, it enables risk stratification within a family and creates
opportunities for targeted intervention. This concept was illustrated by all
three of the cohorts sequenced in this thesis. By identifying one pathogenic
CDH1 variant carrier in the Chilean gastric cancer cohort, a further five
asymptomatic family members were found to carry the same pathogenic
variant. Several lives will almost certainly be saved by the increased
surveillance and prophylactic surgery available to the family as variant
carriers. Similarly, by exome sequencing a cohort of CDH1 variant-negative
gastric cancer patients, two individuals were found to carry clear pathogenic
variants in ATM and TP53, and are now being counselled for the risks
associated with variants in these genes. Undoubtedly, they too will benefit
from the enhanced surveillance and interventions for the cancers associated
with their specific variants.
The benefits of the subsequent interventions available to pathogenic CDH1
variant carriers were also evident in the current thesis. Each of the 15 known
CDH1 variant carriers in the Māori gastric cancer cohort were all still alive five
years post diagnosis. In contrast, the two variant carriers who did not appear
to be aware of their carrier status both died shortly after diagnosis. Clearly, the
translation of genetic screening and the identification of those who are at an
extreme risk of diffuse gastric cancer into targeted interventions is saving lives.
Despite the benefits of genetic screening and subsequent interventions, the
identification of a variant in a high-penetrance genes, such as CDH1, can
occasionally lead to more questions than answers. When a clear pathogenic
CDH1 variant is found in the context of its classically associated phenotype,
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management recommendations are generally well delineated. However, when
a variant of uncertain significance is identified in an individual without a
strong family history of disease, the quantification of risk and subsequent
management can be unsettling.
Variants of uncertain significance in CDH1 are typically rare missense variants
and splice site variants that do not clearly disrupt E-cadherin function.
Variants of uncertain significance are particularly hard to manage. As a
prophylactic gastrectomy may be unwarranted and regular endoscopic
screening may miss early-stage foci, those that are found to carry variants of
uncertain significance are left with major uncertainty about their risk. Genetic
parameters such as the variant frequency in healthy control populations,
recurrence of the variant in independent HDGC families, and co-segregation
of the pathogenic variant and cancer within a pedigree are all helpful in
assessing risk. However when the variant is de novo, a low proportion of
family members with the variant are affected by disease, the variant is not
common in the healthy population, and the variant is absent from disease
databases, in silico and in vitro assays are required to provide further
information on pathogenicity.
In silico assays use various parameters to assess if a variant is deleterious.
These parameters include the degree of interspecies conservation of the
mutated site, the effect of the variant on splicing, and the impact of the variant
on the protein structure to assess pathogenicity (Leong, Stuckey, Lai, Skinner,
& Love, 2015). In silico prediction tools are quick and easy to use, and can be
useful as additional evidence of pathogenicity. However these tools are prone
to over estimating pathogenicity and are limited to assessment of protein
structure (B. A. Thompson et al., 2013). In contrast, in vitro assays can be time
consuming and technically demanding. In addition to being able to determine
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the effect of a variant on protein structure, in vitro assays are able to interrogate
the functional effect of variants on cellular trafficking and signalling
(Figueiredo et al., 2013). Therefore, a combination of in vitro and in silico
techniques seems to be the best approach to guide the genetic counselling,
surveillance, and interventions offered to the carriers of variants of uncertain
significance in the CDH1 gene. Currently, several variants of uncertain
significance in CDH1 are being evaluated by in vitro assays at the Institute of
Molecular Pathology and Immunology of the University of Porto (Portugal)
(van der Post et al., 2015). Results from in vitro assays will undoubtedly
improve our understanding of variants of uncertain significance and improve
the management of patients with these variants.
The rates of variants of uncertain significance are higher in ethnic minorities
and genes that are rarely sequenced (Ricker et al., 2016; Susswein et al., 2015;
Yorczyk, Robinson, & Ross, 2015). However as more cancer patients and
healthy population controls are sequenced, many variants of uncertain
significance are being reclassified. Notably, with widespread BRCA1 and
BRCA2 testing, the prevalence of variants of uncertain significance in these
two genes has declined from approximately 20% to 2% of individuals tested
(Eggington et al., 2014; Frank et al., 2002). As seen in the Māori population
studied in this thesis, the frequency of specific variants can be quite different
to those in large population databases. This type of information is critical in
resolving the effect of variants that may be reasonably common in some
minorities.
The inclusion of CDH1 on multi-gene cancer panels has complicated the
interpretation of hereditary risk. A number of recent studies using gene panels
have identified unexpected and clearly deleterious CDH1 variants in
individuals whose families do not have the expected pattern of HDGC
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associated cancers (Huynh & Laukaitis, 2016; Lajus & Sales, 2015; Xie et al.,
2011). None of the families in these studies have a history of diffuse gastric
cancer, however some, but not all, had a limited history of lobular breast
cancer (Huynh & Laukaitis, 2016; Lajus & Sales, 2015; Xie et al., 2011). As more
families without a classical history of HDGC are being identified, it is
becoming apparent that the penetrance and effect of CDH1 variants may be
much more variable than previously thought.
One possible reason for the the lack of diffuse gastric cancer in families with
pathogenic CDH1 variants is that some CDH1 variants may have a reduced
penetrance of gastric tumours. Specific variants in cancer predisposition genes
are known to be associated with a reduced penetrance, as well as a bias
towards specific cancer phenotypes. For example, BRCA1 p.Arg1699Gln is
characterised by a cumulative risk of breast and ovarian cancer by the age of
70 years of only 24% (Spurdle et al., 2012), much lower than the average for
pathogenic BRCA1 variant carriers (71%) (van der Kolk et al., 2010).
Furthermore, compared to the average risk estimates for breast and ovarian
cancer for BRCA1 variant carriers, the BRCA1 p.Arg1699Gln variant is
associated with a comparatively lower breast cancer risk, but increased
ovarian cancer risk (Spurdle et al., 2012). Currently, the reasons for the
reduced penetrance and cancer phenotypes associated with the BRCA1
p.Arg1699Gln are unclear (Spurdle et al., 2012), and at present there are no
CDH1 variants which have been definitively shown to be associated with a
reduced breast and/or gastric cancer penetrance.
An alternative explanation for a lack of diffuse gastric cancer in families with
pathogenic CDH1 variants is that CDH1 variants are likely subject to genetic
modifiers and/or environmental interactions which affect their penetrance.
Both genetic and environmental factors are known to affect the penetrance of
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variants in other cancer predisposition genes. For instance, breast feeding is
known to reduce the risk of breast and ovarian cancer for BRCA1 variant
carriers (Cullinane et al., 2005; McLaughlin et al., 2007), and carrier status of
certain SNPs is predictive of the risk of developing breast cancer for BRCA1
variant carriers (Kuchenbaecker et al., 2017). Notably, factors that modify the
penetrance of pathogenic variants have been identified for various cancer
predisposition syndromes including hereditary breast and ovarian cancers
(Muranen et al., 2016; Peterlongo et al., 2015), Lynch syndrome (Bellido et al.,
2013), and Li-Fraumeni syndrome (Said & Malkin, 2015). At present there are
no genetic or environmental factors which are known to affect the penetrance
of CDH1 variants.
NGS of multi-gene panels offers the rapid and reliable identification of
variants in hundreds of genes across many samples in parallel, saving time
and reducing costs associated with running multiple separate assays (Kamps
et al., 2017; Kapoor et al., 2015; Sun et al., 2015). Gene panels are equally as
effective for identifying variants as single gene tests, but also have the capacity
to identify variants in multiple genes at the same time (Kamps et al., 2017;
Kapoor et al., 2015). As seen in the current thesis, variants in genes associated
with a moderate gastric cancer risk (such as ATM and TP53) can be a cause of
familial gastric cancer in some CDH1 variant-negative HDGC families.
Because of this, multi-gene panel testing should be considered for all gastric
cancer cases that fit the clinical criteria for HDGC testing.
Similar to the custom gene panel used by Hansford et al. (2015), a clinical gene
panel for screening of those who meet the clinical criteria for HDGC testing
should include genes previously shown to cause HDGC (CDH1 and
CTNNA1), as well as genes which have been associated with gastrointestinal
cancer risk (genes described by Hansford et al. (2015)). In addition to the 40%
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of HDGC cases that would be expected to carry a pathogenic CDH1 variants,
approximately 11% of CDH1 variant-negative cases would be expected to
carry a pathogenic variants in the genes tested on a clinical panel (Hansford et
al., 2015). Genes that have been proposed to cause HDGC but are still awaiting
extensive validation (such as MAP3K6, INSR, FBXO24, and DOT1L) could be
integrated into gene panels in a research capacity, but should not be used to
guide clinical management of gastric cancer patients and their families until
they have been definitively shown to increase gastric cancer risk. By using a
NGS gene panel, additional variants in genes associated with gastric cancer
risk will be identified and will enable risk stratification and targeted
interventions for those at risk.
Despite the potential benefits of gene panel testing, it is also important to
consider that gene panel testing can complicate the management of at risk
families. A major concern for large sequencing panels is the discovery of
variants of uncertain significance, which as previously discussed, do not
always contribute to risk assessment and may prompt anxiety and
over-treatment. Currently, variants of uncertain significance make up
approximately 40% of variants identified in broad cancer predisposition gene
panels (Frey et al., 2015; Tung et al., 2015; Yurgelun et al., 2015). Furthermore,
it is well know that as more genes are tested on gene panels, more variants of
uncertain significance are identified (Sun et al., 2015). Because of the
uncertainty associated with variants of unknown significance, despite the clear
benefits of gene panels, the difficulty in managing patients who are found to
carry variants of unknown significance need to be considered before panels
are integrated into clinical care.
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6.2 Future directions
The Māori gastric cancer and healthy control cohort described in this thesis is a
significant asset that can be utilised for further studies examining the factors
that influence gastric cancer risk. Additional research should examine the
impact of variants in other genes that are associated with gastric cancer risk on
the Māori gastric cancer population. Furthermore, in conjunction with the
environmental exposure data collected for this study, there is potential to
examine the DNA samples from this study for specific polymorphisms which
are thought to modify environmental risk (Section 3.1.5). One possible avenue
of research is to examine polymorphisms in the human interleukin-1 gene
cluster which are associated with increased rates of pre-malignant lesions in
response to H. pylori infection (El-Omar et al., 2000; Tu et al., 2008). As H. pylori
is known to be an major contributor to the high incidence of gastric cancer for
Māori, research regarding this risk factor is a priority.
Considering the positive impact genetic screening and targeted interventions
has had on the New Zealand Māori gastric cancer population, it would be
valuable to identify other populations that are affected by pathogenic CDH1
variants. Interestingly, both the Pacific Island population and the indigenous
Mapuche population in Chile are thought to have a high incidence of diffuse
gastric cancer (Biggar et al., 2011; Heise et al., 2009; Tapia et al., 2010). Despite
the high incidence, to our knowledge, pathogenic CDH1 variants have never
been documented in either group. Given the major impact CDH1 variants
have on the Māori gastric cancer population, I hypothesise that CDH1 variants
are a prevalent cause of diffuse gastric cancer in both of the Pacific Island and
Mapuche populations. If the same prevalence of germline CDH1 variants in
the Pacific Island and Mapuche populations are the same as the Māori
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population, regular endoscopic screening and prophylactic surgeries could be
used to reduce the overall mortality rate from diffuse gastric cancers by 10%.
Future research should also focus on identifying and understanding the
genetic and environmental factors that influence the penetrance of CDH1
variants. Due to the relative rarity of CDH1 variants in most populations,
future research will require large collaborative efforts to catalogue genetic
variation and exposure to environmental risk in HDGC families worldwide.
These studies will be complicated by the endoscopic screening and
preventative prophylactic surgery offered to known pathogenic CDH1 variant
carriers. Cases diagnosed via these methods are typically found to carry early
stage T1a tumours that can remain indolent for an unknown length of time
(Guilford et al., 2010; van der Post et al., 2015). Because of this, it is unclear if
and when, these tumours would have progressed, limiting the utility of the
genetic and environmental exposure information from these variant carriers.
A transgenic mouse model with a knockdown of CDH1 could also be used to
test the impact of different environmental factors on the progression of gastric
tumours in pathogenic CDH1 variant carriers. Previous Cdh1+/− heterozygous
mice mouse models required treatment of with the carcinogen
N-methyl-N-nitrosourea to promote carcinogenesis (Humar et al., 2009). More
recently, an engineered mouse model with an inducible Cre-loxP Cdh1
knockout in the gastric gland’s parietal cell lineage was developed. However,
Cre-loxP Cdh1 knockout mice only developed early stage diffuse gastric cancer
that did not progress to advanced disease (Mimata, Fukamachi, Eishi, &
Yuasa, 2011). I have hypothesised that this model would be improved if the
knockout of Cdh1 could be induced in the proliferative stem cell compartment
of the gastric gland (from which the cancer arises) rather than being restricted
to the parietal cell lineage. For this reason, a Cre/loxP inducible mouse that
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will use the CD44 promoter to knockout Cdh1 and red reporter construct
(tdTomato) in gastric gland stem cells (CD44-Cre/Cdh1loxP/loxP/tdTomato) have
been ordered and will arrive in this laboratory soon.
To generate a heterozygous mouse model, I will breed a version of the
CD44-Cre/Cdh1loxP/loxP/tdTomato mouse that contains one wildtype CDH1
allele (i.e. CD44-Cre/Cdh1loxP/+/tdTomato). I hypothesise that certain
environmental exposures will sensitise the Cdh1 heterozygous mice to
developing diffuse gastric cancer via the downregulation of CDH1 expression
or disruption of the functional E-cadherin. To begin to explore our hypothesis,
a small number of environmental factors that associated with an increased risk
of sporadic diffuse gastric cancer in the Māori have been identified. By
comparing the number of diffuse tumours that develop in
CD44-Cre/Cdh1loxP/+/tdTomato mice, with and without the environmental
exposures, I hope to be able to characterise the risk associated with such
factors.
As demonstrated in this thesis, there are significant difficulties in identifying
genes that are predisposing to diffuse gastric cancer in single probands and
small families using whole-exome sequencing. If there are further genes or
specific variants that are increasing diffuse gastric cancer risk, it is likely that
they are rare. To identify such variants, large cohorts of CDH1
variant-negative families will need to be sequenced in depth. When candidate
genes and variants are identified, further functional analysis will be required
to assess their associated risk. By identifying additional genes that are
increasing diffuse gastric cancer risk, as with germline CDH1 variants,
screening and interventions can be introduced to improve patient
management and save lives.
Beyond studies that identify and characterise cancer predisposing variants, the
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development of synthetic lethal drugs that target E-cadherin-deficient cells
should be considered a priority. In vitro E-cadherin loss is known to create a
series of vulnerabilities in E-cadherin deficient cells (Telford et al., 2015). By
targeting these vulnerabilities using drugs, tumours caused by E-cadherin loss
can be weakened or destroyed. Being able to target E-cadherin deficient
tumours would be particularly useful in treating those that have been
identified with variants of uncertain significance, in which endoscopic
screening may miss tumours but prophylactic surgery is unwarranted. If the
development of drugs targeting these vulnerabilities are successful, they could
be used to circumvent the need for prophylactic surgery for all pathogenic
CDH1 variant carriers and treat all sporadic E-cadherin-deficient tumours.
6.3 Concluding remarks
In summary, the current thesis describes a series of studies investigating
genetic predisposition to gastric cancer. First, pathogenic CDH1 variants were
shown to be a major contributor to the high incidence of early-onset diffuse
gastric cancer in the Māori population. Second, pathogenic CDH1 variants
were shown to be a rare cause of gastric cancer in a cohort of Chilean gastric
cancer patients. Third, CDH1 variant-negative HDGC patients were shown to
carry pathogenic variants in genes that are not associated with HDGC, but are
associated with increased gastric cancer risk, as well rare variants in novel
genes important in diffuse gastric cancer carcinogenesis pathways.
Importantly, as a direct result of this thesis, a series of gastric cancer patients
and their families are now receiving additional targeted care and have a better
prognosis than if they were to present with late stage disease.
Taken together, the studies described here demonstrate the variable frequency
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of germline CDH1 variants in different populations, the absence of other
commonly mutated genes in familial diffuse gastric cancers, and the
importance of genetic screening and targeted interventions for those found to
be at a heightened risk.
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Cohorts in New Zealand. Helicobacter, 20(2), 139–145.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky,
A., . . . DePristo, M. A. (2010). The Genome Analysis Toolkit: a
MapReduce framework for analyzing next-generation DNA sequencing
data. Genome research, 20(9), 1297–1303.
McKinnon, P. J. (2004). ATM and ataxia telangiectasia. EMBO reports, 5(8),
772–776.
McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., & Cunningham, F.
(2010). Deriving the consequences of genomic variants with the Ensembl
API and SNP Effect Predictor. Bioinformatics, 26(16), 2069–2070.
McLaughlin, J. R., Dryer, D., Mao, Y., Marrett, L., Morrison, H., Schacter, B., &
Villeneuve, G. (2006). Canadian cancer statistics 2006. Toronto (Canada):
National Cancer Institute of Canada.
McLaughlin, J. R., Risch, H. A., Lubinski, J., Moller, P., Ghadirian, P., Lynch, H.,
. . . Offit, K. (2007). Reproductive risk factors for ovarian cancer in
carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet
Oncology, 8(1), 26–34.
Medina-Franco, H., Ramos-De la Medina, A., Vizcaino, G., & Medina-Franco,
J. L. (2007). Single nucleotide polymorphisms in the promoter region of
the E-cadherin gene in gastric cancer: case-control study in a young
Mexican population. Annals of surgical oncology, 14(8), 2246–2249.
Metzker, M. L. (2010). Sequencing technologies—the next generation. Nature
reviews genetics, 11(1), 31–46.
Mimata, A., Fukamachi, H., Eishi, Y., & Yuasa, Y. (2011). Loss of E-cadherin in
mouse gastric epithelial cells induces signet ring-like cells, a possible
precursor lesion of diffuse gastric cancer. Cancer science, 102(5), 942–950.
Ministry of Health. (2015). Annual Update of Key Results 2014/15: New
Zealand Health Survey. Wellington, New Zealand: Ministry of Health.
Ministry of Health. (2016a). Annual Update of Key Results 2015/16: New
Zealand Health Survey. Wellington, New Zealand: Ministry of Health.
Ministry of Health. (2016b). Cancer: New registrations and deaths 2013.
Wellington, New Zealand: Ministry of Health.
Miwa, H., Go, M. F., & Sato, N. (2002). H. pylori and gastric cancer: the Asian
enigma. The American journal of gastroenterology, 97(5), 1106–1112.
Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., . . .
Tucker, M. A. (2001). Parity, oral contraceptives, and the risk of ovarian
cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
New England Journal of Medicine, 345(4), 235–240.
Molinaro, V., Pensotti, V., Marabelli, M., Feroce, I., Barile, M., Pozzi, S., . . .
Ranzani, G. N. (2014). Complementary molecular approaches reveal
heterogeneous CDH1 germline defects in Italian patients with hereditary
diffuse gastric cancer (HDGC) syndrome. Genes, Chromosomes and Cancer,
53(5), 432–445.
Monti, P., Perfumo, C., Bisio, A., Ciribilli, Y., Menichini, P., Russo, D., . . .
210
Fronza, G. (2011). Dominant-negative features of mutant TP53 in
germline carriers have limited impact on cancer outcomes. Molecular
Cancer Research, 9(3), 271–279.
Morak, M., Laner, A., Bacher, U., Keiling, C., & Holinski-Feder, E. (2010).
MUTYH-associated polyposis–variability of the clinical phenotype in
patients with biallelic and monoallelic MUTYH mutations and report on
novel mutations. Clinical genetics, 78(4), 353–363.
More, H., Humar, B., Weber, W., Ward, R., Christian, A., Lintott, C., . . . Harlan,
M. (2007). Identification of seven novel germline mutations in the
human E-cadherin (CDH1) Gene. Human mutation, 28(2), 203–203.
Morita, K., Furuse, M., Fujimoto, K., & Tsukita, S. (1999). Claudin multigene
family encoding four-transmembrane domain protein components of
tight junction strands. Proceedings of the National Academy of Sciences,
96(2), 511–516.
Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., . . .
Schwartz, P. (2000). BRCA1 and BRCA2 mutation analysis of 208
Ashkenazi Jewish women with ovarian cancer. The American Journal of
Human Genetics, 66(4), 1259–1272.
Mouchawar, J., Korch, C., Byers, T., Pitts, T. M., Li, E., McCredie, M. R., . . .
Southey, M. C. (2010). Population-based estimate of the contribution of
TP53 mutations to subgroups of early-onset breast cancer: Australian
Breast Cancer Family Study. Cancer research, 70(12), 4795–4800.
Muranen, T. A., Greco, D., Blomqvist, C., Aittomäki, K., Khan, S., Hogervorst,
F., . . . Luben, R. (2016). Genetic modifiers of CHEK2* 1100delC
associated breast cancer risk. Genetics in medicine: official journal of the
American College of Medical Genetics.
Nakamura, H., Hori, K., Tanaka-Okamoto, M., Higashiyama, M., Itoh, Y.,
Inoue, M., . . . Miyoshi, J. (2011). Decreased expression of LMO7 and its
clinicopathological significance in human lung adenocarcinoma.
Experimental and therapeutic medicine, 2(6), 1053–1057.
Neklason, D. W., Stevens, J., Boucher, K. M., Kerber, R. A., Matsunami, N.,
Barlow, J., . . . Burt, R. W. (2008). American founder mutation for
attenuated familial adenomatous polyposis. Clinical Gastroenterology and
Hepatology, 6(1), 46–52.
Nevalainen, T., Laurén, P., & Gavin, J. (1988). The intestinal and diffuse types
of gastric carcinoma in Maori and non-Maori patients in Auckland.
Scandinavian journal of gastroenterology, 23(5), 591–594.
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., . . .
Abraham, J. P. (2014). Global, regional, and national prevalence of
overweight and obesity in children and adults during 1980–2013: a
systematic analysis for the Global Burden of Disease Study 2013. The
Lancet, 384(9945), 766–781.
Ng, P. C., & Henikoff, S. (2003). SIFT: Predicting amino acid changes that
affect protein function. Nucleic acids research, 31(13), 3812–3814.
Nichols, K. E., Heath, J. A., Friedman, D., Biegel, J. A., Ganguly, A., Mauch, P.,
& Diller, L. (2003). TP53, BRCA1, and BRCA2 tumor suppressor genes
211
are not commonly mutated in survivors of Hodgkin’s disease with
second primary neoplasms. Journal of clinical oncology, 21(24), 4505–4509.
Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y., Carter, K. C., Ruben,
S. M., . . . Fraser, C. M. (1994). Mutations of two PMS homologues in
hereditary nonpolyposis colon cancer. Nature, 371(6492), 75.
Oliveira, C., de Bruin, J., Nabais, S., Ligtenberg, M., Moutinho, C., Nagengast,
F. M., . . . Carneiro, F. (2004). Intragenic deletion of CDH1 as the
inactivating mechanism of the wild-type allele in an HDGC tumour.
Oncogene, 23(12), 2236–2240.
Oliveira, C., Ferreira, P., Nabais, S., Campos, L., Ferreira, A., Cirnes, L., . . .
Dias, L. M. (2004). E-Cadherin (CDH1) and p53 rather than SMAD4 and
Caspase-10 germline mutations contribute to genetic predisposition in
Portuguese gastric cancer patients. European journal of cancer, 40(12),
1897–1903.
Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., . . .
Keller, G. (2009). Germline CDH1 deletions in hereditary diffuse gastric
cancer families. Human molecular genetics, 18(9), 1545–1555.
Oliveira, C., Seruca, R., & Carneiro, F. (2009). Hereditary gastric cancer. Best
Practice & Research Clinical Gastroenterology, 23(2), 147–157.
Oliver, W. H. (1981). The Oxford History of New Zealand. Oxford University
Press, USA.
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A.
(2008). Loss of E-cadherin promotes metastasis via multiple downstream
transcriptional pathways. Cancer research, 68(10), 3645–3654.
Ooshio, T., Irie, K., Morimoto, K., Fukuhara, A., Imai, T., & Takai, Y. (2004).
Involvement of LMO7 in the association of two cell-cell adhesion
molecules, nectin and E-cadherin, through afadin and α-actinin in
epithelial cells. Journal of Biological Chemistry, 279(30), 31365–31373.
Out, A. A., Wasielewski, M., Huijts, P. E., van Minderhout, I. J.,
Houwing-Duistermaat, J. J., Tops, C. M., . . . van Asperen, C. J. (2012).
MUTYH gene variants and breast cancer in a Dutch case-control study.
Breast cancer research and treatment, 134(1), 219–227.
Papusheva, E., & Heisenberg, C. (2010). Spatial organization of adhesion:
force-dependent regulation and function in tissue morphogenesis. The
EMBO journal, 29(16), 2753–2768.
Paredes, J., Figueiredo, J., Albergaria, A., Oliveira, P., Carvalho, J., Ribeiro,
A. S., . . . Pinheiro, H. (2012). Epithelial E-and P-cadherins: role and
clinical significance in cancer. Biochimica et Biophysica Acta (BBA)-Reviews
on Cancer, 1826(2), 297–311.
Park, B., Shin, A., Park, S. K., Ko, K., Ma, S. H., Lee, E., . . . Yoo, K. Y. (2011).
Ecological study for refrigerator use, salt, vegetable, and fruit intakes,
and gastric cancer. Cancer Causes & Control, 22(11), 1497–1502.
Park, J., Park, S., Hong, K., Han, Y., Jang, S., Kim, E., & Hahm, K. (2014).
Special Licorice Extracts Containing Lowered Glycyrrhizin and
Enhanced Licochalcone A Prevented Helicobacter pylori-Initiated, Salt
Diet-Promoted Gastric Tumorigenesis. Helicobacter, 19(3), 221–236.
212
Parsonnet, J., Friedman, G., Orentreich, N., & Vogelman, H. (1997). Risk for
gastric cancer in people with CagA positive or CagA negative
Helicobacter pylori infection. Gut, 40(3), 297–301.
Parsonnet, J., Vandersteen, D., Goates, J., Sibley, R. K., Pritikin, J., & Chang, Y.
(1991). Helicobacter pylori infection in intestinal- and diffuse-type gastric
adenocarcinomas. Journal of the National Cancer Institute, 83(9), 640–643.
Peek, R. M., & Crabtree, J. E. (2006). Helicobacter infection and gastric
neoplasia. The Journal of pathology, 208(2), 233–248.
Peleteiro, B., Lopes, C., Figueiredo, C., & Lunet, N. (2011). Salt intake and
gastric cancer risk according to Helicobacter pylori infection, smoking,
tumour site and histological type. British journal of cancer, 104(1),
198–207.
Pentecost, M., Otto, G., Theriot, J. A., & Amieva, M. R. (2006). Listeria
monocytogenes invades the epithelial junctions at sites of cell extrusion.
PLoS Pathog, 2(1), e3.
Peterlongo, P., Chang-Claude, J., Moysich, K. B., Rudolph, A., Schmutzler,
R. K., Simard, J., . . . Wilkening, S. (2015). Candidate genetic modifiers for
breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer Epidemiology and Prevention Biomarkers, 24(1), 308–316.
Pharoah, P., Guilford, P., Caldas, C., International Gastric Cancer Linkage
Consortium, & International Gastric Cancer Linkage Consortium. (2001).
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin)
mutation carriers from hereditary diffuse gastric cancer families.
Gastroenterology, 121(6), 1348–1353.
Pinheiro, H., Bordeira-Carriço, R., Seixas, S., Carvalho, J., Senz, J., Oliveira, P.,
. . . Seruca, R. (2010). Allele-specific CDH1 downregulation and
hereditary diffuse gastric cancer. Human molecular genetics, 19(5),
943–952.
Polk, D. B., & Peek, R. M. (2010). Helicobacter pylori: gastric cancer and
beyond. Nature Reviews Cancer, 10(6), 403–414.
Polkowski, W., van Sandick, J. W., Offerhaus, G. J. A., ten Kate, F. J., Mulder, J.,
Obertop, H., & van Lanschot, J. J. B. (1999). Prognostic value of Lauren
classification and c-erbB-2 oncogene overexpression in adenocarcinoma
of the esophagus and gastroesophageal junction. Annals of Surgical
Oncology, 6(3), 290–297.
Prolla, T. A., Baker, S. M., Harris, A. C., Tsao, J., Yao, X., Bronner, C. E., . . .
Shibata, D. (1998). Tumour susceptibility and spontaneous mutation in
mice deficient in Mlh1, Pms1 and Pms2 DMA mismatch repair. Nature
genetics, 18(3), 276–279.
Rahman, N. (2014). Realizing the promise of cancer predisposition genes.
Nature, 505(7483), 302–308.
Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., . . .
Jayatilake, H. (2007). PALB2, which encodes a BRCA2-interacting
protein, is a breast cancer susceptibility gene. Nature genetics, 39(2),
165–167.
Rahner, N., Steinke, V., Schlegelberger, B., Olschwang, S., Eisinger, F., & Hutter,
213
P. (2010). Clinical utility gene card for: Lynch syndrome (MLH1, MSH2,
MSH6, PMS2). Eur J Hum Genet, 18(9).
Reese, M. G., Eeckman, F. H., Kulp, D., & Haussler, D. (1997). Improved splice
site detection in Genie. Journal of computational biology, 4(3), 311–323.
Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., . . . le
Roux, L. (2006). ATM mutations that cause ataxia-telangiectasia are
breast cancer susceptibility alleles. Nature genetics, 38(8), 873–875.
Reva, B., Antipin, Y., & Sander, C. (2011). Predicting the functional impact of
protein mutations: application to cancer genomics. Nucleic acids research,
gkr407.
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., . . .
Voelkerding, K. (2015). Standards and guidelines for the interpretation of
sequence variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genetics in Medicine, 17(5), 405–423.
Ricker, C., Culver, J. O., Lowstuter, K., Sturgeon, D., Sturgeon, J. D., Chanock,
C. R., . . . Gruber, S. B. (2016). Increased yield of actionable mutations
using multi-gene panels to assess hereditary cancer susceptibility in an
ethnically diverse clinical cohort. Cancer genetics, 209(4), 130–137.
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H.,
Borisy, G., . . . Horwitz, A. R. (2003). Cell migration: integrating signals
from front to back. Science, 302(5651), 1704–1709.
Risinger, J. I., Berchuck, A., Kohler, M. F., & Boyd, J. (1994). Mutations of the
E-cadherin gene in human gynecologic cancers. Nature genetics, 7(1),
98–102.
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S.,
Getz, G., & Mesirov, J. P. (2011). Integrative genomics viewer. Nature
biotechnology, 29(1), 24–26.
Robson, B., Purdie, G., & Cormack, D. (2010). Unequal impact II: Māori and
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Validation of rare variants in Māori
case-control cohort
229
Y307 c.-276T>C  
Figure B.1: Validation of upstream c.-276T>C variant. Sanger sequence in





Figure B.2: Validation of upstream c.-176C>T variant. Sanger sequence in





Figure B.3: Validation of CDH1 5’ UTR c.-71G>A variant. Sanger sequence in
forward direction for controls Y288, Y370, and Y537.
232
Y320 c.88C>A 
Figure B.4: Validation of CDH1 c.88C>A variant (p.Pro30Thr). Sanger






Figure B.5: Validation of CDH1 c.190C>T variant (p.Gln64*). Sanger sequence
in forward direction for cases Y240, Y382, Y647, and Y704.
234
Y301 c.387+5G>A 
Y598  c.387+5G>A 
Y612 c.387+5G>A 
Y633 c.387+5G>A 
Figure B.6: Validation of CDH1 c.387+5A>G variant. Sanger sequence in
forward direction for case Y633 and controls Y301, Y598, and, Y612.
235
Y266 1214A>G 
Figure B.7: Validation of CDH1 c.1214A>G variant (p.Asn405Ser). Sanger









Figure B.8: Validation of CDH1 c.1409C>T variant (p.Thr470Ile). Sanger
sequence in forward direction for cases Y329, Y425 ,and Y659, and controls




Figure B.9: Validation of CDH1 c.1774G>A variant (p.Ala592Thr). Sanger






Figure B.10: Validation of CDH1 CDH1 c.1792C>T variant (p.Arg598*). Sanger
sequence in forward direction for cases Y255, Y579, Y649, and Y709
239
Y618 c.1849G>A 
Figure B.11: Validation of CDH1 c.1849G>A variant (p.Ala617Thr). Sanger
sequence in forward direction for case Y618
240
Y616 c.2195G>A 
Figure B.12: Validation of CDH1 c.2195G>A variant (p.Arg732Gln). Sanger






Figure B.13: Validation of CDH1 c.2287G>T variant (p.Glu763*). Sanger
sequence in forward direction for cases Y335, Y435, Y670, and Y706.
242
Y633 c.2329G>A 
Figure B.14: Validation of CDH1 c.2329G>A variant (p.Asp777Asn). Sanger






Figure B.15: Validation of CDH1 c.2381_ 2386insC variant (p.Arg796fs). Sanger













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Validation of rare variants in
Chilean gastric cancer cohort
251
Proband 17 c.88C>A 
Figure D.1: Validation of CDH1 c.88C>A variant (p.Pro30Thr). Sanger
sequence in forward direction for Proband 17.
Proband 6 c.1521C>T 
Figure D.2: Validation of CDH1 c.1521C>T variant (p.Gln511*). Sanger
sequence in forward direction for Proband 6.
252
Appendix E



















Figure E.1: Sanger sequence analysis of proband 6 family members. Sanger
sequence of CDH1 exon 10 showing carrier status of c.1521C>T.
Chromatogram sequence for: a) II6, maternal grandfather ; b) II7 maternal
grandmother; c) III2, maternal aunt; d) III3, mother; e) III4, father; f) IV1,
maternal cousin; g) IV2, maternal cousin; and h) IV4, sibling, of proband 6
(IV5).
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